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ABSTRACT 
Melanie Nicole Tallman:  The Role of Intestinal UDP-Glucuronosyltransferases in 7-Ethyl-
10-Hydroxy-Camptothecin (SN-38) Conjugation and Toxicity 
(Under the direction of Philip C. Smith, Ph.D.) 
 
 A significant number of cancer patients treated with the topoisomerase inhibitor, 
irinotecan, experience severe, delayed-onset diarrhea.  Clinicians will typically reduce 
subsequent doses of irinotecan in affected patients, which may result in diminished 
effectiveness of the anti-cancer agent.  The active metabolite of irinotecan, 7-ethyl-10-
hydroxy-camptothecin (SN-38), has been implicated as the colon-toxic agent, by causing 
direct injury to colonic epithelial cells.  SN-38 is consequently detoxified to SN-38 
glucuronide (SN-38G) by UDP-glucuronosyltransferase (UGT) isozymes expressed not only 
in the liver, but also in the gastrointestinal tract.  Although luminal SN-38 has been identified 
as an important mediator of diarrhea, the influence of intestinal UGTs at the site of toxicity 
has not been addressed.  Thus, intestinal SN-38 glucuronidation was studied to address the 
hypothesis that UGT activity in the intestine is a critical factor in modulating SN-38 toxicity, 
as enteric cells have the ability to prevent SN-38 toxicity locally through UGT expression.   
 The primary human and rat isoforms that glucuronidate SN-38 were identified, many 
of which are localized in the intestine.  SN-38 carboxylate was found to be a suitable, more 
soluble surrogate for the active lactone form for in vitro glucuronidation, as the rank order of 
UGT isoform catalysis was similar for the two forms, despite different rates of conjugation. 
Intersubject SN-38 glucuronidation in human intestinal tissue from duodenal, jejunal, and 
colonic regions was variable, and was highly correlated with both UGT1A1 and 1A9 probe 
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substrate glucuronidation, indicating a primary role for these isoforms in intestinal SN-38G 
formation.  The hypothesis that intestinal UGTs modulate SN-38-induced diarrhea was 
directly tested in a Gunn rat model with reconstituted hepatic UGT activity via adenoviral 
gene delivery.  These rats, devoid of intestinal UGT1A activity, were highly susceptible to 
intestinal damage and diarrhea after irinotecan administration, compared to control 
heterozygote rats, which possessed both hepatic and intestinal UGTs.  Collectively, this 
research advanced the knowledge of the metabolic detoxification of SN-38 in the intestine by 
establishment and identification of appropriate in vitro reaction conditions, isoform 
specificity and expression, and variability in glucuronidation.  These studies have also 
supported the hypothesis that intestinal UGT expression modulates the incidence of 
gastrointestinal toxicity to SN-38. 
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INTRODUCTION
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A. INTRODUCTION 
Drug metabolizing enzymes often play a critical role in mediating drug effect and 
drug toxicity.  In most cases, these enzymes chemically modify their xenobiotic substrates, 
such that pharmacological activity is lost.  Highly efficient drug metabolism may 
compromise a compound’s efficacy, while inefficient metabolism may predispose patients to 
adverse effects due to accumulation of drug with chronic dosing.  Keeping these 
considerations in mind, rational drug design and development would ideally include 
knowledge of a compound’s therapeutic and toxic windows, but also the influence that 
variability in drug metabolizing enzymes have on the dosing regimen to provide 
concentrations that fall within these windows. 
 Without downplaying the importance of drug metabolism, other factors can also play 
a role in mediating xenobiotic concentrations at sites of pharmacologic effect and toxicity, 
such as transporters or protein binding.  Additionally, multiple drug metabolizing enzymes 
may recognize the drug substrate, obscuring the importance of any one factor in mediating 
drug disposition. 
 These complexities related to efficacy, toxicity, metabolism, and systemic disposition 
are highlighted with a clinical example involving 7-ethyl-10-hydroxy-camptothecin (SN-38), 
the active metabolite of the anti-cancer agent, irinotecan, and the UDP-
Glucuronosyltransferase (UGT) family of drug metabolizing enzymes (Figure 1.1).  
Irinotecan and SN-38 are substrates for numerous enzyme systems and transporters in the 
liver.  Upon biliary excretion, both are substrates for intestinal metabolic enzymes and 
transporters, which may be similar or different from those responsible for the disposition of 
these compounds systemically.  To further complicate this scenario, each compound can exist 
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in two chemically different forms that take on distinct biological and physicochemical 
properties.  It is ultimately the UGTs that detoxify SN-38 by forming its glucuronide, SN-
38G, which is not stable when in the intestinal lumen.  Irinotecan, through the actions of SN-
38, has a narrow therapeutic window, with a large subset of patients experiencing life-
threatening neutropenia or diarrhea.  Thus far, despite an enigmatic disposition for 
irinotecan/SN-38, a clear role for low UGT activity has been linked to neutropenia, however, 
primary mechanisms for mediating diarrhea are still ambiguous. 
 In this review, an extensive background regarding the UGT1A family will be given, 
highlighting tissue-specific differences in expression and glucuronidation, as well as 
environmental and genetic factors that can alter expression and function.  Irinotecan 
pharmacology will also be discussed.  The hypotheses and methodologies explored thus far 
to predict and prevent irinotecan-induced toxicity will be detailed.  Ultimately, it is hoped 
that the reader will understand that research is lacking with respect to elucidation of specific 
mechanisms behind the incidence of diarrhea and protective enzymes at the site of toxicity, 
the intestinal UGTs.  
 
B. URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASES (UGT) 
B.1. FUNCTION 
Uridine Diphosphate Glucuronosyltransferases (UGTs or UDP-
Glucuronosyltransferases) are a superfamily of enzymes that catalyze the transfer of a 
glucuronic acid moiety from the nucleotide sugar UDP-glucuronic acid (UDPGA) to a lipid-
soluble molecule (Mulder, 1992; Burchell, 1999).  UGTs are anchored in the membrane of 
the endoplasmic reticulum and following conjugation, the more hydrophilic conjugates are 
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expelled by transporters into the lumen of the ER.  In an SN2 reaction, a nucleophilic attack 
by the substrate on the C1 pryanose acid carbon of UDPGA results in the formation of a β-D 
glucuronic acid product (Figure 1.1) (Clarke and Burchell, 1994).  The nucleophilic moiety 
of the substrate might be one or more functional groups, including carboxylic acids, 
hydroxyl, thiol, amino, or activated carbon centers (Burchell, 1999).  The addition of a polar 
glucuronic acid group often reduces the volume of distribution and increases elimination 
through urinary and biliary excretion relative to the aglycone.  The latter processes are 
facilitated by either an increase in hydrophilicity (urinary excretion), an increase in molecular 
weight or charge state (biliary excretion), or affinity for transporters (both excretory 
processes) (Fisher et al., 2000; Johnson and Klaassen, 2002).   
The common role of the UGTs is detoxification of both endogenous and exogenous 
compounds.  Conjugation reduces the likelihood that nucleophilic sites will be converted to 
electrophilic species that may otherwise cause protein damage (Bock and Lilienblum, 1994).  
The hepatotoxin acetaminophen has several metabolic pathways and can be metabolized to a 
glucuronide or a reactive quinoneimine.  The latter compound can chemically modify 
numerous cellular proteins and induce apoptotic events at higher doses.  In rats deficient in 
UGTs, a higher percentage of quinoneimine is formed than in rats with conjugating ability.  
This deficiency significantly predisposes rats to hepatic damage, underscoring the 
importance of UGTs in abating toxicity (de Morais and Wells, 1988; Park et al., 2005).  
Electrophilic compounds can also react with DNA, a process that is a well-known precursor 
to carcinogenesis.  Recent evidence suggests that having a mutation that results in less 
efficient UGT catalysis may predispose people to developing gastrointestinal or digestive 
system cancers (Strassburg et al., 2002; Ockenga et al., 2003).  UGTs can react with such 
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compounds and reduce their potential for toxicity, in addition to providing an alternative 
metabolic pathway that decreases the percentage of a toxin that can undergo conversion to an 
electrophile.  In its detoxifying or protective role, UGTs prevent genotoxic and cytotoxic 
substances from accumulating in the cell and causing irreversible damage. 
B.2. GENOMIC STRUCTURE AND PHYLOGENY OF UGTs 
In mammals, there have been 47 UGT genes isolated, which belong to one of three 
families.  Within a family, each member has greater than 45% sequence homology with other 
members.  Genes within two families, UGT1 and UGT2, are divided into four subfamilies, 
with each gene in a subfamily having at least 60% homology.  Following proper 
nomenclature, the family is denoted with an Arabic number, followed by the subfamily 
denoted with a letter, and finally each gene with an Arabic number (Mackenzie et al., 1997).  
The UGT1A and UGT2B family contain the isoforms most responsible for glucuronidation 
in humans.  UGT2B transcripts are formed from individual genes encoded on chromosome 
4q13, encoded by six exons.  There are seven functional UGT2B proteins:  UGT2B4, UGT 
2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17, and UGT2B28 (Tukey and Strassburg, 
2000; Guillemette, 2003).  Although encoded by individual genes, all members of this family 
are at least 78% homologous with each other at the protein level.  The homology may be as 
much as 94%, as between UGT2B15 and UGT2B17 and UGT2B11 and UGT2B28 
(Guillemette, 2003).  UGT1A isozymes are transcribed from one gene on chromosome 2q37.  
The UGT1A gene has thirteen 5’ first exons with 12 unique promoters and four 3’exons.  
The DNA polymerase complex recognizes the promoter sequence of one of the 5’exons and 
transcription is initiated. The primary transcript will contain the 5’exon, all other downstream 
5’ exons, as well as the four 3’exons.  Differential splicing then occurs, with the downstream 
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5’exons becoming intronic.  Each final UGT1A transcript possesses one 5’ exon sequence 
and the four 3’ exons.  Therefore, each UGT1A protein contains the same 245 carboxy 
terminal sequence (the four shared 3’ exons) and an isoform-specific N-terminal comprised 
of 280-289 amino acids (first 5’ exon) (Ritter et al., 1992; Owens and Ritter, 1995; Tukey 
and Strassburg, 2000).  Substrate binding occurs at the N-terminal region, whereas the co-
substrate UDP-glucuronic acid binds to the conserved region (Mackenzie, 1990).  Despite 13 
possible UGT1A isoforms that could exist due to the presence of 13 promoter regions and 13 
distinct exons 1, four encode UGT1A pseudogenes in humans.  The nine functional UGT1A 
proteins are:  UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, 
UGT1A9, and UGT1A10 (Guillemette, 2003).  The rat UGT1A locus is arranged and 
transcribed similarly, although there are only nine divergent first exons reported to date, and 
rat UGTs 1A4 and 1A9 are pseudogenes (Emi et al., 1995).  Like the UGT2B family, the 
UGT1A family is also highly homologous.  UGT1A7-10 are 93% homologous in the first 
exon, while UGT1A3 and 1A4 share 94% of the same amino acids (Tukey and Strassburg, 
2001; Guillemette, 2003).  A consequence of highly conserved protein sequences within the 
UGT1A family is the difficulty in generating specific antibodies to individual isoforms.  As 
UGT1A1 and 1A6 have the most unique amino acid sequences among the UGT1A isoforms, 
laboratory and commercially prepared antibodies are available to UGT1A1 and 1A6 (Tukey 
and Strassburg, 2001).  A UGT1A antibody, which recognizes all UGT1A isoforms and is 
generated against a sequence in the conserved C-terminal region, is also commonly used to 
assess UGT1A expression.   
 
 
 7
B.3. SUBSTRATES 
Due to the high level of homology between the UGT isoforms, there is 
understandably a broad overlap in substrate specificity.  Thus, there are very few isoform-
specific probe substrates that have been identified to date.  Investigators have used morphine 
(3’ glucuronide, UGT2B7), azidothymidine (UGT2B7), propofol (UGT1A9), flavopiridol 
(UGT1A9), serotonin (UGT1A6), naphthol (UGT1A6), bilirubin (UGT1A1) and estradiol (3’ 
glucuronide, UGT1A1) as probe substrates for the isoforms in parenthesis; however, most of 
these compounds are glucuronidated from a small to a substantial degree by other isoforms, 
(Bosma et al., 1994; Ramirez et al., 2002; Court et al., 2003; Krishnaswamy et al., 2003; 
Soars et al., 2004).  Elucidating the substrates of the UGTs has been made possible by the 
generation of cDNA-expressed cellular systems of individual isoforms.  UGT substrate 
specificity and or capacity has recently been attributed to two factors beyond enzyme-
substrate recognition:  the extent of UGT phosphorylation and the association of the UGTs 
into dimers or tetramers (Ouzzine et al., 2003; Basu et al., 2005). 
The UGT family recognizes numerous endogenous and exogenous compounds as 
substrates.  Major classes of endogenous compounds that are substrates for the UGTs include 
bile acids, steroids, thyroid hormones, and retinoic acids (Clarke and Burchell, 1994).  As a 
general rule in humans (albeit with several exceptions), the UGT2B family typically 
glucuronidates more endogenous substrates, whereas the UGT1A family normally 
glucuronidates more xenobiotics and exogenous compounds (Ethell et al., 2003).  UGTs are 
responsible for the conjugation reactions of more xenobiotics than any other conjugating 
enzyme, accounting for over a third of all conjugation reactions that occur (Evans and 
Relling, 1999).  There are multiple UGT substrates where high levels of unmetabolized or 
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unconjugated drug may lead to toxicity, thus glucuronidation rates may be important in 
modulating exposure and toxicity.  These include the analgesics acetaminophen (UGT1A1, 
1A6, 1A9 substrate) and morphine (multiple UGT1A and 2B7), the anti-cancer agents SN-38 
(UGT1A1, 1A7, 1A9) and etoposide (UGT1A1), the immunosuppressive drugs 
mycophenolic acid (MPA) (UGT1A8, 1A9), tacrolimus and cyclosporine (UGT2B7), the 
anti-convulsant valproic acid (UGT1A6, 1A9, and 2B7), the anti-diabetic troglitazone 
(UGT1A1, 1A8-10) and the tri-cyclic antidepressants imipramine and amitriptyline 
(UGT1A4) (Breyer-Pfaff et al., 1997; Court et al., 2001; Strassburg et al., 2001; Cummings 
et al., 2002; Gagne et al., 2002; Nakajima et al., 2002; Watanabe et al., 2002; Ethell et al., 
2003; Stone et al., 2003; Watanabe et al., 2003; Bernard and Guillemette, 2004).  Despite the 
potential for UGT substrates to be co-administered to humans, which may lead to drug 
interactions and toxicity, this rarely occurs.  Most UGT substrates have high Km values (a 
measure of affinity) and are glucuronidated by multiple UGT isoforms (Williams et al., 
2004). 
B.4. HEPATIC AND INTESTINAL GLUCURONIDATION 
Given the existence of unique promoter regions for each UGT1A exon, tissue-specific 
expression of the UGT1A isoforms was predicted to occur.  This has indeed been observed 
by a number of investigators (see Table 1.1).  Due to the lack of specific antibodies as 
discussed above, UGT isoform localization has been characterized by the presence or 
absence of its transcript mRNA, which may or may not reflect protein expression.  Certain 
isoforms are expressed exclusively in extra-hepatic tissues (UGT1A7, 1A8, and 1A10), while 
others are found in most organs of elimination (UGT1A1).  Little is known about why this 
occurs, however, several transcription factors have been found to play a role in the 
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constitutive expression of the UGTs in particular tissues.  A binding site for hepatocyte 
nuclear factor 4α in the UGT1A9 promoter seems crucial for 1A9 expression in the liver.  
The lack of such a binding site in the promoters of UGT1A7, 1A8, and 1A10 may be a factor 
in the absence of these isoforms from the liver (Barbier et al., 2005).  The intestinal 
expression of UGT1A8 and UGT1A10 (and to a certain degree 1A9) is thought to be 
governed by a transcription factor complex composed in part by hepatocyte nuclear factor 1, 
Sp1, and the caudal homeodomain 2 protein.  The latter transcription factor is expressed 
exclusively in the intestine (Gregory et al., 2004).  Regionality in the expression of the 
UGT1A family is also found in the rat (Table 1.2). 
Since the capacity of a tissue to glucuronidate a substrate depends on the UGT 
isoforms present in a tissue and their abundance, it is inevitable that tissue differences in 
catalytic activity will exist, despite overlapping substrate specificities of the UGT1A 
isoforms (Radominska-Pandya et al., 1999). It is generally noted that liver tissue possesses 
greater glucuronosyltransferase activity in comparison with the intestine or colon for a wide 
range of compounds, due in part, to greater hepatic UGT1A levels as measured through 
mRNA (Strassburg et al., 1998; Strassburg et al., 1999a). However, large differences in 
protein levels of the UGT1A family are not observed, and hepatic and extrahepatic tissues 
have been shown to have similar catalytic rates (normalized to the amount of tissue protein) 
for a number of substrates, including carcinogens, tertiary amines and steroids (Strassburg et 
al., 1999a; Strassburg et al., 2000).  Considering that intestinal and colonic UGTs may be 
exposed to high levels of orally administered substrates or glucuronides excreted into the bile 
and deconjugated by β-glucuronidase, their relative contribution to drug disposition may be 
greater than anticipated (Tukey et al., 2002).    
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The importance of intestinal UGTs towards modulating the bioavailability of substrates 
has been shown in early studies with substrates such as ethinyl estradiol, morphine, 1-
naphthol, and salicylamide (Goon and Klaassen, 1992).  By comparing arterial and portal 
vein concentrations in the rat, intestinal glucuronidation of an intravenous dose of 4-
methylumbelliferone accounted for 40% of the clearance of the drug (Mulder et al., 1984).  
Recently, it was estimated that intestinal glucuronidation accounted for up to two-thirds of 
the metabolism of the flavonoid apigenen in the perfused rat intestine, which would largely 
explain its poor bioavailability (Chen et al., 2003).  The idea of intestinal UGTs functioning 
as a barrier is further substantiated by their predominant location in the villi, the 
physiological region of the intestinal mucosa most likely to come in contact with foreign 
substances introduced into the body (Strassburg et al., 2000). 
B.5. ENTEROHEPATIC RECIRCULATION 
After oral administration of a UGT substrate, the aglycone can be glucuronidated in 
the intestine or absorbed as unconjugated drug.  In the liver, if the substrate is 
glucuronidated, it then may become a substrate for a canalicular transporter, namely by the 
organic anion transporter MRP2 (Gerk and Vore, 2002; Roberts et al., 2002).  MRP3, on the 
sinusoidal membrane, can also transport glucuronides from the hepatocyte into blood 
(Hirohashi et al., 1999; Gerk and Vore, 2002).  Glucuronides extruded into the bile can be 
subject to intestinal β-glucuronidase, a bacterial enzyme which cleaves the glucuronic acid 
resulting in the regeneration of the aglycone.  The aglycone can then be reabsorbed in a 
process termed enterohepatic recirculation (EHC).  This phenomenon may manifest in a 
characteristic plasma concentration versus time profile including one or more peaks in 
species with gallbladders (Roberts et al., 2002).  Compounds administered intravenously can 
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also undergo EHC.  Often, EHC can significantly enhance drug exposure, with this process 
accounting for 40% of the area under the concentration versus time curve (AUC) for MPA 
(Naderer et al., 2005).  Antibiotic therapy can eliminate the bacteria that produce β-
glucuronidase, introducing the potential for decreased efficacy of substrates like MPA and 
ethinylestradiol (Shenfield and Griffin, 1991; Naderer et al., 2005). 
B.6. VARIABILITY IN UGT EXPRESSION AND FUNCTION 
B.6.a. GENETIC POLYMORPHISMS OF UGTs 
Interindividual variability in glucuronidation rates can be conferred through 
polymorphic expression of the UGT isoforms.  Flavopiridol glucuronidation, catalyzed by 
UGT1A9 and 1A4, varied 12-fold in a sample of 62 liver microsomes (Ramirez et al., 2002).  
Fisher et al. (2000) found that glucuronidation rates for the probes morphine (2B7 substrate) 
and acetaminophen (1A6 and 1A9 substrate) varied 3 and 7-fold respectively, in a sample of 
microsomes prepared from 20 livers (Fisher et al., 2000).  When a probe for UGT1A1 was 
examined (estradiol), 30-fold variations in glucuronidation rates were observed, largely due 
to low rates in patients with Gilbert’s syndrome (Fisher et al., 2000).  Gilbert’s syndrome 
arises most often arises with an inherited extra TA repeat in the UGT1A1 promoter sequence 
(TA)6TAA to form (TA)7TAA (known as UGT1A1*28 allele).  Patients homozygous for 
(TA)7TAA typically glucuronidate bilirubin at rates that are approximately 30% of normal.  
Gilbert’s patients (those homozygous for UGT1A1*28) often will have elevated bilirubin 
levels, however, due to the large influence of environmental factors, a large number of 
patients will have no overt signs of the syndrome.  Thus, glucuronidation rates of drug 
substrates for UGT1A1 are often significantly lower in Gilbert’s patients, predisposing these 
patients to toxicities from elevated drug or bilirubin levels (Burchell and Hume, 1999).  
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Although a diagnosis of Gilbert’s syndrome necessitates homozygosity for increased TA 
repeats, patients heterozygous for a (TA)7TAA repeat may have higher bilirubin levels and 
lower glucuronidating capacity (Miners et al., 2002).  The incidence of the UGT1A1*28 
allele is anywhere from 7 to 55% of the population.  Racial differences in glucuronidation 
rates may also occur due to unequal distribution of the mutation throughout different 
populations.  One-fourth of the African population is found to be homozygous, whereas only 
3% of Asians have Gilbert’s syndrome (Burchell and Hume, 1999). 
Crigler-Najjar Type I and II are more rare and serious diseases that are associated 
with one or more of 30 mutations documented in either the promoter or exons 1-5 of the 
UGT1A1 gene.  Type I patients have no UGT1A1 activity and cannot survive without liver 
transplantation, whereas Type II patients possess about 10% activity toward bilirubin.  The 
hyperbilirubinemia observed in these patients is often treated with inducing agents such as 
phenobarbital (Ritter et al., 1999; Tukey and Strassburg, 2000).  An animal model of Crigler-
Najjar syndrome Type I, the Gunn rat, has led to a significant understanding of the role that 
UGTs play in homeostasis, drug disposition, and detoxification.  A mutant strain derived 
from the Wistar rat, the Gunn rat has no functional UGT1A protein, as a result of a single 
base pair deletion in exon four of the UGT1A gene.  These animals predictably have much of 
the same pathophysiology as human Crigler Najjar patients:  jaundice, low survival rates, and 
encephalopathy (Iyanagi et al., 1998).   
There is literature to support the presence of numerous polymorphisms or gene 
mutations in virtually all other UGT1A genes or promoters.  In most cases, after the mutation 
is discovered, a typical experimental approach is where cells expressing the mutated UGT are 
incubated with substrates for the isoform and glucuronidation rates are compared with those 
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from wild-type expressed enzyme.  Although a number of the mutations impart altered UGT 
activity in vitro, their functional significance in vivo is unclear.  For instance, a UGT1A7 
allele with three missense mutations (UGT1A7*3) glucuronidated SN-38 at a much lower 
efficiency relative to wild-type alleles, as evidenced by a 59% loss of activity (Gagne et al., 
2002).  However, patients with one or more UGT1A7*3 alleles were at no greater risk for 
developing toxicity when treated with SN-38 (Ando et al., 2002a).  The UGT1A7*3 allele 
has been shown to be strongly associated with the occurrence of lung, hepatic, and 
gastrointestinal tract cancer, although the basis for this is not understood, as UGT1A7 
appears to have limited distribution in vivo (Strassburg et al., 2002; Araki et al., 2005; Tseng 
et al., 2005).  Propofol and MPA glucuronidation rates in human microsomes were 
significantly higher in those containing two single nucleotide polymorphisms (T-275A and 
C-2152T ) in the promoter of UGT1A9 relative to those from wild-type individuals (Girard et 
al., 2004).  In renal transplant patients with these polymorphisms who received high-dose 
mycophenolate mofetil (the prodrug of MPA), exposure to MPA was lower as characterized 
by a lower area under the concentration curve (AUC), less MPA was estimated to undergo 
enterohepatic recirculation, and higher MPA clearance values were calculated.  These altered 
pharmacokinetic parameters could be responsible for graft rejection, or lower incidences of 
MPA adverse effects, including diarrhea and leukopenia, however these outcomes are 
unknown (Kuypers et al., 2005).  In contrast to the above examples where the incidence of 
UGT1A7*3, UGT1A1*28, and the UGT1A9 promoter mutations all have an allelic 
frequency of at least five percent, numerous polymorphisms reported in the literature are 
either isolated mutations found in a single subject or exist in a small fraction of the 
population (Saeki et al., 2005a; Saeki et al., 2005b).  Thus, small sample sizes preclude an in 
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vivo investigation of the effect of the genetic mutation.  The following are additional 
polymorphisms identified in a significant proportion of the population and that demonstrate 
alterations in in vitro glucuronidation activity of substrates tested:  UGT1A6*2 (higher 
activity versus wild-type, 30% allelic frequency), UGT1A3, 4 different amino acid changes 
(frequency of 5-13%, activity 70-370% of wild-type activity, and UGT1A8*3 (frequency of 
3%, lower activity) (Huang et al., 2002; Iwai et al., 2004; Krishnaswamy et al., 2005).  Other 
polymorphisms, such as UGT1A9*3 (4% allelic frequency) and UGT 1A4 L48V (16%), 
show altered conjugating ability for some substrates, while the glucuronidation of other 
aglycones are unaffected (Villeneuve et al., 2003; Mori et al., 2005). 
B.6.b. INDUCTION/INHIBITION OF UGTs 
Environmental exposures can also contribute to interindividual variability in 
glucuronidation rates, namely through induction or inhibition.  Compounds capable of 
induction are traditionally classified as belonging to either the monofunctional or 
bifunctional class of inducers.  Bifunctional inducers have been shown to upregulate both 
Phase I (i.e., cytochrome P450s) and II enzymes (i.e., conjugating enzymes, such as UGTs 
and glutathione-S transferases) through the aryl hydrocarbon receptor (Prochaska and 
Talalay, 1988).  These compounds include polyhalogenated arylhydrocarbons (PAHs) such 
as 3-methylcolanthrene, 2,3,7,8-tetrachlorodibenzo-p-dioxin, and β-napthoflavone.  
Monofunctional inducers, such as 1,7-phenanthroline, butylated hydroxyanisole, butylated 
hydroquinone, and the isothiocyanates more selectively stimulate the production of Phase II 
enzymes.  The precise mechanism for monofunctional induction is largely unknown, 
however, electrophilic stress is thought to trigger an intracellular phosphorylation cascade 
that results in nuclear transcription factors binding to UGT promoters and facilitates 
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transcription (Wasserman and Fahl, 1997; Rushmore and Kong, 2002).  There can be 
significant interplay between the monofunctional and bifunctional pathways.  For example, 
certain PAHs (such as β-napthoflavone) are metabolized to strong electrophiles, which might 
then activate the monofunctional pathway (Bock et al., 1998; Munzel et al., 1999).  Recent 
data has suggested that certain UGTs are also responsive to pregnane X receptor (UGT1A1), 
constitutive androstane receptor (UGT1A1), glucocorticoid receptor (UGT1A1) and 
peroxisome proliferator-activated receptor ligands (UGT1A1 and 1A9) (Sugatani et al., 2001; 
Barbier et al., 2003; Xie et al., 2003; Sugatani et al., 2005).  Numerous drugs, food additives, 
and environmental compounds have the ability to alter UGT expression which is anticipated, 
given the variety of mechanisms by which UGT1A1 protein can be upregulated. 
Inducers have been noted to elicit different effects on intestinal and hepatic 
glucuronidation, which may be a function of inducer exposure or isoform-specific regulation.  
For instance, van der Logt et al. (2003) treated rats orally with a series of anticarcinogenic 
compounds and assessed their effects on UGT expression.  Ellagic acid and brussel sprouts 
induced only hepatic UGTs; curcumin and tannic acid induced only intestinal UGTs; and 
coumarin and quercetin induced UGTs in both organs (Van Der Logt et al., 2003).  The 
inducibility of an isoform in a given tissue has also been noted to be inversely related to its 
constitutive expression (Munzel et al., 1994; Munzel et al., 1996).   
In vitro reactions have identified a number of UGT inhibitors, the coadministration of 
which may influence glucuronidation rates.  There are very few potent in vitro UGT 
inhibitors, however, vinorelbine, chrysin, tangeretin, and silybin are among a small number 
of compounds with inhibitor concentrations which elicit a 50% reduction in substrate 
turnover (IC50) values less than 10 μM as assessed in liver microsomes or expressed isoforms 
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(Said et al., 1992; Grancharov et al., 2001; Charasson et al., 2002; Williams et al., 2002; 
Sridar et al., 2004).  Coupled with the fact that most inhibitors have low systemic 
concentrations relative to their IC50 concentrations and the reasons given previously, there 
are very few clinically significant drug interactions with UGT inhibitors and substrates 
(Williams et al., 2004).  In vivo, valproic acid and indinavir have been shown to inhibit 
glucuronidation (Gupta et al., 1997b; Samara et al., 1997; Zucker et al., 2001).  Only with the 
latter compound was any phenotypic interaction observed.  Indinavir was shown to increase 
bilirubin levels relative to pretreatment values in patients, especially in patients hetero- or 
homozygous for UGT1A1*28 (Zucker et al., 2001). 
 
C. IRINOTECAN 
C.1. CLINICAL USES 
The anticancer agent irinotecan (or CPT-11) is approved in the US for use, either 
alone or with fluorouracil and leucovorin, in the treatment of metastatic colorectal cancer 
(Saltz et al., 2000).  Regimens containing irinotecan are not currently used as first-line 
therapy, since the combination of oxaliplatin, flurouracil, and leucovorin proved to be 
superior in terms of survival rates and side effect profiles (Goldberg et al., 2004).  
Nevertheless, irinotecan is used to treat thousands of cancer patients each year, as it is also 
being included in chemotherapy regimens for small cell and non-small cell lung cancer, 
refractory lymphoma, malignant gliomas, and gynecological cancers (Langer, 2003; Reardon 
et al., 2003).  In the most common colon cancer regimen, irinotecan is dosed at 125 mg/m2 to 
be given intravenously over 90 minutes once weekly for 4 weeks in 6 week cycles.  
Subsequent cycles are given based upon patient response and tolerability, with a 20-40% 
 17
reduction in dose for grade 3-4 adverse reactions (namely diarrhea, vomiting, or neutropenia) 
(Saltz et al., 2000). 
C.2. CHEMOTHERAPEUTIC ACTIVITY/METABOLISM 
Members of the camptothecin family, including irinotecan, function in the S-phase of 
the cell cycle, by forming a stable complex with DNA and topoisomerase I, an enzyme that 
relieves supercoiling strain through transient nicking of the template DNA, ahead of the 
DNA replication fork.  When the fork collides with the complex, cell division arrests.  The 
DNA breaks become irreversible and cell death then ensues through the apoptotic pathway 
(Rivory et al., 1997).  The cytotoxicity of irinotecan is achieved largely through its primary 
metabolite, SN-38, which is at least 100-fold more potent in inducing cell death in vitro.  
Irinotecan is administered as a prodrug for SN-38, as the latter compound cannot be directly 
administered to patients due to its poor aqueous solubility (Kawato et al., 1991).  SN-38 is 
formed by the metabolism of irinotecan by carboxylesterases in human liver, blood, 
intestinal, and tumor tissue (Khanna et al., 2000; Mathijssen et al., 2001).  SN-38 is then 
glucuronidated by UGT1A1, UGT1A7, and UGT1A9, with similar reported catalytic 
efficiencies, to form SN-38 glucuronide (SN-38G) (Gagne et al., 2002) (Figure 1.1).  
Cytochrome P-450 3A4 mediated metabolism of irinotecan does occur, resulting in the 
formation of two inactive metabolites, APC and NPC (Figure 1.2).  Roughly 11% of an 
irinotecan dose is accounted for as APC (Slatter et al., 2000).  This metabolite is not a potent 
topoisomerase inhibitor and is not metabolized further (Rivory et al., 1996).  NPC, 
accounting for 1.5% of an irinotecan dose in bodily fluid, is not an active metabolite, but is 
subject to esterase cleavage by carboxylesterases to form SN-38  (Dodds et al., 1998; Slatter 
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et al., 2000).  Irinotecan circulates through the body predominantly as unchanged drug, with 
55% of a dose being eliminated as irinotecan (Slatter et al., 2000). 
C.3. PHARMACOKINETICS 
Peak plasma concentrations of irinotecan typically occur at the end of a 90-minute 
infusion, and disposition then follows a two-compartment model.  The half-life of 
distribution is approximately 2 hours, and the elimination half-life varies, but averages 6-15 
hours.  Irinotecan extensively distributes to tissue, as demonstrated by the average 
distribution volume of 136 L/m2 in humans.   Irinotecan displays linear kinetics in adults over 
a wide range of doses (50-750 mg/m2), with a clearance value of roughly 430 mL/min.  Peak 
plasma levels of SN-38 occur approximately 30 minutes after those of irinotecan, and are 
roughly 60-100 fold lower than those of irinotecan on a molar basis.   Most studies have 
found that the half-life of SN-38 is longer than that of the parent, however, large differences 
in the measurement exist (reports of 7 to 29 hr).  SN-38G levels are highest approximately 
one hour after the infusion of irinotecan.  After an infusion, SN-38G levels are 3-7 fold 
higher than those of SN-38.  The half-life of SN-38G is reported to be 12-35 hours (de Forni 
et al., 1994; Gupta et al., 1997a; Rivory et al., 1997; Sparreboom et al., 1998b; Slatter et al., 
2000; Mathijssen et al., 2001).  Large interpatient variability in the glucuronidation of SN-38 
is frequently seen, as AUC ratios of SN-38G to SN-38 can vary 3 to 18-fold within treatment 
groups administered commonly used dosages of irinotecan (Rivory et al., 1997).  The 
disposition of irinotecan and its metabolites generally display similar trends in humans and 
rats, however the half-life of irinotecan is much shorter in rats at only 1.3 hours (Kaneda and 
Yokokura, 1990).  Although the half-life of SN-38 in rats is reported to be 2.8 hours after 
irinotecan administration, an intravenous dose of SN-38 to rats has a half-life of seven 
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minutes, indicating formation-rate limited kinetics of the metabolite (Atsumi et al., 1995).  
Plasma protein binding estimates are 92-99% for SN-38.  Irinotecan is mainly localized in 
erythrocytes with a blood to plasma typically greater than one, but is highly dependent upon 
concentration and subject smoking status (Mathijssen et al., 2001; Dumez et al., 2005).  
Irinotecan is protein bound in plasma at 30-65% (Mathijssen et al., 2001; Garcia-Carbonero 
and Supko, 2002; Dumez et al., 2005). 
Biliary secretion, and urinary and fecal excretion data for irinotecan and its 
metabolites are summarized in Table 1.3.  In humans, SN-38 has shown to be much less 
efficiently cleared into bile than its parent or glucuronide (Lokiec et al., 1995; Slatter et al., 
2000).  The high ratio of SN-38 to SN-38G in feces is likely due to β-glucuronidase activity 
in the colon, which cleaves SN-38G to SN-38.  The contribution of enterohepatic recycling 
(EHC) to the disposition of SN-38 is unclear.  Coadministration of antibiotics with irinotecan 
has no effect on SN-38 AUC (Kehrer et al., 2001).  In support of this study, intestinal β-
glucuronidase activity, which was found to vary one hundred fold between subjects, was not 
correlated to any SN-38 pharmacokinetic parameter (Kehrer et al., 2000).  Taken together, 
these results indicate that any SN-38 liberated via β-glucuronidase does not contribute 
appreciably to the systemic disposition of SN-38.  Further, almost no published studies show 
the characteristic multiple peak phenomenon linked to EHC for SN-38 (Mathijssen et al., 
2001).  However, in a study where a secondary SN-38 peak is apparent in some patients, 
EHC may contribute up to 12% to the total SN-38 AUC (Gupta et al., 1994).  Additionally, 
although the bioavailability for irinotecan is estimated to be just 12-25% after an oral dose, 
appreciable levels of SN-38 are detected in the plasma (Stewart et al., 1997; Stewart et al., 
2004).  Presumably, this is due to the relatively high concentrations of irinotecan achieved in 
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the intestine or portal circulation cleaved by esterases (Drengler et al., 1999; Soepenberg et 
al., 2005).  This same phenomenon may also occur after gall bladder contraction, facilitating 
a contribution to SN-38 EHC.  Furthermore, upon analyzing plasma samples 500 hours after 
an intravenous dose of irinotecan, SN-38 half-life and AUC were increased by two-fold 
compared with estimates from a more abbreviated sampling schedule.  A shorter sampling 
schedule may not capture the recirculation phase, which would manifest in a lower AUC and 
quicker half-life (Kehrer et al., 2000).  The presence of a secondary plasma concentration 
peak for irinotecan is noted in the plasma profiles of some studies, which can at least 
partially be explained by its uptake into erythrocytes after an intravenous infusion, followed 
by its rapid release (Mathijssen et al., 2001).   
C.4. LACTONE HYDROLYSIS/RECYCLIZATION OF IRINOTECAN/SN-38 
The lactone rings of all camptothecins, including irinotecan and its metabolites, can 
undergo a reversible pH-dependent hydrolysis to form a carboxylate group both in vitro and 
in vivo (lactone moieties shown in Figure 1.1).  The lactone and carboxylate may essentially 
be considered as two distinct compounds with only the lactone form of SN-38 active in 
binding to topoisomerase.  Additionally, the lactone and carboxylate forms express different 
affinities for transporters and exhibit differences in pharmacokinetics in animals and humans.  
The passive and overall uptake rate of SN-38 and irinotecan lactone into HT-29 cells was 
higher than the corresponding carboxylates, which were transported actively (Kobayashi et 
al., 1999).  In rats devoid of MRP2, SN-38 and irinotecan carboxylate biliary clearance 
values were reduced whereas lactone forms were unchanged, suggesting a role of MRP2 in 
the hepatic transport of the carboxylate forms only (Chu et al., 1997).  These differences in 
transport may stem from the fact that the lactone form of SN-38 is not charged at 
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physiological pH.  Additionally, the negative charge imparted by the carboxylate moiety of 
SN-38 and CPT-11 is typical of the substrates for MRP2. 
The in vitro half-life of SN-38 lactone (for conversion to the carboxylate) is 32 
minutes in Tris buffer at physiological pH, and at equilibrium the lactone represents 18% of 
total SN-38 concentrations (Chourpa et al., 1998).  After an infusion of irinotecan, irinotecan 
carboxylate becomes the predominate form in plasma, comprising 64% of the total AUC 
(Rivory et al., 1994).  This may be due to the above-mentioned pH-dependent conversion, 
but is also at least partially due to higher clearance of irinotecan lactone in humans (Xie et 
al., 2002b).  The higher clearance of irinotecan lactone may also contribute to the higher 
levels of SN-38 lactone, which comprises 63% of the total SN-38 AUC.  SN-38 plasma 
lactone levels range from 70% of total SN-38 equivalents at the end of the infusion to 50% in 
24 hours (Rivory et al., 1994).  Based upon in vitro measurements, this ratio would not be 
predicted, however, the preferential binding of SN-38 lactone to albumin stabilizes this form 
and modifies the equilibrium (Mathijssen et al., 2001; Garcia-Carbonero and Supko, 2002). 
C.5. TRANSPORT OF IRINOTECAN/SN-38 
As previously mentioned, transport of SN-38 and irinotecan carboxylate from the 
liver to the bile is mediated by MRP2.  As indicated by bile studies in MRP2 competent and 
deficient rats, the majority of SN-38 excreted in the bile is in the ionic, carboxylate form, and 
any SN-38 lactone that is excreted is not due to MRP2 (Chu et al., 1997).  Both SN-38G 
lactone and carboxylate are also predictably transported by MRP2 (Chu et al., 1997; 
Sugiyama et al., 1998).  For irinotecan carboxylate, MRP2 represents the low affinity 
transport pathway into bile, while the high affinity pathway is mediated through MDR1, or P-
gp (Chu et al., 1999a; Iyer et al., 2002).  SN-38 and its glucuronide are not substrates for P-
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gp, as demonstrated both in vitro and in mouse P-gp knockout biliary excretion studies (Chu 
et al., 1999b; Iyer et al., 2002).  Numerous in vitro studies have found that both SN-38 and 
SN-38G are substrates for the canalicular efflux transporter BCRP (Schellens et al., 2000; 
Nakatomi et al., 2001).  In mice in vivo, BCRP is found to modulate the bioavailability of 
irinotecan and systemic levels of SN-38, through the inhibition of intestinal BCRP (Stewart 
et al., 2004).  Currently, it is unknown whether MRP3 may transport SN-38G from the liver 
to the blood, however, it does not recognize SN-38 as a substrate (Cummings et al., 2004).  
The accumulation of irinotecan and SN-38 in cells transfected with the sinusoidal transporter 
MRP1 was dramatically decreased and imparted chemotherapeutic resistance to these cells, 
indicating a role for MRP1 in irinotecan and SN-38 transport (Chen et al., 1999).  SN-38G is 
also a substrate of MRP1, as shown by high uptake rates in the presence of ATP and 
membrane vesicles made from an MRP1 overexpressing cell line (Chu et al., 1999b).  The 
contribution of MRP1 to the systemic disposition to irinotecan or metabolites is unknown, 
since all data has been generated in in vitro studies.  Recently, another sinusoidal transporter, 
MRP4, has been shown to confer resistance to irinotecan and SN-38 in a cell line 
overexpressing this protein (Tian et al., 2005b). 
Little is known about active uptake with regards to irinotecan and metabolites.  
OATP-C facilitates the uptake of SN-38 into hepatocytes, but is not involved in the transport 
of SN-38G or irinotecan (Nozawa et al., 2005).  In intestinal cells isolated from hamsters, the 
lactone forms of SN-38 and irinotecan were taken up at a much faster rate when compared 
with the carboxylate forms.  The carboxylate forms also exhibited saturable uptake into these 
cells, indicating active uptake (Kobayashi et al., 1999).  Each transporter with affinity for 
irinotecan, SN-38, or SN-38G, with the exception of OATP-C, is also expressed in human 
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intestine (Tirona and Kim, 2002).  Thus, intestinal transporters also play a role in systemic 
disposition and enterocyte intracellular levels, which may influence therapeutic efficacy or 
toxicity. 
C.6. ADVERSE EFFECTS OF IRINOTECAN/SN-38 
The major dose-limiting toxicities of irinotecan are neutropenia and diarrhea (Iyer et 
al., 1998; Saliba et al., 1998).  Approximately 23-31% of treated patients experience severe 
grade 3-4 diarrhea, characterized by incontinence and/or greater than seven stools per day 
(grade 3) or life threatening systemic sequelae, such as hypotension or electrolyte 
disturbances (grade 4) (Saltz et al., 2000).  Pathophysiologically, irinotecan-induced diarrhea 
is mainly secretory, with exudative components.  Stools have increased weight and sodium 
content (secretory) yet also have increased levels of protein, resulting from a decrease in 
mucosal integrity (exudative) (Saliba et al., 1998).  The onset of diarrhea typically occurs on 
the 5th-12th day after therapy and lasts for 5-7 days.  Loperamide and octreotide are used to 
reduce diarrheal episodes, but are of mediocre efficacy (Barbounis et al., 2001).  Patients 
experiencing this toxicity will receive lower doses on any subsequent cycles, possibly 
compromising the full therapeutic potential of their anti-cancer regimen.  Accumulation of 
SN-38 in enterocytes is thought by most to be the causative agent behind the incidence of 
diarrhea (Araki et al., 1993; Iyer et al., 1998).   
C.6.a. PREDICTION OF ADVERSE EFFECTS 
Investigators have tried to elucidate predictive factors that might identify patients 
susceptible to irinotecan-induced diarrhea.  Early studies focused on pharmacokinetic 
indicators linked to toxicity, the most common modality of therapeutic drug monitoring.  
Several studies found a significant correlation between SN-38 AUC or maximal plasma 
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concentration (Cmax) with the incidence of diarrhea.  However, this is not a reliable finding, 
even in studies with similar administered doses and regimens (Kudoh et al., 1995; Sasaki et 
al., 1995a; Mathijssen et al., 2001; Xie et al., 2002a).  An early hypothesis was that low rates 
of hepatic glucuronidation may result in elevated bile concentrations of SN-38, leading to an 
increase of unconjugated SN-38 in the intestine, and thus increased toxicity.  To examine this 
hypothesis, Gupta et al. predicted a correlation of diarrhea with the ‘biliary index,’ defined as 
the ratio of SN-38 to SN-38G AUCs multiplied by the AUC of CPT-11.  In this study, 
patients with a higher ‘biliary index’ were more likely to experience diarrhea (Gupta et al., 
1994; Gupta et al., 1997a).  Another large study found that the ‘biliary index’ did not predict 
toxicity, albeit different CPT-11 regimens were administered (Xie et al., 2002a).  Using the 
‘biliary index’ to anticipate diarrhea may be potentially flawed on a physiological level.  
Since it has been consistently demonstrated that essentially no SN-38G is found in the feces 
with correspondingly high levels of SN-38 (Table 1.3), β-glucuronidase is efficient at 
cleaving SN-38G to SN-38.  Thus, patients with a high AUCSN-38G, and lower biliary index 
score, may still be expected to have high intestinal levels of SN-38 (Tukey et al., 2002).   
Patients having poor UGT expression, as might occur through polymorphisms in 
UGT1A1, 1A7, or 1A9, may predispose patients to intestinal toxicity due to relatively high 
levels of the aglycone, SN-38.  As previously mentioned, the presence of UGT1A7*3 or any 
other known 1A7 polymorphism does not seem to increase the likelihood for diarrhea, and in 
fact, may decrease the possibility (Ando et al., 2002a; Carlini et al., 2005).  The presence of 
one or two UGT1A9*22 alleles, a single nucleotide polymorphism (SNP) that confers a 
thymidine insertion into the UGT1A9 promoter, may protect patients from irinotecan-
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mediated toxicity.  This mutation is associated with greater gene transcription, but has not yet 
been shown to impart high SN-38 conjugation (Yamanaka et al., 2004; Carlini et al., 2005). 
 Mutations in the UGT1A1 gene have been explored and appear much more 
frequently to predict patients with toxicity.  Patients with UGT1A1*28 alleles typically have 
a lower AUCSN-38G/AUCSN-38 ratio, but the use of this ratio does not always correlate with 
toxicity (Gupta et al., 1994; Ando et al., 2002b; de Jong et al., 2005).  Nevertheless, 
significant differences in SN-38 glucuronidation rates in human liver microsomes between 
UGT1A1 genotypes were observed, such that patients hetero- and homozygous for 
UGT1A1*28 exhibited lower catalytic rates. Patients with 2 UGT1A1*28 alleles may have 
up to a 17-fold lower activity than a person with 2 wild-type alleles (Iyer et al., 1999).  With 
respect to gastrointestinal toxicity, in a study of 118 Japanese patients, those with at least one 
UGT1A1*28 allele were 7 times as likely to experience severe diarrhea and/or neutropenia 
(Ando et al., 2000).  Considerable differences in the occurrence of diarrhea that correlates 
with genotype was also substantiated in one additional trial with a large number of patients 
(Marcuello et al., 2004).  Numerous studies link the incidence of neutropenia to UGT1A1*28 
genotype (de Jong et al., 2005).  Due to the high correlation between neutropenia and 
UGT1A1*28, an FDA advisory panel has recommended changes to the package insert for 
irinotecan, recommending lower initial doses for patients homozygous for UGT1A1*28, and 
kits for widespread UGT1A1*28 genotyping have recently become commercially available 
(Invader®, UGT1A1 molecular assay, Third Wave Technologies).  Genotyping is necessary 
to determine patients with Gilbert’s syndrome, as baseline serum bilirubin levels do not 
always predict toxicity or the presence of mutant TATA box promoters (Meyerhardt et al., 
2004).  Recent work in limited clinical studies suggests that mutations in the UGT1A1 
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promoter may also predict toxicity independently or through high linkage disequilibrium 
with UGT1A1*28 (Innocenti et al., 2004a; Kitagawa et al., 2005).  Haplotype analysis of 
mutations within genes (i.e., UGT 1A1) or between genes (i.e., UGT1A1 and UGT1A9) is 
quickly introducing groups of mutations that may predict toxicity in patients treated with 
irinotecan (Sai et al., 2004; Innocenti et al., 2005).  Obviously, the analysis of thousands of 
possible gene permutations is difficult to sort out, and is only in its infancy. 
Although polymorphisms in transporters have not been linked to the incidence of 
adverse effects in patients treated with irinotecan, there are reports where transporter SNPs 
are associated with pharmacokinetic alterations.  These reports however, are not always 
consistent.  In an analysis of the effect of single SNPs on irinotecan pharmacokinetics, 
patients homozygous for the P-gp mutation 1236C>T were found to have higher irinotecan 
and SN-38 AUC values (Mathijssen et al., 2003).  The presence of this SNP, along with two 
other P-gp mutations in high linkage disequilibrium, was associated with a decrease in renal 
clearance of irinotecan and SN-38, but did not influence AUC values of these two 
compounds (Sai et al., 2003).  The presence of the 3972C>T variant in MRP2 in preliminary 
findings is reported to increase irinotecan and SN-38G AUCs (de Jong et al., 2005; Smith et 
al., 2006).  Although BCRP is thought to significantly mediate the transport of SN-38 and 
SN-38G within tumors, thus far, there have been no links to SNPs within the BCRP gene and 
the systemic disposition of irinotecan and its metabolites (de Jong et al., 2004). 
C.6.b. PREVENTION OF ADVERSE EFFECTS 
In addition to prediction of which patients will be susceptible to irinotecan 
gastrointestinal toxicity, a significant effort has been put forth to prevent it.  In doing so, 
investigators have uncovered mechanisms crucial to the disposition of irinotecan, SN-38, and 
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SN-38G.  Hypotheses put forth to prevent SN-38 mediated diarrhea with only preliminary 
data include the inhibition of cyclooxygenase-2 and intestinal carboxylesterases which can 
generate SN-38 from irinotecan at the site of toxicity (Trifan et al., 2002; Wadkins et al., 
2004). 
As a means to exploit the poor cytotoxicity profile and slow uptake of SN-38 
carboxylate into intestinal cells, it was hypothesized that by shifting the equilibrium in the 
intestine to predominantly the carboxylate form, diarrhea might be evaded (Kobayashi et al., 
1999).  This was accomplished by raising the intestinal pH by giving sodium bicarbonate in 
drinking water of both hamsters and humans (Takeda et al., 2001; Ikegami et al., 2002).  It is 
currently unknown whether this intervention altered either efficacy or the pharmacokinetic 
profiles of irinotecan, SN-38, or SN-38G. 
Little SN-38G is found in the feces relative to that found in bile, indicating a role for 
β-glucuronidase cleavage of the conjugate.  An inhibitor of β-glucuronidase, saccharic acid 
1,4-lactone, protected rats from pathological changes common in the intestine after irinotecan 
treatment (Fittkau et al., 2004).  By the administration of antiobitics that ameliorate the 
bacteria that form β-glucuronidase, intestinal toxicity was avoided, both in rats and humans 
(Takasuna et al., 1996; Kehrer et al., 2001).  Coupled with positive pharmacodynamic 
outcomes, antibiotics reduce the SN-38 AUC in the large intestine by 85%, indicating that β-
glucuronidase liberation of SN-38 is often sufficient to drive a patient from tolerating therapy 
to succumbing to its adverse effects (Takasuna et al., 1998).  However, whether such 
perturbations of EHC would extend to other drugs or endogenous bile acids is not clear. 
As a related hypothesis, Horikawa et al. (2002) sought to test whether or not 
inhibiting the primary biliary transport system of SN-38 and SN-38G would protect an 
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animal from gastrointestinal toxicity, as intraluminal concentrations of SN-38 would be 
reduced.  In this study, probenecid, an inhibitor of MRP2, was found to reduce the biliary 
clearance of irinotecan, SN-38, and SN-38G in rats after a 5 mg/kg dose of irinotecan given 
intravenously, which concomitantly reduced intestinal concentrations and diarrhea scores.  
As a result of this inhibition, plasma concentrations were higher, such that a reduced dose 
could be given in the presence of probenecid.  Because probenecid is a non-specific inhibitor 
of organic anion transporters that are also present in the kidney, renal clearance of SN-38 
also was reduced (Horikawa et al., 2002).  Although reduced biliary excretion of irinotecan 
and metabolites seems to protect against gastrointestinal toxicity, higher plasma levels of SN-
38 may predispose patients to neutropenia or alter SN-38 disposition in tumor tissues.   
Investigators from the University of Chicago have explored the coadministration of 
cyclosporine with irinotecan in humans to test a similar hypothesis to the one proposed 
previously, that only SN-38 excreted in the bile is responsible for gastrointestinal adverse 
effects and is independent of systemic SN-38.  Cyclosporine, as both an MRP2 and P-gp 
inhibitor, increased the AUC of SN-38 and irinotecan and appeared to have a low incidence 
of diarrhea in a small number of patients (Innocenti et al., 2004b; Desai et al., 2005).  
Phenobarbital, a UGT inducer found to reduce the SN-38 AUC in rodents, was then added to 
the regimen (Gupta et al., 1997b).  By doing so, it was hoped that inducing hepatic formation 
of SN-38G would reduce the amount of SN-38 available for biliary excretion, hence reducing 
the incidence of diarrhea.  The AUC of SN-38 was reduced in these patients, allowing an 
increase in the maximum tolerated dose, and the incidence of diarrhea was similar to or 
slightly less than historical controls.  However, the authors do not mention the potential for 
phenobarbital induction on intestinal UGTs and the possible protective consequences that 
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may have.  Also, as the SN-38G/SN-38 ratio is increased with phenobarbital treatment, the 
authors fail to recognize the importance of excreted SN-38G, in that this compound is the 
primary source for SN-38 in the intestine, which was shown directly in biliary excretion 
studies and in indirectly in those involving β-glucuronidase inhibition.  Since cyclosporine 
and phenobarbital also inhibit and induce transporters, respectively, it is suspected that if a 
protective effect of these drugs is observed in subsequent studies, it is likely due to a much 
more complex interplay than that simply stated by the authors’ hypotheses (Innocenti et al., 
2004b). 
In a recent publication, investigators gave chrysin, a UGT inducer with poor 
bioavailability, concomitantly with irinotecan to patients and evaluated the pharmacokinetics 
and tolerability of the chemotherapeutic against historical controls.  The pharmacokinetics of 
irinotecan and metabolites were unchanged with chrysin.  The incidence of diarrhea in the 
chrysin study was lower than the controls (10% versus 19%), albeit there were no Gilbert’s 
patients in the former study.  There was no critical data that came from this publication, 
although it is among the first to suggest that alterations in the SN-38G/SN-38 ratio via 
intestinal UGTs may be a prime factor in mediating diarrhea (Tobin et al., 2006).   
 The role of intestinal UGTs in mediating SN-38 toxicity has been demonstrated in 
vitro.  Kobayashi et al. (1999) reported that higher intracellular SN-38 concentrations 
resulted in a greater incidence of cell death in the HT-29 colon carcinoma cell line 
(Kobayashi et al., 1999).  In this same cell line, propofol, a UGT1A9 substrate was found to 
lower the IC50 of SN-38 in this UGT-expressing cell line.  In HCT-116 cells, which not do 
have any functional UGTs, propofol had no effect upon the SN-38 IC50 (Cummings et al., 
2003).  Although this manuscript does focus primarily upon glucuronidation as a resistance 
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mechanism in tumors, they do highlight that in the intestine, glucuronidation may have a role 
in modulating toxicity, as resistance and reduced toxicity both should result from lower 
intracellular SN-38 concentrations.   
 
D. RATIONALE AND OVERVIEW OF PROPOSED RESEARCH 
Currently, there is no pharmacokinetic or genetic indicator to predict or prevent 
diarrhea in susceptible patients.  Despite all of the research devoted to finding such a “magic 
bullet” to spare vulnerable patients, data from current clinical studies indicate that patients 
are still experiencing grade 3 or 4 diarrhea at rates upwards of 20% (Ziotopoulos et al., 
2005).  The change in dosing irinotecan to Gilbert’s patients discussed above comes in 
response to the data supporting the high incidence of neutropenia in these patients when 
treated with standard doses.  In fact, every voting member of the FDA Clinical Pharmacology 
Subcommittee responsible for recommending this dosage change agreed that there was not 
sufficient evidence linking the incidence of diarrhea in patients with Gilbert’s syndrome 
(Scharen, 2004).  The lack of a connection between diarrhea and the UGT1A1*28 genotype 
may be due to the following:  a patient with Gilbert’s syndrome will excrete less SN-38G due 
to inefficient production of this metabolite, but should excrete SN-38 at the same low rate as 
a person without Gilbert’s genotype.  This suggests that in a patient with wild-type UGT1A1 
alleles, more SN-38 will exist in the intestinal lumen than a patient with UGT1A1*28, as SN-
38G is efficiently cleaved in the intestine by β-glucuronidase.  Few dispute that direct 
enterocyte injury due to high intestinal levels of SN-38 is ultimately the preceding cause of 
toxicity, as demonstrated by studies with both β-glucuronidase and SN-38 biliary excretion 
inhibition, so patients with normal UGT1A1 genes may still get diarrhea.  However, 
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intestinal UGTs are presumably a local protective mechanism that can reduce the amount of 
intracellular SN-38, and may be a key factor to modulating toxicity.  This would explain why 
some patients with UGT1A1*28 ultimately get diarrhea, which is not due to a lack of hepatic 
glucuronidation, but because the intestine cannot effectively glucuronidate SN-38 through 
UGT1A1.  Diarrhea may be avoided in some Gilbert’s patients for a number of reasons, 
including higher intestinal expression of UGT1A1, or from the glucuronidation of SN-38 by 
other individual isoforms.  Since UGT1A9 catalyzes SN-38 glucuronidation at a similar rate 
to 1A1, high intestinal expression or the presence of common extensive-metabolizer 
polymorphisms such as T-275A and C-2152T in UGT1A9 may help spare patients from 
gastrointestinal toxicity.  These are all factors that are largely unknown, due to the limited 
availability of human intestinal tissue, or UGT isoform probe substrates and antibodies.  
Although proposed in the literature by Tukey et al. (2002), no publications have surfaced to 
address the contribution of intestinal UGTs to SN-38 gastrointestinal toxicity, which may be 
due in part to the difficulty in designing experiments to separate the contribution of intestinal 
UGTs from those of the liver in a toxicological model that takes days to develop (Tukey et 
al., 2002).  As discussed earlier, hepatic glucuronidation may not be a surrogate for, or highly 
correlated with, intestinal glucuronidation capacity, due to the presence of tissue-specific 
transcriptional proteins, differential isoform composition, levels of expression, and exposure 
to dietary and environmental compounds that can induce the expression of UGTs.  
Ultimately, the amount of residual intestinal UGT activity needed to prevent diarrhea is 
unknown, and avoiding diarrhea is likely a balance between the efficiency of UGT catalysis 
and intracellular levels of SN-38.  It is recognized that intracellular exposure of SN-38 
involves more than the UGTs, and the overall prediction of diarrhea is probably a 
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combination of all these factors, but one of the most important seems to be glucuronidation 
for the reasons outlined above. 
The major hypothesis governing the experiments in this thesis proposal is that 
intestinal UGTs are a critical factor in mediating SN-38 induced diarrhea.  In order for 
this hypothesis to be directly addressed, it is crucial to first investigate intestinal UGTs and 
whether this hypothesis is physiologically feasible through the following specific objectives: 
1. Identify differences in SN-38 lactone and carboxylate glucuronidation for 
hepatic and intestinal UGT isoforms.  Almost all data about isoform specificity and 
UGT catalysis is for the inactive carboxylate form of SN-38 due to its better 
solubility.  Should intestinal UGT isoforms preferentially glucuronidate the 
carboxylate form, these UGTs may do little in sparing the enterocyte from SN-38-
induced cytotoxicity.  Also, understanding the catalysis of specific isoforms will 
allow interpretation of in vitro data obtained with human and animal tissues, such as 
liver and intestine.  The following experiments were conducted to assess possible 
differences: 
(a) Establish a high performance liquid chromatography (HPLC) method for 
simultaneous detection of SN-38 lactone and carboxylate.   
(b) Determine rates of hydrolysis or lactonization for SN-38 lactone and 
carboxylate in the incubation mixtures. 
(c) Measure glucuronidation rates of each form with recombinant isoforms and 
microsomes with SN-38 lactone and carboxylate, using rates above in (b) to 
determine incubation time minimizing interconversion between the forms. 
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(d) Utilize pharmacokinetic modeling to recover glucuronidation rates of pure SN-
38 lactone and carboxylate. 
2. Assess the variability of SN-38 glucuronidation in the human intestine and 
correlate the glucuronidation with probe substrates of active UGT isoforms.  
Prior to substantiating the hypothesis that intestinal UGTs mediate SN-38 diarrhea, it 
is important to determine whether there was significant interpatient variability in the 
population with respect to intestinal SN-38G formation.  These studies are among the 
first to characterize intestinal UGT1A isoform expression: 
(a) Establish in vitro glucuronidation assays, HPLC, and liquid 
chromatography with mass spectrometry detection (LC-MS) methods for 
SN-38, and propofol (UGT1A9) probe. 
(b) Validate etoposide as a UGT1A1 probe and establish an in vitro 
glucuronidation assay and LC-MS method for etoposide-glucuronide 
detection. 
(c) Perform genotype analysis for highly polymorphic allele UGT1A1*28, 
which has been shown to modulate the pharmacokinetics of substrates and 
the incidence of SN-38-induced neutropenia.  The presence of this genotype 
could potentially explain high or low SN-38 glucuronidation rates. 
Finally, the hypothesis will be directly tested in Specific Objective #3: 
3. The gastrointestinal toxicity and pharmacokinetic profile of irinotecan, SN-38, 
and SN-38G will be compared in rats with and without intestinal UGT1As.  In 
order to evaluate the contribution of the intestinal UGTs to diarrhea, systemic 
exposure to these compounds must remain similar.  In order to do this, hepatic 
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glucuronidation will be restored in the Gunn rat through gene transfer of rat UGTs 
using an adenoviral vector.  The series of experiments to test the above stated 
hypothesis are as follows: 
(a) Establish a model for irinotecan gastrointestinal toxicity in the UGT-
transfected Gunn rat and compare it to the toxicity profile of a heterozygote 
Gunn/Wistar rat. 
(b) Determine the systemic disposition of irinotecan, SN-38, and SN-38G in 
both groups of rats. 
(c) Compare the in vitro expression and glucuronidation capacity of intestines 
and livers from UGT-transfected Gunn rats and the Gunn/Wistar 
heterozygotes. 
(d) Assess the intestinal exposure of irinotecan and metabolites through biliary 
excretion studies in both groups of rats. 
In addition to the above studies, preliminary experiments in the HT-29 colon 
carcinoma cell line are described in Chapter 5.  In these experiments, the co-incubation of 
SN-38 and piperine, a UGT inhibitor, was intended to predispose cells to SN-38-mediated 
apoptosis and cell death.  Finally, potential clinical implications, future studies, and the 
conclusions drawn from the research presented within this dissertation project will be 
addressed in Chapter 6. 
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Table 1.1  Localization of UGT1A mRNA in human tissues (Strassburg et al., 1997; 
Strassburg et al., 1998; Strassburg et al., 1999b; Strassburg et al., 2000). 
Enzyme Localization 
UGT1A1 Biliary and liver tissue, colon, most duodenal samples, a few jejunal and 
ileal samples 
UGT1A3 Liver, biliary, gastric, colon, most duodenal, jejunal, ileal samples 
UGT1A4 Liver, biliary, colon, most duodenal, jejunal, ileal samples 
UGT1A6 Liver, biliary, gastric, colon, most duodenal, ileal, and a few jejunal 
samples 
UGT1A7 Gastric, esophagus 
UGT1A8 Colon, esophagus 
UGT1A9 Liver, colon, esophagus 
UGT1A10 Biliary, gastric, colon, esophagus, duodenum, jejunum, ileum 
 
** UGT1A2, 1A11, and 1A12 are pseudogenes and do not encode functional proteins (Emi 
et al., 1995; Owens and Ritter, 1995). 
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Table 1.2  Localization of UGT1A mRNA in rat tissues (Emi et al., 1995; Grove et al., 1997; 
Grams et al., 2000; Shelby et al., 2003). 
Enzyme Localization 
UGT1A1 Liver, kidney, stomach, small and large intestine, brain, lung, testis 
UGT1A2 Small and large intestine, stomach 
UGT1A3 Small and large intestine 
UGT1A5 Liver 
UGT1A6 Small and large intestine, stomach, kidney, liver, lung, brain, esophagus 
UGT1A7 Small and large intestine, stomach, kidney, lung, spleen, ovary 
UGT1A8 Low expression in liver and kidney 
 
**Rat UGT1A4 and 1A9 are pseudogenes and do not encode functional proteins (Emi et al., 
1995).
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Table 1.3  Cumulative biliary, urinary, and fecal excretion in humans expressed as 
percentage of dose (Lokiec et al., 1995; Sparreboom et al., 1998b; Slatter et al., 2000).  
 Irinotecan SN-38 SN-38G Total 
Bile 3-22% 0.1-0.9% 1.2-3% 3.6-30% 
Urine 11-22% 0.1-0.4% 3-3.4% 21-30% 
Feces 15-32% 2.5-8.2% 0.3% 24-62% 
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Figure 1.1  Glucuronidation of SN-38 after carboxylesterase cleavage of irinotecan.  
UGT1A1, 1A7, and 1A9 facilitate the transfer of glucuronic acid from UDPGA to the 
substrate, generating the β-glucuronide of the substrate and uridine diphosphate (UDP).  The 
pH-labile lactone moiety is indicated with a (*) on irinotecan.  An equilibrium exists between 
the lactone form and its hydrolysis product, the carboxylate form, for all three compounds.
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Figure 1.2  Cytochrome P450 3A4-mediated metabolism of irinotecan.
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A. ABSTRACT 
SN-38, the active metabolite of the anti-cancer agent irinotecan, contains a lactone 
ring that equilibrates with a carboxylate form.  Since SN-38 lactone is the active and toxic 
form, it is prudent to examine whether the more soluble carboxylate is a surrogate for SN-38 
lactone conjugation.  Therefore, relative rates of glucuronidation and isoform specificity of 
SN-38 lactone and carboxylate were characterized.  The stability of SN-38 lactone and 
carboxylate in incubation mixtures of microsomes and UGT isoforms was used to determine 
optimal incubation times. Microsomal incubations were conducted using rat and human 
intestinal and hepatic microsomes and human and rat recombinant UGT 1A isoforms.  Where 
estimates of lactone and carboxylate glucuronidation rates could not be established due to 
short incubation times and detection limits, kinetic modeling was used to recover these rate 
constants. The stability experiments revealed that the lactone was stabilized by rat 
microsomes, however, the opposite was observed in human microsomes and recombinant 
isoforms. For all tissues and most UGT isoforms examined, the lactone consistently had 
catalytic rates up to 6-fold greater than the carboxylate. The rank order of glucuronidation for 
both SN-38 lactone and carboxylate was 1A7 > 1A1 > 1A9 > 1A8 and 1A7> 1A8 > 1A1 for 
human and rat isoforms, respectively.  This study provides further support that SN-38 lactone 
and carboxylate may be considered pharmacokinetically distinct agents. The in vivo impact 
of this conjugation difference is unknown, since variations in protein binding and transport 
proteins may affect intracellular concentrations of the lactone or carboxylate.  
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B. INTRODUCTION 
The topoisomerase-I inhibitor, irinotecan (manufactured as irinotecan hydrochloride 
trihydrate [Camptosar®, Pfizer Inc.]), in combination with fluorouracil and leucovorin is 
approved in the treatment of metastatic colorectal cancer.  Irinotecan is increasingly being 
utilized in chemotherapy regimens for many other malignancies, including pancreatic and 
lung cancers (Rothenberg, 2001).  The cytotoxicity of irinotecan is achieved largely through 
a metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), which is at least 100-fold more 
potent in inducing cell death in vitro (Kawato et al., 1991).  Irinotecan is a prodrug, as SN-38 
is not directly administered to patients due to its poor aqueous solubility and unacceptable 
toxicity (Rajkumar and Adjei, 1998).  SN-38 is formed by the metabolism of irinotecan by 
carboxylesterases in various tissues (Khanna et al., 2000; Mathijssen et al., 2001).  SN-38 is 
then glucuronidated by UDP-glucuronosyltransferase (UGT) 1A1, UGT1A7, and UGT1A9, 
with similar reported catalytic efficiencies, to form SN-38 glucuronide (SN-38G) (Gagne et 
al., 2002) (Figure 2.1). 
The lactone ring of SN-38, like all camptothecin derivatives, can undergo reversible, 
pH-dependent hydrolysis to yield the corresponding carboxylate (Figure 2.1).  The 
equilibrium favors the poorly soluble lactone form at lower pH values, and at neutral and 
basic pH values, the more soluble carboxylate form predominants.  Both forms exist 
considerably in vivo, with the lactone accounting for 54-64% of the total SN-38 area under 
the plasma concentration versus time curve (Rivory et al., 1994; Sasaki et al., 1995b).  The 
lactone and carboxylate are considered two pharmacologically distinct compounds, as the 
intact lactone is necessary for topoisomerase binding and carboxylate is only weakly 
cytotoxic (Hertzberg et al., 1990).  Additionally, SN-38 lactone and carboxlyate possess 
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different affinities for transporters and exhibit differences in pharmacokinetics in animals and 
humans.  In EHBR rats (rats deficient in MRP2), SN-38 carboxylate biliary clearance was 
reduced whereas for the lactone form it was unchanged, suggesting a role of mrp2 in the 
hepatic transport of only the carboxylate (Chu et al., 1997).  SN-38 lactone has a greater 
volume of distribution and binds more tightly to albumin when compared with SN-38 
carboxylate (Burke and Mi, 1993; Kaneda et al., 1997; Xie et al., 2002b).  An intact lactone 
may also be favored for substrate-enzyme binding or catalysis, as irinotecan lactone is 
metabolized to SN-38 at a greater rate than irinotecan carboxylate (Haaz et al., 1997b).  It is 
unknown whether or not this phenomenon occurs for SN-38 with the UGTs, and there is 
contradictory data suggesting metabolic differences between SN-38 lactone and carboxylate.  
Haaz et al. (1997a) assessed rates of lactone and carboxylate glucuronidation from a 15 
minute microsomal incubation of SN-38 in human liver microsomes.  The authors estimated 
that by 15 minutes, 70% of the lactone form was hydrolyzed to the carboxylate, and no 
significant differences in glucuronidation were noted.  However, it did appear that the lactone 
form was metabolized more quickly (Haaz et al., 1997a).  SN-38 lactone administered by 
intravenous bolus to rats was cleared 2-fold faster by metabolism and excretion when 
compared with administration of SN-38 carboxylate (Kaneda et al., 1997).  In contrast, a 
population pharmacokinetic study in humans predicted via extensive modeling that SN-38 
lactone and carboxylate had similar total clearance values (Xie et al., 2002b).   
The purpose of these studies was to assess whether SN-38 lactone and carboxylate are 
glucuronidated by human and rat tissues and recombinant isoforms at different rates and 
whether the lactone and carboxylate differed in their specificity for individual UGT isoforms.  
Deciphering the latter is important, as the more soluble carboxylate is often used as a 
 60
surrogate for the active lactone form in microsomal metabolism studies (Ciotti et al., 1999; 
Hanioka et al., 2001a; Hanioka et al., 2001b; Gagne et al., 2002).  Knowledge of differences 
in glucuronidation rates or isoform specificity between SN-38 lactone and carboxylate may 
be instrumental in understanding cellular toxicity or resistance to the chemotherapeutic agent. 
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C. MATERIALS AND METHODS 
Chemicals and reagents.  Irinotecan and SN-38G methyl ester were a gift from Dr. Robert 
Kelly at Pfizer (Kalamazoo, MI), previously Pharmacia.  SN-38 was cleaved from irinotecan 
by hydrolysis with base according to a procedure provided by Dr. Kelly.  The purity of SN-
38 obtained was confirmed by high performance liquid chromatography (HPLC) with UV 
detection and by liquid chromatography-mass spectrometry.  SN-38G methyl ester was also 
hydrolyzed by base to produce SN-38G.  The concentration of SN-38G diluted in methanol 
was determined by β-glucuronidase treatment and the resultant SN-38 generated was 
analyzed by HPLC using SN-38 standards.  Chemicals used in the microsomal preparations 
and reactions were purchased from Sigma-Aldrich (St. Louis, MO).  All other chemicals and 
solvents used were of reagent grade and obtained through commercial vendors. 
Microsome and recombinant isoform preparation.  Human recombinant UGT isoforms 
and human liver microsomes were obtained commercially from Gentest (Woburn, MA).  
Human intestinal microsomes were purchased from Xenotech LLC (Lenexa, KS).  Rat 
recombinant UGT isoforms were prepared from HEK cell membranes as previously 
described (Kessler et al., 2002).  Rat hepatic and intestinal microsomes were prepared and 
pooled from four male Sprague-Dawley rats, weighing 250 g (Charles River, Raleigh, NC).  
Mucosal scrapings of the enterocytes or portions of the liver were subject to homogenization 
in 250 mM sucrose with ethylenediaminetetraacetic acid (1mM), dithiothreitol (0.1mM), and 
phenylmethylsulfonyl fluoride (PMSF) (0.25mM) and centrifuged at 10,000g x20 min.  The 
supernatant was then spun at 100,000g x1 hr.  The resulting pellet was reconstituted in 250 
mM sucrose containing PMSF (0.25 mM) and leupeptin (10 mM).  Protein concentrations 
were determined by the Bradford method, using albumin as a standard. 
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HPLC Analysis.  The HPLC method to analyze SN-38 and SN-38G was modified from a 
published method (Sparreboom et al., 1998a).  The HPLC system consisted of an isocratic 
pump (LC-600, Shimazdu, Tokyo, Japan), autosampler (AS-100; Biorad, Hercules, CA), and 
fluorescence detector (HP1046A, Hewlett Packard, Palo Alto, CA). A Hypersil BDS C-18 
column (5 uM, 150x4.6 mm) was used to separate analytes (Thermo Hypersil, Woodstock, 
GA).  For the SN-38G glucuronidation assay, the mobile phase consisted of methanol: 
tetrabutylammonium sulfate (10mM) and ammonium acetate (100 mM), pH 4.9 (37%: 63%).   
For the purposes of quantitating SN-38G in microsomal reactions, 200-300 μL microsomal 
aliquots were precipitated with acetonitirile (800 μL) containing irinotecan (70 ng) as internal 
standard and perchloric acid (5%, 5 μL).  SN-38 (30 μg) was added to prevent adsorption of 
irinotecan and SN-38G to the reaction tubes.  The acetonitrile was evaporated under a stream 
of nitrogen.  The residue was then reconstituted in 120 μL weak mobile phase, pH 4.9 (30% 
methanol).  The pH of this solution ensures that all SN-38G is in the lactone form.  SN-38G 
was detected by fluorescence using excitation and emission wavelengths of 229 and 420 nm, 
respectively, which provided optimal sensitivity for SN-38G, but not SN-38.  The 
chromatographic separation of SN-38G (3.5 minute retention time), irinotecan (5 minutes), 
and SN-38 (17 minutes) is shown in Figure 2.2.  Standard curves for SN-38G were linear 
between 1 ng/mL - 1000 ng/mL.   
When assessing SN-38 lactone and carboxylate stability, the mobile phase pH was 
not adjusted, and a pH of approximately 5.6 was employed.  Also, to elute SN-38 carboxylate 
and lactone more quickly, the mobile phase strength was increased to 42% methanol.  SN-38 
lactone and carboxylate were detected using optimized excitation and emission wavelengths 
of 229 and 543 nm, respectively.  Under these conditions, the retention times were 
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approximately 3.0 and 6.0 minutes for the carboxylate and lactone, respectively.  To assess 
whether a similar response was obtained when SN-38 carboxlyate and lactone were injected 
onto the HPLC in equal amounts, the relative response ratio was determined.  Aliquots (20 
µL) from three separate solutions of SN-38 carboxylate and lactone (5 µM) were analyzed 
and SN-38 lactone consistently had a 1.78-fold greater response than the carboxylate.  
Therefore, when relating the peak areas of SN-38 lactone to carboxylate and vice versa in 
assessing their stability, the area of the carboxylate was multiplied by 1.78 to account for the 
lower fluorescence response. 
Stability Studies.  Solutions of SN-38 lactone and carboxylate were made by dissolving SN-
38 in DMSO/ 0.1M sodium acetate (50:50, pH 4.5) and  DMSO/ 1 x 10-5 M sodium 
hydroxide (50:50, pH 9.5), respectively, and incubated for 24 hours at 37°C.  This procedure 
produced lactone or carboxylate, respectively, at approximately 99% content, as verified by 
HPLC.  SN-38 lactone or carboxylate (5 μM, final concentration in solution) was added to 
either buffer or the reaction mixture containing recombinant isoforms or microsomes 
described below at 37°C without uridine diphosphate glucuronic acid (UDPGA).  At various 
times, 20 μL of the buffer or incubation mixture was directly injected onto HPLC.  First-
order rate constants for conversion (kL→C or kC→L) were generated by using non-linear 
regression analysis software (Winnonlin, Pharsight; Palo Alto, CA).  These rate constants 
were used to determine the length of incubation where <5% conversion from the lactone to 
carboxylate (and vice versa) occurred or were used as constants in kinetic modeling.   
Microsomal Reaction Conditions.  Incubation mixtures contained Brij 35 (0.5 mg/mg 
protein), D-Saccharic acid 1,4-lactone (10mM), magnesium chloride (10 mM), UDPGA (2 
mM), and microsomal or recombinant protein (0.1 mg/mL for human recombinant UGTs, 
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0.25 mg/mL for rat recombinant UGTs, or 0.5 mg/mL for human and rat hepatic and 
intestinal microsomes) in a final volume of 500-1600 μL of 0.1M Tris, pH 7.0.  The protein 
concentrations for each matrix were fixed and used previously to determine the stability of 
SN-38 lactone and carboxylate.  The reaction was initiated by spiking in SN-38 lactone or 
carboxylate (5 μM, final concentration in solution), and terminated at times predetermined by 
the stability studies to minimize lactone and carboxylate interconversion (<5%).  The 
concentration of dimethyl sulfoxide in the incubation was 1%.For incubations where 
quantitation of SN-38G from relatively pure SN-38 lactone or carboxylate was not possible 
due to rapid conversion, SN-38G concentrations from at least five time points from 5-60 
minutes were analyzed to allow glucuronidation rate constants for SN-38 lactone and 
carboxylate to be recovered from kinetic modeling. 
Kinetic Modeling.  Compartmental modeling using Winnonlin provided estimates of the 
glucuronidation rate constants of SN-38 lactone and carboxylate by various microsomes and 
isoforms.  Data used in this model (Figure 2.3) to generate the glucuronidation rate constants, 
kgluc, lactone and kgluc, carboxylate, was expressed as cumulative formation of SN-38G over time.  
Both SN-38 lactone and carboxylate are depicted to form SN-38 lactone due to the acidified 
solution injected onto the HPLC, which converts any SN-38G carboxylate to SN-38G lactone 
(see HPLC analysis under MATERIALS AND METHODS).  Simultaneous modeling of the 
cumulative SN-38G formed when the carboxylate and lactone were spiked (Xo, carboxylate or Xo, 
lactone) in separate experiments allowed the rate constants to be recovered. Interconversion rate 
constants between SN-38 lactone and carboxylate (kL→C or kC→L) found in the stability 
studies were held as constants.  Initial iterative values for the glucuronidation rate constants 
were set as the slope of the percent of SN-38 remaining versus time.  An assumption was 
 65
made that glucuronidation proceeded under non-saturable conditions.  It was also assumed 
that the initial conversion rates found in the stability studies were uni-directional conversion 
rates, since the stability profiles (Figure 2.4) were log-linear, reflective of a first-order 
process. 
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D. RESULTS 
The stability of SN-38 lactone and carboxylate in various buffers is shown in Figure 
2.4.  The experimentally-derived rate constants were similar to what was expected and 
previously reported, as the half-life of SN-38 lactone at pH 7.0 and 37°C is 95 minutes 
versus 96 minutes as calculated from rate constants published by Akimoto et al (1994).  
These values were also in rough agreement with Chorupa et al (1998), who reported a half –
life of approximately 32 minutes at a higher pH (7.3), were lactonolysis is increasingly 
favored (Akimoto et al., 1994; Chourpa et al., 1998).Consistently,  the lactone remained 
intact at low pH values, and the carboxylate was more stable in neutral and basic aqueous 
buffers.  These findings gave confidence that the HPLC method used to determine the first-
order rate constants for hydrolysis and lactonization in microsomes and recombinant 
isoforms was accurate with no conversion on the column during the analysis (Table 2.1).  
The stability of SN-38 lactone and carboxylate was initially assessed in buffers with 
recombinant human UGT1A1 and 1A8, with virtually identical hydrolysis and lactonization 
rates.  Therefore, these values were employed for these and other human UGT isoforms.  The 
same was observed for recombinant rat UGT1A1, 1A8, and 2B2.  The data in Table 2.1 
indicate that hydrolysis (i.e. kL→C) is facilitated by the addition of human microsomes or 
human or rat recombinant isoforms to Tris buffer.  Conversely, the presence of rat 
microsomes stabilized the lactone moiety.  SN-38 carboxylate was cyclized to the lactone 
(i.e. kC→L) at a faster rate in rat microsomes relative to Tris buffer.  However, both SN-38 
lactone and carboxylate were sufficiently stable in rat hepatic and intestinal microsomes to 
allow SN-38G quantitation from a microsomal reaction with little conversion to the other 
form (less than 3%).   
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Once the stability of the lactone/carboxylate forms was established, catalytic rates of 
formation of SN-38G from each form was estimated in vitro with the presence of UDPGA.  
In both rat intestinal and hepatic microsomes, SN-38 lactone was glucuronidated more 
quickly compared with the carboxylate (Table 2.2), where these reactions could be conducted 
in 6.0-15.3 minutes with insignificant conversion to the carboxylate (<2.5%).  However, a 
1.5 minute or less reaction time would have been required to estimate such values for the 
lactone in human microsomes and recombinant isoforms due to rapid hydrolysis in these 
matrices (Table 2.1).  Since these constraints were experimentally unfeasible for the lactone, 
kinetic modeling was used to recover glucuronidation rates for SN-38 carboxylate and 
lactone in human microsomes and human and rat recombinant isoforms (Figure 2.5 and 
Table 2.3).  Although glucuronidation rates (nmol/min/mg protein) could be recovered for 
pure carboxylate without modeling, modeling was used so that a comparison could be made 
between SN-38 lactone and carboxylate by using first-order glucuronidation rate constants.  
SN-38 lactone and carboxylate had glucuronidation rates in the same rank order, with 
UGT1A7 being the most active, followed by UGT1A1, 1A9, and 1A8.  Barely quantifiable 
levels of SN-38G were produced with UGT1A6 and UGT1A10 at 60 minutes, and UGTs 
1A3, 1A4, 2B4, 2B7, 2B15, and 2B17 were inactive towards both forms of SN-38.  Rat 
UGT1A7 glucuronidated SN-38 carboxylate and lactone at the fastest rate, with rat UGT1A8 
and 1A1 also having activity.  Rat UGT1A2, 1A3, 1A5, 1A6, 2B2, 2B3, and 2B18 did not 
glucuronidate SN-38.  Virtually every isoform or tissue that had measurable catalysis 
glucuronidated SN-38 lactone at a greater rate compared to the carboxylate.  This difference 
was typically a 3.6-fold increase in glucuronidation, however, up to a 6-fold difference was 
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observed with UGT1A1.  UGT1A8 was the lone exception, with the carboxylate being 
metabolized approximately twice as quickly compared to the lactone. 
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E. DISCUSSION 
 It is well established that SN-38 lactone and carboxylate exhibit pharmacodynamic 
and pharmacokinetic differences.  Here, we have verified that these differences also extend to 
rates of glucuronidation.  For all the rat and human isoforms that appreciably catalyze SN-
38G formation, the lactone is almost always conjugated at a faster rate compared to the 
carboxylate.  The faster SN-38 lactone turnover relative to the carboxylate by individual 
isoforms should translate into higher glucuronidation rates for the lactone by tissues, which 
was found for microsomes prepared from human and rat liver and intestine.  A potential 
explanation for this difference may be an increased ability of the lactone to gain access to the 
catalytic site of the UGT in the relatively lipophilic environment of the microsome.  
Although a detergent (Brij 35) was used to expose the active site, the carboxylate may still 
not partition well due to its negative charge.  It is likely that in vivo, the lactone would more 
easily access the active site of the UGT if passive processes are operative, as the enzyme 
exists in the inner lumen of the endoplasmic reticulum (Yokota et al., 1992; Meech and 
Mackenzie, 1997).  Alternatively, the UGTs may simply preferentially recognize and have a 
higher binding affinity (discussed below) for the intact SN-38 lactone compared to the acid 
functional group. 
The extrahepatic isoform UGT1A8 does metabolize SN-38 carboxylate faster than the 
lactone.  An in vivo effect of this unusual behavior is not likely, as the rate of glucuronidation 
by this isoform is approximately 150, 40, and 4 fold less than UGT1A7, 1A1, and 1A9 
respectively (Table 2.2).  It is possible that a preference for SN-38 carboxylate conjugation 
may be observed in tissues where UGT1A8 is highly expressed compared to UGT 1A7, 1A1, 
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and 1A9.  1A8 has not been reported to be in the liver and small intestine but is found in the 
colon and esophagus (Strassburg et al., 1998). 
Although intrinsic clearance determinations may be a more relevant in vivo value to 
obtain compared with a velocity at a certain concentration, the latter approach was used to 
rank active isoforms and compare the efficiency of lactone and carboxylate glucuronidation 
since solubility limitations of SN-38 lactone preclude estimation of Michaelis-Menten 
enzyme kinetics.  The solubility of SN-38 lactone in aqueous buffers published by Zhang et 
al. (2004) is approximately 18 μM (7.2 μg/mL), which is a value similar to that obtained in 
our laboratory.  Michaelis-Menten studies were initially conducted using SN-38 lactone and 
did yield the characteristic concentration versus velocity curve, and the apparent Vmax was 
obtained at approximately the solubility limit (data not shown).  Therefore, it is not clear 
whether a true Vmax was reached or that the plateau was due to solubility.  For this reason, 
we conducted studies at 5 μM, a concentration at which both SN-38 lactone and carboxylate 
are soluble and does not saturate the enzyme (Haaz et al., 1997a) (data not shown).  
Elucidation of a Km for SN-38 in various tissues and UGT isoforms was not attempted in 
this study due to the solubility limitations of the lactone as previously discussed.  Although 
Km values are helpful for in vitro-in vivo predictions, knowledge of these values for SN-38 
lactone or carboxylate in tissues or UGT isoforms would not be expected to be helpful.  Peak 
plasma concentrations of SN-38 are in the nanomolar range after a standard irinotecan dose, 
which is significantly below any literature-reported Km in the micromolar range (Haaz et al., 
1997a; Hanioka et al., 2001b; Gagne et al., 2002).  Hence, the rank-order of active isoforms 
and the relative differences observed between SN-38 lactone and carboxylate that are 
reported here should mimic the true in vivo situation.  Since SN-38 concentrations in vivo and 
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in the experiments presented here are below the Km, Michaelis-Menten kinetics are operative 
and the rates of glucuronidation both in vivo and in vitro are proportional to SN-38 
concentrations. 
 The results of this study substantiate those of previous publications identifying 
UGT1A7, 1A1, and 1A9 as having the highest relative glucuronidation activity towards SN-
38 (Ciotti et al., 1999; Hanioka et al., 2001b; Gagne et al., 2002).  In these studies, either the 
authors state that SN-38 carboxylate was utilized as the substrate (Hanioka et al., 2001b), or 
the upper concentrations of SN-38 used in the microsomal reactions implies that the 
carboxylate was used due to solubility limitations with the lactone form, allowing a larger 
concentration range over which to conduct Km and Vmax studies (Ciotti et al., 1999; Gagne 
et al., 2002).  Should SN-38 lactone and carboxylate be preferentially glucuronidated by 
different UGT isoforms, SN-38 carboxylate would not be a suitable surrogate for assessing 
the glucuronidation profiles of the more cytotoxic lactone form.  From this study, it is clear 
that investigators may continue to compare relative glucuronidation patterns of cells and 
tissues using SN-38 carboxylate in in vitro reactions.  However, investigators should not rely 
upon Vmax and intrinsic clearance values generated for SN-38 carboxylate, as they may 
underestimate the true values for the active species, the lactone. 
Interestingly, rat intestinal and hepatic microsomes were the only matrices in which 
the lactone was relatively stable to hydrolysis, and were the only matrices prepared with the 
protease inhibitors PMSF and leupeptin.  It was then theorized that proteases in the 
recombinant isoforms and human microsomes were catalyzing SN-38 lactonolysis.  To test 
this theory, human hepatic microsomes were treated with PMSF and leupeptin in 
concentrations equal to that in rat microsomes prior to the stability study with SN-38 lactone.  
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The addition of these protease inhibitors did not have an effect on the conversion rate of SN-
38 lactone to carboxylate (data not shown).  Therefore, it is unknown why lactonolysis 
proceeds so rapidly in recombinant isoforms and human microsomes compared with rat 
microsomes or buffer alone. 
The in vivo impact of the differential catalysis of SN-38 lactone and carboxylate is 
unknown.  The predominance of SN-38 lactone observed in the plasma of patients may not 
be observed intracellularly at the site of action, if SN-38 lactone is more rapidly 
glucuronidated.  Since cellular damage is presumably mediated by intracellular SN-38 
lactone, one might propose that reducing intracellular levels of SN-38 lactone by 
glucuronidation may increase tumor resistance or reduce the toxicity profile of 
irinotecan/SN-38 (Gupta et al., 1994; Tukey et al., 2002).  Although glucuronidation may 
reduce SN-38 lactone relative to carboxylate, other factors may exist that would impact 
intracellular levels, such as pH or differential protein binding, uptake or efflux.  
To summarize, SN-38 lactone and carboxylate are glucuronidated in the same rank 
order by both rat and human UGT1A isoforms.  However, the lactone was almost 
consistently glucuronidated at a faster rate by these isoforms, which translated into faster 
overall catalysis of SN-38 lactone in rat and human hepatic and intestinal microsomes.  Due 
to the solubility limitations of SN-38 lactone, investigators are unable to elucidate Km values 
for this form in various matrices.  Therefore, utilizing SN-38 carboxylate as a more soluble 
surrogate will allow investigators to obtain an in vitro Km, Vmax, and intrinsic clearance.  
However, these values should be cautiously interpreted, as the Vmax is likely to be 
underestimated and the Km values for the two forms are not necessarily equivalent. 
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Table 2.1  First-order rate constants for lactonization and hydrolysis of SN-38 carboxylate 
and lactone, respectively, in Tris buffer and biological matrices/Tris buffer at 37°C, pH 7.0.  
Incubations contained 0.5 mg protein/mL for human and rat hepatic and intestinal 
microsomes, 0.1 mg/mL for human recombinant UGTs, and 0.25 mg/mL for rat recombinant 
UGTs and were conducted without cofactor, UDPGA.  Subsequent glucuronidation 
experiments were conducted using these fixed protein concentrations. 
 
 
Matrix 
 
 
kC→L 
(min-1) 
 
kL→C 
(min-1) 
 
0.1 M Tris, pH 7.0 
 
5.49 x 10-4 71.1 x 10-4 
Human intestinal microsomes 
 
11.2 x 10-4 103 x 10-4 
Human hepatic microsomes 
 
2.30 x 10-4 138 x 10-4 
Human recombinant UGTs 
 
3.74 x 10-4 161 x 10-4 
Rat intestinal microsomes 
 
37.9 x 10-4 16.6 x 10-4 
Rat hepatic microsomes 
 
42.4 x 10-4 16.4 x 10-4 
Rat recombinant UGTs 
 
3.13 x 10-4 108 x 10-4 
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Table 2.2  SN-38 lactone and carboxylate glucuronidation ratesa in rat hepatic and intestinal 
microsomes.  Values in parentheses indicate the standard deviation between the averages of 
two different experiments (each with three replicates). 
 
Matrix 
 
 
Lactone 
(pmol/min/mg protein) 
 
Carboxylate 
(pmol/min/mg protein) 
 
Rat intestinal microsomes 
 
18.5 
(1.6) 
6.5 
(0.6) 
Rat hepatic microsomes 
 
5.7 
(0.6) 
3.0 
(0.4 
 
a:  Study performed with an incubation time that only permitted 2.5% conversion of lactone 
to carboxylate or carboxylate to lactone
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Table 2.3  First-order rate constants for glucuronidation of SN-38 lactone and carboxylate in 
microsomes and recombinant isoforms.  Numbers in parentheses indicate the parameter 
coefficient of variance (%). 
 
Matrix kgluc, lactone 
(min-1) 
kgluc, carboxylate 
(min-1) 
 
Human UGT 1A1 
 
5.17 x 10-4 
(3.51) 
 
0.855 x 10-4 
(11.5) 
 
Human UGT 1A7 
 
8.52 x 10-4 
(4.62) 
 
2.73 x 10-4 
(12.4) 
 
Human UGT 1A8 
 
0.0526 x 10-4 
(10.3) 
 
0.0940 x 10-4 
(4.11) 
 
Human UGT 1A9 
 
0.427 x 10-4 
(4.13) 
 
0.121 x 10-4 
(3.51) 
 
Human hepatic microsomes 
 
68.0 x 10-4 
(4.23) 
 
15.4 x 10-4 
(12.5) 
 
Human intestinal microsomes 
 
9.54 x 10-4 
(3.51) 
 
2.73 x 10-4 
(11.1) 
 
Rat UGT 1A1 
 
8.23 x 10-4 
(8.05) 
 
4.49 x 10-4 
(12.7) 
 
Rat UGT 1A7 
 
81.2 x 10-4 
(10.0) 
 
23.6 x 10-4 
(20.1) 
 
Rat UGT 1A8 
 
27.9 x 10-4 
(3.51) 
 
5.06 x 10-4 
(30.6) 
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Figure 2.1  Glucuronidation of SN-38 lactone and carboxylate after esterase cleavage of 
irinotecan.  The scheme depicts the lactone and carboxylate species of each compound.  Loss 
of water is not shown with lactone cyclization. 
SN-38G lactone
SN-38 lactone SN-38 carboxylate 
SN-38G carboxylate 
Irinotecan lactone Irinotecan carboxylate 
UGT UGT 
carboxylesterase carboxylesterase 
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Figure 2.2  Sample chromatogram of rat recombinant 1A1 glucuronidation of SN-38 lactone 
over a 10 minute incubation period.  SN-38G has a retention time of 3.5 minutes, irinotecan 
(internal standard) elutes at 5 minutes, and SN-38 is detected at 17 minutes (although poorly 
fluorescent at excitation 229 nm and emission 420 nm). 
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Xo, lactone 
kC→L kL→C 
kgluc,lactone 
kgluc,carboxylate 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
Figure 2.3  Kinetic model used to determine glucuronidation rate constants of SN-38 lactone 
or carboxylate (kgluc, lactone and kgluc, carboxylate).  This model utilizes SN-38G lactone 
concentrations generated from spiking either SN-38 lactone or carboxylate (Xo, lactone, or Xo, 
carboxylate) in two separate experiments.  Any SN-38G carboxylate formed is converted to SN-
38G lactone in the sample workup, as an acidified solution was used to reconstituted each 
sample (see HPLC Analysis under MATERIALS AND METHODS).  Hence, both SN-38 
lactone and carboxylate are depicted to form SN-38G lactone.  The hydrolysis and 
lactonization rate constants, kL→C or kC→L, respectively, were generated from studies 
assessing the stability of each form in microsomal or recombinant isoform matrix.   
SN-38 
Carboxylate 
SN-38 
Lactone 
SN-38G 
LactoneXo, carboxylate 
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Figure 2.4  Representative plots of the stability of SN-38 lactone (A) or carboxylate (B) as 
determined by HPLC in 0.1 M sodium acetate, pH 4.5 (▲), 0.1 M sodium phosphate, pH 6.0 
(●), 0.1 M Tris, pH 7.0 (■), or 1 x10-5 M sodium hydroxide, pH 9.5 (▼) over time at 37° C.  
Data shown are from up to three incubations per pH studied.
A 
B 
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Figure 2.5  Representative plots of the formation of SN-38G in human hepatic microsomes 
when SN-38 carboxylate (-■-) or SN-38 lactone (-▲-) was the substrate.  SN-38G 
concentration is represented in SN-38 equivalents in ng/mL.  The points on each line shown 
represent data from three different incubations, as more than one incubation was needed to 
provide this number of data points.
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VARIABILITY OF SN-38 GLUCURONIDATION IN HUMAN INTESTINE:  THE 
INFLUENCE OF ISOFORMS AND GENOTYPE
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A. ABSTRACT 
SN-38 is the active metabolite of irinotecan, a drug included in numerous regimens to 
treat solid tumors.  Diarrhea is a primary dose-limiting toxicity which is believed to be 
caused by the accumulation of SN-38 in rapidly dividing enterocytes.  As SN-38 can be 
detoxified by UDP-glucuronosyltransferases (UGTs), intestinal UGT activity may be a major 
factor in determining which patients experience diarrhea.  In order for this hypothesis to be 
supported, significant variability in glucuronidation must exist across the population.  Thus, a 
bank of tissue and biopsy samples from human duodenum, jejunum, and colon were screened 
for variability in SN-38 glucuronidation.  These samples were also used to assess UGT1A1 
and UGT1A9 activity through glucuronidation of the probe substrates, etoposide and 
propofol, respectively.  Probe substrate experiments confirmed the presence of UGT1A1 and 
1A9 protein throughout the small and large intestine.  SN-38, propofol, and etoposide 
glucuronidation was highly variable throughout the intestine, with up to a 37-fold difference 
between subjects for SN-38 glucuronidation in the jejunum.  Average SN-38G formation 
rates were similar in the duodenum and jejunum, but colon had about one-half of these rates.  
SN-38 conjugation exhibited significant correlation with propofol and etoposide conjugation 
in all regions of the intestine, supporting the role of UGT1A1 and 1A9 as primary 
detoxifying isoforms in the gastrointestinal tract.  Interestingly, the presence of one or more 
UGT1A1*28 alleles did not appear to reduce SN-38 glucuronidation in the intestinal regions 
analyzed.  Results indicate that in addition to UGT1A1, polymorphisms of UGT1A9 and its 
expression should be examined for potential effects on SN-38 mediated toxicity.   
 87
B. INTRODUCTION 
UDP-glucuronosyltransferases (UGT) are a superfamily of enzymes that catalyze the 
transfer of UDP-glucuronic acid to a number of xenobiotic and endobiotic substrates (Figure 
1.1).  Glucuronidation typically renders a substrate pharmacologically inactive, and makes it 
more readily excretable from the body (Mulder, 1992; Guillemette, 2003).  Although hepatic 
UGTs have been more extensively studied and thought to be the primary site of systemic 
glucuronidation, intestinal glucuronidation may contribute significantly to first-pass due to 
the initial contact that the intestinal mucosa has with orally administered drugs (Strassburg et 
al., 1999a; Tukey and Strassburg, 2000).  Additionally, intestinal UGTs play a primary role 
in enteric and enterohepatic cycling, which may limit or prolong systemic exposure of 
substrates, respectively (Chen et al., 2003).  UGT1A family expression is regionally 
regulated, which may lead to striking differences between overall glucurondiation rates 
between two tissues (Strassburg et al., 1999a; Gregory et al., 2004).  For instance, UGT1A8 
and 1A10 message is confined to the gastrointestinal tract, whereas UGT1A1 and 1A6 
mRNA is more ubiquitously expressed in various organs (Tukey and Strassburg, 2001).  
Despite differences in localization, UGT1A isoforms often have considerable overlap in 
substrates, which is a consequence of highly conserved amino acid sequences (Guillemette, 
2003).  Because of this homology, generation of antibodies that recognize specific isoforms 
in the 1A family have been limited to the most divergent members, UGT1A1 and 1A6 (Ritter 
et al., 1999; Tukey and Strassburg, 2001).  Thus, probe substrate glucuronidation is a 
valuable surrogate for quantitative isoform expression and activity in a given tissue. 
Irinotecan is a topoisomerase I inhibitor approved as a staple of several chemotherapy 
regimens treating colon cancer, but is widely being used in other solid tumor malignancies.  
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Its pharmacological effect is achieved through SN-38, the metabolite formed by 
carboxylesterase-mediated hydrolysis.  SN-38 is rendered inactive by glucuronidation, 
forming SN-38G primarily by UGT1A1, UGT1A7, and UGT1A9 (Gagne et al., 2002; 
Tallman et al., 2005).  Irinotecan causes severe diarrhea in roughly 20% of patients, which is 
purportedly due to accumulation of SN-38 within the enterocyte (Araki et al., 1993; Iyer et 
al., 1998; Saltz et al., 2000).  This has been indirectly supported by studies in both humans 
and rats showing that reduced intraluminal concentrations of SN-38 will diminish the 
incidence of diarrhea (Takasuna et al., 1996; Kehrer et al., 2001; Horikawa et al., 2002; 
Ikegami et al., 2002).  In addition to experiencing a poor quality of life, patients that suffer 
from irinotecan-induced diarrhea will receive lower subsequent doses, which may adversely 
influence the efficacy of the oncology drug regimen (de Jong et al., 2005). 
 Intestinal glucuronidation of SN-38 may be an important, though seldom studied, 
factor in the incidence of diarrhea.  Low activity may predispose patients to diarrhea, as cells 
would have limited defense in the detoxification of SN-38.  Intestinal UGT levels are likely a 
function of numerous factors, among them, genetic polymorphisms or dietary components 
that may increase or decrease SN-38 conjugation. 
 In this study, the variability of SN-38 glucuronidation in human duodenum, jejeunum, 
and colon was assessed.  Variability in intestinal SN-38 glucuronidation across patients is a 
requisite of the hypothesis that low UGT activity increases the likelihood of SN-38 toxicity.  
SN-38G formation will also be examined for correlations with the expression of UGT1A1 
and UGT1A9, through glucuronidation of the novel probe, etoposide (1A1) and propofol 
(1A9) (Figure 3.1) (Watanabe et al., 2003; Soars et al., 2004).  Finally, the effect of 
UGT1A1*28 genotype on SN-38 glucuronidation will be evaluated.  This genotype imparts a 
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clinical condition known as Gilbert’s syndrome, and is genotypically characterized by an 
extra TA repeat in the TATA box promoter of UGT1A1 (seven or more repeats versus the 
wild-type six repeats).  Patients with Gilbert’s syndrome possess reduced UGT1A1 
glucuronidation, retaining approximately 30% activity of this isoform (Miners et al., 2002).  
The Gilbert’s genotype has been found to significantly increase the incidence of irinotecan-
associated neutropenia, but thus far, its correlation with the incidence of diarrhea has not 
been fully substantiated (Bosma et al., 1995; Innocenti et al., 2004a; Marcuello et al., 2004; 
Carlini et al., 2005)
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C. MATERIALS AND METHODS 
Materials.  SN-38G methyl ester and irinotecan were gifts from Dr. Robert Kelly of Pfizer 
(Kalamazoo, MI), previously Pharmacia.  Propofol, etoposide, and chemicals used in 
biopsy/tissue preparation and incubations were obtained from Sigma-Aldrich (St. Louis, 
MO).  Recombinant UGT isoforms were purchased from BD Biosciences (Franklin Lakes, 
NJ).  Human liver and intestinal microsomes were obtained from Xenotech (Lenexa, KS).  
Monoclonal anti-villin antibody and anti-mouse immune globulin G (IgG) were purchased 
from Chemicon (Temecula, CA).  All Western blotting apparatuses and reagents were 
obtained from Biorad (Hercules, CA) unless otherwise noted.   
Patient Treatment and Samples.  Jejunal sections were obtained from hepatic transplant 
recipients at the University of North Carolina at Chapel Hill.  During the transplant, 
reconnection of the bile duct of the new liver into the intestine required the excision of 
jejunal tissue, which was preserved on dry ice.  Duodenal and colonic biopsies were obtained 
from two separate studies conducted at UNC Hospitals, both of which were conducted under 
protocols approved from the University’s Institutional Review Board.  In the first, colon 
cancer patients underwent both endoscopy and flexible sigmoidoscopy.  Enrolled patients did 
not have immunodeficiencies, renal, liver, or other bowel disease, as assessed by neutrophil 
count, creatinine, transaminases, and bilirubin levels.  Additionally, patients could not be 
receiving medications for anticoagulation or that may affect glucuronidation, including, but 
not limited to, phenobarbital and valproic acid.  During these procedures, six pinch biopsies 
were obtained from normal duodenum and colon tissue, respectively.  Samples were 
immediately stored on dry ice and later transferred to -80° C.  Patients later received 
irinotecan (125 mg/m2), followed by leucovorin and fluorouracil in most cases.  Irinotecan 
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was subsequently administered in six week cycles, consisting of once weekly dosing for four 
weeks.  Patients were asked on a weekly basis to report diarrheal episodes.  In the second 
study, patients undergoing routine or diagnostic endoscopy, colonoscopy, or flexible 
sigmoidoscopy at UNC Hospitals were approached to consent to biopsy excision during their 
procedure.  Upon consent, six biopsies were obtained and stored as described above.  
Exclusion criteria included overt renal, liver, or bowel disease, age below 18 or older than 
70, obesity, anticoagulants or other contraindications to biopsy, and glucuronidation-
modulating medications.  Biopsies and tissues from all studies were stored at -80°C until use.   
Tissue Preparation.  Biopsies (n = 4 per patient) and tissue samples were homogenized on 
ice in 20% glycerol/50 mM Tris (600 µL), pH 7.4, containing EDTA (2 mM), 
phenylmethylsulfonylfluoride (1 mM), and leupeptin (100 µM).  Protein concentration was 
determined by the Bradford assay and based upon standard curves of bovine serum albumin.  
Aliquots of homogenate (100 µL) were stored at -80 until use.  Separate aliquots were used 
for each glucuronidation assay such that freeze-thaw effects were avoided.  One biopsy or 
small piece of tissue was devoted to the isolation of genomic DNA using a DNeasy Tissue kit 
(Qiagen, Valencia, CA). 
SN-38 Glucuronidation and Analysis.  SN-38 was synthesized by irinotecan hydrolysis as 
previously described (Chapter 2).  Reactions to determine the maximal glucuronidation rate 
(Vmax) and the substrate affinity (Km) for SN-38 were conducted in rat hepatic microsomes 
and contained the following:  Brij 35 (0.5 mg/mg protein), D-saccharic acid 1,4 lactone (10 
mM), magnesium chloride (10 mM), SN-38 carboxylate (5-400 µM), and microsomal protein 
(0.5 mg/mL) in a final volume of 200 μL of 0.1 M Tris, pH 7.0.  Reactions were initiated 
with UDP-glucuronic acid (UDPGA) (2 mM) and quenched after 30 minutes at 37° C with 
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four volumes of acetonitrile containing internal standard (25 ng irinotecan).  Incubations for 
intestinal biopsies and microsomes were similar, except for differing protein concentrations 
(biopsy, 0.2 mg/mL or jejunal tissue, 0.5 mg/mL), a fixed SN-38 concentration (300 µM), 
and an incubation time of one hour.  After centrifugation at 15,000g for 10 minutes, the 
supernatant of all samples was evaporated under nitrogen and reconstituted in 30% methanol/ 
100 mM ammonium acetate (200 µL).  Aliquots of 15 µL were injected onto the high 
performance liquid chromatography (HPLC) column for analysis of SN-38G formed. 
 The SN-38G standards were prepared from SN-38G methyl ester as previously 
described (Chapter 2).  Standards were spiked into incubation matrix from 0.75 ng/mL to 200 
ng/mL.  After workup, 6-25 µL of standards were injected onto the HPLC column, providing 
a range of 19-1200 pg of SN-38G injected on-column.  The HPLC system used to separate 
and detect SN-38G was similar to that used previously (Chapter 2), with an SIL10A 
autosampler used for sample injection (Shimadzu, Tokyo, Japan).  Standard curves were 
linear throughout the range and were reproducible (less than 15% coefficient of variance in 
peak area ratio at high and low concentrations).  Interday variability was assessed, as samples 
were prepared and analyzed on two separate occasions.  SN-38 glucuronidation rates in 
human liver microsome controls were within 15% of each other. 
Propofol Glucuronidation and Analysis.  The in vitro reaction to generate propofol 
glucuronide (propofol-G) in human intestinal biopsies and tissues contained the following:  
Brij 35 (0.5 mg/mg protein), D-saccharic acid 1,4-lactone (10 mM), magnesium chloride (10 
mM), propofol (1 mM), and biopsy/tissue (0.2 mg/mL) in a final volume of 250 μL of 0.1 M 
Tris, pH 7.0.  Reactions were initiated with UDPGA (2 mM) and quenched after 40 minutes 
at 37°C with two volumes of acetonitrile containing internal standard (2 µg ibuprofen).  
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Samples were centrifuged at 15,000g for 10 minutes and the acetonitrile supernatant was 
evaporated under nitrogen.  Samples were reconstituted with 20% acetonitrile/ 10 mM 
ammonium acetate (100 µL).  Prior to this experiment, incubations were performed in human 
intestinal microsomes (0.2 mg/mL) with propofol concentrations ranging from 0.025 mM-5 
mM in order to obtain Michaelis-Menten parameters.  
 Propofol-G standards were synthesized via a large-scale in vitro incubation of 
propofol with human liver microsomes and prepared as described above, which was then 
separated using preparative HPLC.  The fractions containing propofol-G were verified by 
liquid chromatography with mass spectrometry detection (LC-MS), pooled, lyophilized, and 
reconstituted with 50% acetonitrile.  As the glucuronide of propofol is not liable to β-
glucuronidase cleavage, strong acid was used to generate propofol from an aliquot of 
propofol-G stock.  The liberated propofol was then quantified, which yielded the 
concentration of propofol-G standard stock solution in propofol equivalents.   
 Propofol and propofol-G were quantified using LC-MS using ibuprofen as an internal 
standard.  The liquid chromatography system used consisted of an HP1050 quaternary pump, 
mobile phase degasser and autosampler (Agilent, Palo Alto, CA) and a Zorbax RX-C8 
column (150 x 2.1 mm, 5 µM) (Agilent).  Compounds were eluted in 15 minute runs with 
ammonium acetate (10 mM, A) and acetonitrile in a gradient elution (0.3 mL/min):  at 0 
minutes, 90% A; at 9 minutes, 10% A; at 10 minutes, 10% A; at 11 minutes, 90% A.  A 
single quadrupole mass spectrometer (Sciex API 100; MDS Sciex, Concord, CA) coupled 
with an electrospray interface in negative ion mode detected the compounds.  Ion source 
conditions include a voltage of -3300V, temperature of 400° C, and a dwell time of 300 ms.  
Selected ion monitoring was used to detect propofol-G (m/z 353), ibuprofen (m/z 205), and 
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propofol (m/z 177) at 3.2, 6.4, and 7.8 minutes, respectively.  Calibration curves of propofol-
G were linear from 0.05 µg/mL to 4 µg/mL, with an injection volume of 15 µL for all 
samples and standards.  Human liver microsome control samples (0.1 mg/mL) conducted on 
seperate analysis days had propofol glucuronidation rates within 25% of each other.  A 
representative chromatogram is given in Figure 3.2. 
Etoposide Glucuronidation and Analysis.  In order to assess the selectivity of etoposide for 
UGT1A1, incubations (2 hours) of etoposide in all commercially available UGT isoforms 
were performed as follows:  alamethacin (50 µg/mg protein), D-saccharic acid 1,4-lactone 
(10 mM), magnesium chloride (10 mM), etoposide (400 µM), recombinant isoform (0.5 
mg/mL), and UDPGA (2 mM) in a final volume of 250 μL of 0.1M Tris, pH 7.0.  
Incubations conducted with human microsomes (0.5 mg/mL) for determination of etoposide 
Km and Vmax were similar to above, but utilized an etoposide concentration range of 5 µM 
to 2,000 µM in a final volume of 200 µL over 30 minutes.  Due to limited amounts of tissue, 
etoposide glucuronidation was not conducted in jejunal tissue or several distal and proximal 
intestinal biopsies.  In the final set of etoposide incubations, intestinal biopsies (0.2 mg/mL) 
were incubated with conditions outlined in the Km/Vmax experiment, except a fixed 
etoposide concentration of 1 mM was used.  After each incubation, three volumes of 
acetonitrile containing internal standard (azidothymidine (AZT), 6.25 µg) was used to 
quench the reaction.  The supernatant was then blown to dryness under nitrogen and 
reconstituted with 125 µL of 0.1% formic acid/ acetonitrile (80% : 20%). 
 Etoposide glucuronide (etoposide-G) standards were also synthesized in an in vitro 
reaction with human liver microsomes.  After the final reconstitution of a 20 mL reaction, 
preparative HPLC with UV detection at 254 nm was used to separate analytes.  Fractions 
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containing etoposide-G (as assessed by mass spectrometry) were pooled, lyophilized, and 
reconsitituted in 50% acetonitrile.  A small aliquot of this solution was treated with β-
glucuronidase and the liberated etoposide was quantitated against a standard curve.  This 
allowed the concentration of etoposide-G (in etoposide equivalents) to be calculated in the 
standard stock solution. 
 The chromatography system, column, and mass spectrometer used for quantitation of 
etoposide-G was described in the propofol-G section.  The turbo ionspray source in negative 
ion mode was also set with the same parameters as the propofol-G assay:  Etoposide, 
etoposide-G, and AZT were eluted via a gradient over 18 minutes using 0.1% formic acid 
(A) and acetonitrile (B) (0.3 mL/min) following the following time course:  at 0 minutes, 
90% A; from 10-12 minutes, 50% A; and at 14-18 minutes, 90% A.  Using selective ion 
monitoring, AZT (m/z 266), etoposide-G (m/z 763.2), and etoposide (m/z 587.2) were 
detected at 6.1, 8, and 10.6 minutes, respectively.  Etoposide-G standard curves were linear 
and reproducible after 20 µL injections of concentrations ranging from 2.5 to 1000 ng/mL.  
All samples within the three described experimental procedures were prepared and analyzed 
on the same day, negating the need for interday variability assessment.  A representative 
chromatogram is given in Figure 3.2. 
Villin Western Blot Analysis.  Intestinal biopies and tissues may contain different levels of 
enterocytes per weighed amount of tissue for numerous reasons, including the biopsy 
technique of the physician.  As such, simply normalizing glucuronidation rates to the amount 
of total protein in the preparation is erroneous, as only enterocytes contain UGTs (Strassburg 
et al., 2000).  Thus, all glucuronidation rates were normalized for the enterocyte content of 
the respective sample, as measured by villin expression (Lown et al., 1997). 
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Biopsy or tissue proteins (40 µg) that underwent one freeze-thaw cycle were 
seperated by electrophoresis on 4-15% gradient Tris gels (Ready Gel, Bio-Rad).  Proteins 
were then transferred for one hour at 110 volts to nitrocellulose membranes.  After the 
transfer, membranes were blocked in 5% milk/0.1% Tween in Tris-Buffered Saline (TBS-T) 
for one hour to prevent non-specific antigen-antibody binding.  Blots were probed with anti-
villin antibody (in 0.1% TBS-T/0.5% milk) overnight, followed by the secondary antibody, 
anti-mouse IgG in (0.1% TBS-T/0.5% milk), for one hour.  After the blocking, primary, and 
secondary antibody step, the blots were washed three times for five minutes each with 0.1% 
TBS-T.  Following the final wash, chemiluminescent reagent (SuperSignal, Pierce, Rockford, 
IL) was pipetted over the blot.  Protein bands were then imaged via a Versadoc Imaging 
System (Biorad).  A molecular weight marker was added to each gel to identify the villin 
protein (95 kDa).  Densities of the protein bands were determined using Quantity One 
software (Biorad).  Protein content and image time were both validated for linearity.  As 
electrophoresis was conducted in multiple gels, an aliquot of concentrated intestinal sample 
was added to each blot as an internal standard.  Densities were reported as the ratio of the 
densities of the protein of interest relative to the internal standard of the respetive blot.  To 
ensure the accuracy of this method of quantification, seven samples were run on two seperate 
days.  The interday variability of the normalized band densities of proteins was no higher 
than 12%.   
UGT1A1 Genotyping.  Upon isolation of DNA from the biopsies and tissue, DNA 
concentration was spectrophotometrically determined.  Genotypes for the UGT 1A1 [TA]n 
promoter region (GenBank Accession Number AF297093) were ascertained by direct 
sequencing. Forward (5’-TCC CTG CTA CCT TTG TGG AC-3’) and reverse (5’-AGA GGT 
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TCG CCC TCT CCT AC-3’) primers were designed using Primer3 (primer3_www.cgi v 
0.2).  DNA (30 ng) was amplified in a 50 μl reaction volume containing 800 nM of each 
primer, 200 μM dNTPs (Amersham Biosciences Inc., Piscataway, NJ), 1.5 mM MgCL2, 1x 
PCR Buffer (Invitrogen, Carlsbad, CA), and 0.25U Platinum Taq (Invitrogen).  Polymerase 
chain reaction (PCR) cycling conditions including an initial denaturation at 95°C for 5 min, 
35 cycles of 94°C for 30 s, 54°C for 40 s, 72°C for 40 sec, and a final extension at 72°C for 
10 min. The PCR product was resolved by gel electrophoresis on a 3% agarose gel and the 
121 bp fragment was excised and purified using the QIAquick Gel Extraction Kit (Qiagen, 
Valencia, CA). The sequencing reaction, containing 2 μL of purified product and 10 pmoles 
of forward primer, was done using the ABI PRISM BigDye Version 1.1 Terminator Cycle 
Sequencing Ready Reaction Kit with AmpliTaq DNA Polymerase, FS (Applied Biosystems, 
Foster City, CA). Samples were sequenced at the UNC Genome Analysis Facility on a 3730 
DNA Analyzer (Applied Biosystems, Foster City, CA).  
Data Analysis.  Vmax and Km values for propofol and etoposide were determined using 
nonlinear regression software (Winnonlin version 5.0, Pharsight, Mountain View, CA).  Due 
to the small amount of available sample, data from incubations with intestinal biopsies and 
tissues are presented as the average of duplicate incubations from one experiment.  All 
glucuronidation rates are normalized for the villin content in the biopsy or tissue.  
Comparisons between substrate glucuronidation in duodenum, jejunum, and colon or 
between UGT1A1 genotype groups were made with the Kruskal-Wallis test, followed by the 
Dunn’s post-hoc test.  In the case of etoposide, the comparison of duodenal and colonic 
glucuronidation was made using the Mann Whitney Rank sum test.  Correlations between 
UGT1A1 and UGT1A9 probe substrates and SN-38 were compared using Spearman rank 
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order test.  All statistical tests were performed using Sigma Stat software (version 2.0, Systat, 
Point Richmond, CA) and p values ≤ 0.05 were considered significant.
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D. RESULTS 
Propofol had previously been identified as a UGT1A9 probe by Soars et al. (2004), 
and is widely used as such (Girard et al., 2004; Soars et al., 2004; Court, 2005).  While 
UGT1A8 does retain approximately six percent of the activity of UGT1A9 based on 
commercially available recombinant isoforms, its use a probe is relatively free from the 
contribution of other isoforms (Soars et al., 2004).  Watanabe et al. (2003) identified 
etoposide as an exclusive substrate for UGT1A1, although not all UGT isoforms were tested 
(Watanabe et al., 2003).  Results from experiments in our lab with all commercially available 
isoforms identify UGT1A1 as the main enzyme responsible for glucuronidation, with 
UGT1A8 retaining only five percent of the activity that UGT1A1 possesses (Figure 3.3).  
Because of this data, etoposide was used to quantitatively evaluate relative protein levels of 
UGT1A1 in the intestinal tissue samples. 
Michaelis-Menten kinetic parameters were determined for SN-38, propofol, and 
etoposide in various microsomal matrices (Figure 3.4-Figure 3.6).  A concentration two to 
four times greater than the Km estimate would be used to assess interpatient differences in 
the intestinal glucuronidation for each aglycone.  As the biopsies and tissues provided less 
than 1 mg of homogenate protein, a single measure of glucuronidation for each substrate was 
attained in these samples, rather than a full kinetic profile.  Incubations in rat liver 
microsomes showed that SN-38 glucuronidation reached a maximal velocity at 
approximately 300 µM SN-38 (Figure 3.4).  At 500 µM, SN-38 visibly precipitated out of the 
reaction.  Since 300 µM SN-38 was soluble in the incubation matrix, this concentration was 
used in further incubations.  Likewise, high concentrations of propofol were also not soluble, 
so 1 mM was used in the reaction (Figure 3.5).  Based on the Km data for both human 
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intestine and human liver, 1 mM etoposide was used in additional in vitro reactions (Figure 
3.6, Table 3.1). 
Overall, 53 normal intestinal samples were collected from patients or subjects (n = 18 
duodenal biopsies, n = 16 jejeunal tissue pieces, n = 19 colon biopsies).  Eight paired 
duodenum and colon biopsy sets were obtained from colon cancer patients prior to receiving 
irinotecan.  Demographic information available on these patients is given in Table 3.2.  
Although different comorbidities segregated amongst the intestinal area excised (i.e., more 
liver transplant patients donated jejunum), it appears that coexisting conditions did not affect 
glucuronidation.  Likewise, age, race, and sex were not mitigating factors in glucuronidation 
rates in this study.  Roughly 0.6 mg of total protein was derived upon the homogenization of 
the biopsies and jejunal segments. 
The average duodenal, jejunal, and colonic glucuronidation rates for SN-38, 
etoposide, and propofol are given in Table 3.3.  Considerable variability between subjects 
was evident in all intestinal regions for both SN-38 and the probe substrates.  For SN-38, 
there was an 8.1, 37, and 36-fold range of SN-38G formation for the duodenum, jejunum, 
and colon, respectively.  Despite the high intersubject variability in the glucuronidation of the 
substrates, SN-38 and etoposide glucuronidation was significantly lower in the colon.  To 
add support to this finding, the proximal intestine consistently displayed higher catalytic rates 
for SN-38 and etoposide in paired duodenum and colon samples (Figure 3.7).  In contrast, 
propofol glucuronidation was highest in the distal intestine, although the broad range of 
propofol-G formation rates prohibited any statistical difference (Table 3.3).  In the paired 
samples, propofol activity was higher in the colon versus the duodenum, although this was 
not a consistent outcome from the eight matched pairs of tissue biopsies (Figure 3.7).  In 
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order to gain insight into isoform-specific glucuronidation of SN-38, etoposide and propofol 
glucuronidation was correlated with that of SN-38 (Figures 3.8 and 3.9).  In all areas of the 
intestine, SN-38G formation was highly associated with that of UGT1A9 and UGT1A1 
activity as determined by propofol and etoposide glucuronidation, respectively. 
Because UGT1A1*28 genotype has been associated with low hepatic SN-38 
glucuronidation, subjects in this study were genotyped in an attempt to explain the variability 
in intestinal SN-38 glucuronidation.  Roughly 44% of the population sampled here was 
homozygous for wild-type UGT1A1, 33% was heterozygous, and 20% were homozygous for 
UGT1A1*28, characterized by having two alleles with 7 or 8 TA repeats in the TATA box 
promoter of the gene (Miners et al., 2002) (Table 3.4).  Interestingly, the presence of one or 
more UGT1A1*28 alleles does not appear to appreciably influence intestinal SN-38 
glucuronidation rates, though the sample size is not large (Table 3.5).  Two out of the eight 
patients who received irinotecan experienced Grade 3 diarrhea, characterized by incontinence 
or an increase of at least seven stools per day.  Neither patient had Gilbert’s syndrome and 
neither had the lowest duodenal or colonic SN-38 glucuronidation rate of the patients who 
received irinotecan (Table 3.6). 
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E. DISCUSSION 
 The capacity of the intestine to glucuronidate substrates no doubt arises from the fact 
that it physically contacts potentially toxic, orally administered compounds or those excreted 
through the bile, necessitating a detoxification pathway (Tukey and Strassburg, 2000).  This 
has been demonstrated in the proximal gastrointestinal tract with tobacco containing 
carcinogens and UGT1A7.  Several polymorphisms in the UGT1A7 isoform impart low 
glucuronidation rates of benzo-α-pyrene and derivatives and also correlate with a patient’s 
predisposition to develop to orolaryngeal cancers (Zheng et al., 2001; Strassburg et al., 
2002).  UGT1A7 transcripts are localized exclusively to upper gastrointestinal tissues, 
suggesting a potential role for the importance of UGT isoforms expressed in the 
gastrointestinal tract in mediating toxicity (Tukey and Strassburg, 2000; Zheng et al., 2002).  
A similar phenomenon may exist with SN-38 and intestinal UGTs.  As the intestine is the site 
of SN-38 toxicity and contains local detoxification mechanisms in the expression of UGTs, 
polymorphisms or low UGT activity may predispose patients to experiencing SN-38 related 
diarrhea.  In contrast to the benzo-α-pyrene and UGT1A7 example, the specific role of the 
intestine in mediating diarrhea is less clear, as UGT1A1 and UGT1A9, the enzymes 
purportedly responsible for intestinal SN-38 catalysis, are also hepatically expressed 
(Strassburg et al., 1997; Gagne et al., 2002; Tallman et al., 2005).  Although SN-38 is also 
cleared by UGT1A7 in in vitro reactions, the location of this isoform in the proximal 
gastrointestinal tract likely excludes a role for it in the intestinal glucuronidation of SN-38 
(Tukey and Strassburg, 2000; Gagne et al., 2002; Tallman et al., 2005). 
 The variability of SN-38 glucuronidation observed in the intestinal samples in this 
study is similar to the interpatient variability in glucuronidation reported previously for SN-
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38 and other UGT substrates.  When SN-38 glucuronidation was assessed in normal colon 
biopsies from eight patients, an approximate seven-fold difference in glucuronidation was 
observed between patients, excluding data from two patients with barely quantifiable SN-
38G levels (Cummings et al., 2003).  The glucuronidation of estrone in colonic microsomes 
made from four female patients ranged from roughly 100-2500 pmol/min/mg protein 
(Czernik et al., 2000).  Strassburg et al. (1999) report a 2-5 fold difference in glucuronidation 
rates of various flavones, bile acids, steroids, and phenolic compounds in colon samples from 
five subjects (Strassburg et al., 1999a).  Although SN-38 glucuronidation rates did vary to a 
greater degree in the present study (up to 37-fold in jejunal samples), the number of patients 
sampled was much greater compared to these earlier studies, allowing increased likelihood 
that intestinal samples from subjects with extremely low or high SN-38 conjugation would be 
analyzed.  The formation of SN-38G was also highly variable in the colon, albeit slower than 
the proximal intestine.  The large intestine did, however, retain significant UGT activity to 
SN-38.  Glucuronidation in this portion of the intestine may be an especially important 
determinant of diarrhea, as this is the specific site of pathophysiological changes induced by 
SN-38.  Additionally, enterocytes in this region may come in contact with more SN-38 
relative to other intestinal segments, as β-glucuronidase-facilitated cleavage of SN-38G to 
SN-38 is highest in the distal intestine (Ilett et al., 1990). 
 The use of probe substrates as a measure of UGT activity has several advantages over 
other methods to assess UGT1A isoform expression.  The first is that probe substrates allow 
a quantitative measure of relative isoform levels, whereas the band densities generated from 
western blots are only semi-quantitative.  Unfortunately, for accurate glucuronidation rates in 
these intestinal samples, quantitative measures of UGT1A9 and UGT1A1 activity were 
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normalized for villin expression as determined by Western blot.  However, a second 
advantage to utilizing probe substrates is that there is a lack of antibodies that specifically 
recognize most UGT1A isoforms, including UGT1A9.  We and others have prepared a 
UGT1A9 antibody, however, cross-reactivity with UGT1A7, 1A8, and 1A10 exists, as these 
isoforms are highly homologous (Girard et al., 2004; Miles et al., 2005).  Both flavopiridol 
and propofol have proven useful UGT1A9 probe substrates, however the latter compound is 
more widely used and is commercially available (Ramirez et al., 2002; Soars et al., 2004; 
Court, 2005).  Although suitable UGT1A1 antibodies have been produced and could have 
been used in this study, the amount of available intestinal tissue was limiting.  Various 
intestinal segments have been previously probed for UGT1A1 protein via western blots in 
several studies, albeit with small numbers of patients (Paine and Fisher, 2000; Strassburg et 
al., 2000).  There is only one known report of human intestinal UGT1A1 expression as 
assessed by probe substrate activity.  Fisher et al. (2000) assessed estradiol-3 glucuronide 
formation in three human intestinal microsome preparations (Fisher et al., 2000).  However, 
UGT1A3, 1A8, and 1A10 have been found to have significant or higher catalytic activity 
relative to UGT1A1 for this compound, limiting use of estradiol as a UGT1A1 probe (Soars 
et al., 2004).  Besides estradiol, bilirubin has been extensively used as a UGT1A1 probe, 
although this compound is highly photosensitive.  Although Watanabe et al. (2003) identified 
etoposide as a UGT1A1 probe, not all isoforms were tested for specificity and, until the 
current investigation, has not been utilized in the reported literature (Watanabe et al., 2003). 
 The UGT1A phenotyping with etoposide and propofol provides some interesting 
insight into the intestinal expression of these two isoforms.  In studies detecting RNA, 
UGT1A9 and 1A8 were not detected in any small intestinal segment (Strassburg et al., 2000).  
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Interestingly, although the colon overall had a higher rate of propofol glucuronidation than 
the other two segments on average, the duodenum and colon retained significant propofol 
catalytic activity.  With respect to UGT1A1, both transcript and protein analysis confirmed 
the presence of UGT1A1 throughout the intestine (McDonnell et al., 1996; Strassburg et al., 
1998; Strassburg et al., 2000).  The current study confirms anecdotal evidence that UGT1A1 
activity declines in the distal regions of the intestine (Peters et al., 1989; McDonnell et al., 
1996).  One disadvantage to using probe substrate glucuronidation is that glucuronidation 
rates for specific probes cannot be used to compare the expression levels between UGT 
isoforms.  Along with intrinsic clearance rates for a given substrate and isoform, this 
information would allow investigators to determine which isoforms contribute most 
significantly to glucuronidation within a given tissue.  From these results, both UGT1A1 and 
1A9 seem to contribute considerably to the in vitro formation of SN-38G throughout the 
intestine as assessed through correlation analyses, and it is only speculative to support the in 
vivo involvement of one isoform over another. 
Genetic polymorphisms and environmental exposures are the two factors likely 
contributing to the variability in glucuronidation observed with the aglycones studied.  The 
latter may greatly influence rates in the intestine relative to other organs, due to its exposed 
location and direct physical contact with ingested substances.  In fact, normalized UGT1A 
transcript levels extracted from the liver showed little variability, whereas those derived 
across the small intestine exhibited marked differences in abundance (Strassburg et al., 
2000).  Should this finding be translated into UGT1A protein expression, it may be expected 
that the variability in the intestinal glucuronidation might be higher than from the liver.  
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To date, only the UGT1A1*28 polymorphism in these two genes has been found to 
affect both glucuronidation and toxicity of SN-38.  In numerous studies, homozygosity for 
this isoform predisposes patients to neutropenia (de Jong et al., 2005).  Additionally, SN-38 
glucuronidation in liver microsomes from patients hetero- and homozygous for UGT1A1*28 
were lower than patients with two wild-type alleles (Iyer et al., 1999).  As reported by Carlini 
et al. (2005), the association of the UGT1A1*28 allele and diarrhea is not always 
substantiated, which may suggest that more than one isoform may be responsible for SN-38 
catalysis and detoxification (Carlini et al., 2005).  In the current study, there was no clear 
association between the Gilbert’s genotype and glucuronidation.  However, there were very 
few samples analyzed within each genotype group and intestinal region, so the results should 
be cautiously interpreted.  Hepatic microsomal experiments conducted with the probe 
substrates bilirubin and estradiol revealed that glucuronidation rates varied tremendously 
between Gilbert’s patients, with coefficients of variance of 113 and 60%, respectively (Iyer 
et al., 1999; Fisher et al., 2000).  This illustrates that even within a genotype group, 
tremendous variability can occur and with small numbers of patients, differences based upon 
genotype may be difficult to detect.  The results of the present study indicate also that 
relative UGT1A1 protein expression as measured by the probe substrate, etoposide, is clearly 
a better predictor of SN-38 glucuronidation than genotype. 
 In conclusion, the small and large intestine exhibit large interpatient variability in the 
glucuronidation of SN-38.  This variability is highly linked to both UGT1A1 and UGT1A9 
protein expression, as assessed through probe substrate glucuronidation, and not 
UGT1A1*28 genotype, as preliminary results indicate.  Although the influence of UGT1A1 
genotype on SN-38 glucuronidation and toxicity has been extensively studied, the effects of 
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UGT1A9 polymorphisms have received scant attention.  Poor and extensive metabolizer 
phenotypes have been established for several genotypes in vitro, using SN-38 and other 1A9 
substrates, one of which has been shown affect tumor response and toxicity (Villeneuve et 
al., 2003; Girard et al., 2004; Yamanaka et al., 2004; Carlini et al., 2005).  Coupled with the 
results of this study, the previous reports provide support that UGT1A9 may play a major in 
vivo role in the conjugation of SN-38.  Although not directly addressed in this study, the 
results suggest that the substantial differences in intersubject intestinal SN-38 
glucuronidation may be a major factor in the development of SN-38-mediated diarrhea.  
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Table 3.1  Vmax and Km estimates for etoposide glucuronidation in pooled human intestinal 
and human liver microsomes.  Values were obtained through nonlinear regression software, 
and the associated coefficients of variance of the parameters are given in parenthesis. 
 
 
Vmax 
(pmol/min/mg protein) 
 
 
Km 
(µM) 
 
Intestine 
 
34.0 
(3.0%) 
 
435 
(8.6%) 
Liver 
 
82.2 
(5.1%) 
 
157 
(19%) 
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Table 3.2  Demographic information available on enrolled patients.  This list is not 
exhaustive, as information on all patients was not available and all demographic factors are 
not listed. 
 Duodenum Jejunum Colon 
Age    
         20-30 2  1 
         30-40 2 1 1 
         40-50 1 6 2 
         50-60 7 2 11 
         60-70 4 3 3 
Sex    
         Male 7 9 10 
         Female 11 5 9 
Race    
         Lumbee Indian  1  
         Black 4 0 6 
         White 13 12 13 
Coexisting Conditions    
         Diverticulitis 1  2 
         Colon cancer 8  8 
         Liver transplant 3 16  
         Hepatitis B  2  
         Hepatitis C 1 4  
Medications    
         Mycophenolate mofetil 1 2  
         Tacrolimus 3 3  
         Interferon  2  
         Cyclosporine  1  
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Table 3.3  Average in vitro glucuronidation rates of SN-38, propofol, and etoposide in 
human duodenum, jejunum, and colon.  Substrate concentrations employed in assays were 
300 μM for SN-38, and 1 mM for both propofol and etoposide.  Each sample contributing to 
the mean ± SD is an average of duplicate incubations.  All rates are given in pmol/min/mg 
protein normalized to villin density.  Statistical tests on raw data were conducted using 
Kruskal-Wallis test, followed by the Dunn’s post-hoc test, except with etoposide rates from 
the colon and duodenum, which was conducted with the Mann Whitney Rank sum test. 
 
Rate of Glucuronidation 
(pmol/min/mg protein) 
 
 
 
Duodenum 
(n = 18) 
 
 
Jejunum 
(n = 16) 
 
 
Colon 
(n = 19) 
 
 
SN-38 
 
12.4 ± 7.95 
 
13.0 ± 7.99 
 
6.60 ± 5.90* 
 
Propofol 
 
426 ± 371 
 
693 ± 361 
 
1150 ± 1490 
 
Etoposide 
 
12.3 ± 5.24a 
 
N/A 
 
2.41 ± 0.85***, b 
 
* p < 0.05, *** p< 0.001 
a n = 15, b n = 12 
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Table 3.4  UGT1A1 genotype distribution in study subjects.  Each box contains the number 
of subjects with the genotype and are also segregated based upon intestinal segments.  
Biopsies are from 45 subjects (53 samples total), with 18 providing duodenal biopsies, 16 
providing jejeunal tissue, and 19 providing colon samples.  Genotypes are as given as the 
number of TA repeats per allele:  6/6 refers to a patient homozygous for wild-type UGT1A1 
alleles, 6/7 is heterozygous, and 7/7 is homozygous for Gilbert’s syndrome (UGT1A1*28).  
TA repeats lower then 6 impart normal UGT1A1 function, whereas TA repeats higher than 7 
impart poor function (Miners et al., 2002). 
Genotype 
 
5/7 6/6 6/7 7/7 7/8 
 
Duodenum 
 
1 
 
9 
 
6 
 
2 
 
0 
 
Jejunum 
 
0 
 
5 
 
6 
 
4 
 
1 
 
Colon 
 
1 
 
11 
 
5 
 
2 
 
0 
 
Total number of subjects with 
genotype 
 
1 20 15 8 1 
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Table 3.5  SN-38 glucuronidation rates (pmol/min/mg protein) as a function of genotype.  
Each sample contributing to the mean ± SD is an average of duplicate incubations.  Rates are 
normalized for villin content of the sample. 
Duodenum Jejunum Colon 
 Rate 
(pmol/min/mg) 
 
n Rate (pmol/min/mg) 
 
n Rate (pmol/min/mg) 
 
n 
6/6 8.86 ± 2.9 9 10.9 ± 5.7 5 6.72 ± 6.9 11 
6/7 12.5 ± 6.2 6 12.3 ± 9.1 6 6.30 ± 4.2 5 
7/7 15.4 ± 0.28 2 15.9 ± 9.3 5* 3.30 ± 3.3 2 
 
*Glucuronidation rate from subject with 7/8 genotype was included 
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Table 3.6  Intestinal glucuronidation, genotype, and toxicity profiles of eight patients 
receiving irinotecan 125 mg/m2 plus leucovorin and 5-flurouracil.  Glucuronidation rates are 
the average of two incubations and are normalized for biopsy villin content.  To assess the 
incidence of diarrhea, patients were phone weekly and medical charts were examined for 
dosage reduction or notes on toxicity. 
 
 
SN-38 glucuronidation 
(pmol/min/mg protein) 
 
 
Patient Age Sex Race Duodenum Colon 
Grade 3/4 
diarrhea 
Genotype 
1 47 Female Black 20.6 8.22 No 6/7 
2 63 Female White 17.7 11.8 Yes 6/7 
3 24 Male White 10.3 3.6 No 6/6 
4 55 Male Black 38.6 13.3 No 5/7 
5 59 Female White 6.04 4.33 Yes 6/6 
6 59 Female White 12.6 2.3 No 6/6 
7 68 Male Black 11.1 3.58 No 6/6 
8 38 Female Black 4.74 3.53 Unknown 6/6 
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Figure 3.1  Chemical structures of propofol (A) and etoposide (B).  Site of propofol 
glucuronidation and proported site of etoposide glucuronidation is indicated with *. 
A 
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Figure 3.2  LC-MS chromatograms for propofol-G (A) and etoposide-G (B).  Elution times 
for A are 6.2 minutes for propofol-G (0.2 µg/mL) and 7.6 minutes for ibuprofen (internal 
standard) and for B are 6.1 minutes for AZT (internal standard) and 8 minutes etoposide-G 
(0.25 μg/mL).  Compounds were detected with electrospray interface using negative ion 
mode.  Selected ion monitoring was utilized in both assays.  Assay conditions are provided in 
METHODS. 
 
B 
A 
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Figure 3.3  Etoposide glucuronidation by recombinant isoforms.  Reactions contained 0.5 
mg/mL of recombinant isoform or human liver microsome and 400 µM etoposide, and 
proceeded for 2 hours at 37°C.  Each bar is the average peak area of etoposide-G yielded 
from duplicate incubations relative to the average of that for UGT1A1, multiplied by 100%.   
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Figure 3.4  SN-38 glucuronidation in rat hepatic microsomes.  Incubations proceeded at 
37°C for 30 minutes with 0.5 mg/mL protein.  Data points are mean ± SD (n = 3-6 replicates 
per concentration).
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Figure 3.5  Propofol glucuronidation in human intestinal microsomes.  Incubations were 
conducted over 40 minutes at 37°C with 0.2 mg/mL microsomal protein.  Points are 
glucuronidation rates for individual samples (duplicate incubations per concentration). 
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Figure 3.6  Kinetic profiles of etoposide in human intestinal (A) and human liver 
microsomes (B).  Reactions contained 0.5 mg/mL of microsomal protein and proceeded for 
30 minutes at 37°C.  Data are mean ± SD (n = 3 replicates). 
 
A 
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Figure 3.7  SN-38 (A), propofol (B), and etoposide (C) glucuronidation in patients providing 
both duodenal (filled bars) and colonic (open bars) biopsies.  Bars are an average of two 
incubations.  Numbers along horizontal axis correspond to a patient identifier.  
A 
C 
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Figure 3.8  Correlation analyses of SN-38 and propofol glucuronidation (pmol/min/mg 
protein) in human duodenum (A), jejunum (B), and colon (C).  The best-fit regression line, 
Spearman correlation coefficient, and associated p value are given for each plot.
A 
B 
C 
r2 = 0.88 
p < 0.001 
r2 = 0.71 
p < 0.001 
r2 = 0.86 
p < 0.001 
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Figure 3.9  Correlation analyses of SN-38 and etoposide glucuronidation in human 
duodenum (A) and colon (B).  Rates are pmol/min/mg protein.  The best-fit regression line, 
Spearman correlation coefficient, and associated p value are given for each plot.
B 
A 
r2 = 0.85 
p < 0.001 
r2 = 0.88 
p < 0.001 
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THE CONTRIBUTION OF INTESTINAL UDP-GLUCURONOSYLTRASFERASES 
IN THE MODULATION OF SN-38 INDUCED GASTROINTESTINAL TOXICITY 
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A. ABSTRACT 
Life-threatening diarrhea afflicts a considerable percentage of patients treated with 
irinotecan, an anti-cancer agent with effects elicited through its active metabolite, SN-38.  
The primary detoxification pathway for SN-38 is glucuronidation.  The purpose of this study 
was to evaluate the role that intestinal UDP-glucuronosyltransferases (UGTs) have from 
hepatic UGTs in modulating this diarrhea.  To investigate this, Gunn rats devoid of UGT1A 
activity were injected with recombinant adenoviral vectors expressing UGT1A1, 1A6, and 
1A7, resulting in reconstituted hepatic UGT expression comparable to a heterozygote.  
Hepatic microsome studies indicated that four to seven days after adenoviral injection, 
transfected Gunn rats (j/jAV) had SN-38 glucuronide (SN-38G) formation rates three times 
higher than control heterozygote rats (j+AV).  The adenovirus did not impart any 
glucuronidating capacity to the intestine in j/jAV rats, while j+AV rats possess intestinal 
UGT function.  After the administration of 20 mg/kg/day irinotecan i.p. to j/jAV rats four 
days after adenovirus injection, diarrhea ensued before the fourth irinotecan dose.  j+AV rats 
were spared the diarrhea, and the toxicity was mild compared to the j/jAV rats, as measured 
by diarrhea scores, weight loss, and histological assessments of the cecum and colon.  The 
pharmacokinetics of irinotecan, SN-38, and SN-38G indicate that the systemic exposure of 
SN-38 and SN-38G was higher and lower, respectively, in j/jAV rats.  However, the 
excretion of irinotecan and metabolites were similar between the two groups.  As intestinal 
UGTs are the main discriminating factor between j/jAV and j+AV rats, their presence may 
be responsible for the gastrointestinal protection observed in j+AV rats.
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B. INTRODUCTION 
The UDP-glucuronosyltransferases (UGT) are a superfamily of metabolic enzymes 
that catalyze the transfer of UDP-glucuronic acid to endogenous and xenobiotic substrates.  
Glucuronidation is a detoxification mechanism from several standpoints.  It decreases the 
apparent volume of distribution, increases the molecular weight, and increases substrate 
specificity for active transport by imparting a negative charge, which are all processes that 
facilitate substrate elimination from the body.  Also, in most cases, glucuronidation renders 
the substrate inactive with respect to its pharmacological or physiological target.  A Wistar-
derived rat model of UGT1A subfamily deficiency, the Gunn rat, has allowed tremendous 
insight into the importance of the UGT1A family in the metabolism and toxicity of substrates 
(Wells et al., 2004).  The abolition of UGT1A glucuronidation in these rats stems from a 
frameshift mutation that yields a truncated, nonfunctional protein unable to bind UDP-
glucuronic acid (Iyanagi et al., 1989). 
Although the primary organ of glucuronidation is historically thought to be the liver, 
research on intestinal UGTs has shown their importance.  Large differences in protein levels 
of the UGT1A family are not observed between these organs, and hepatic and intestinal 
tissues have been shown to have similar catalytic rates for a number of substrates, including 
carcinogens, tertiary amines, and steroids (Strassburg et al., 1999a; Strassburg et al., 2000).  
Differences in the tissue glucuronidation profile for a given substrate is likely due to tissue-
specific UGT isoform expression evident in both humans and rodents (Strassburg et al., 
1999a; Shelby et al., 2003; Gregory et al., 2004).  Due to their localization, intestinal UGTs 
have been shown to contribute significantly to first-pass metabolism after oral administration 
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of substrates and may limit the systemic exposure of substrates undergoing enterohepatic 
recirculation (Sfakianos et al., 1997; Chen et al., 2003). 
SN-38, the active metabolite of the chemotherapeutic drug irinotecan (Camptosar®, 
Pfizer, Inc), is a substrate for hepatic and intestinal UGT1A isoforms in both rats and humans 
(Hanioka et al., 2001b; Gagne et al., 2002; Tallman et al., 2005).  SN-38 glucuronide (SN-
38G), the resulting metabolite, is inactive and non-toxic (Figure 1.1).  By directly injuring 
enteric cells, SN-38 causes a dose-limiting diarrhea in approximately 20% of patients (Araki 
et al., 1993; Iyer et al., 1998; Saltz et al., 2000).  Several strategies have been successfully 
employed to prevent this diarrhea.  These have focused mostly upon reducing intraluminal 
SN-38 concentrations, and include the inhibition of SN-38 and SN-38G biliary excretion and 
the inhibition of β-glucuronidase, an intestinal enzyme that will hydrolyze SN-38G to form 
SN-38 (Takasuna et al., 1996; Kehrer et al., 2001; Horikawa et al., 2002; Desai et al., 2005).  
Similarly, it was proposed by Gupta et al. (1994) that patients with poor hepatic SN-38 
glucuronidation would have high biliary SN-38 concentrations and likely experience 
gastrointestinal toxicity.  They devised a mathematical equation to describe this scenario, 
given as the ratio of the AUC values of SN-38 to SN-38G multipled by irinotecan AUC.  In 
this study, the values, termed ‘bilary index’, were significantly higher in patients with 
diarrhea (Gupta et al., 1994).  However, the biliary index has not been reproducibly validated 
by other investigators, probably because SN-38G excreted in the bile also contributes to 
toxicity after cleavage with β-glucuronidase to form SN-38 (Canal et al., 1996; Xie et al., 
2002a). 
Thus far, the approaches to both predict and prevent SN-38 mediated diarrhea have 
neglected the capacity for inherent enterocyte protection through intestinal UGT expression.  
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This concept of intestinal UGT protection in irinotecan gastrointestinal toxicity was 
originally proposed by Tukey et al. in 2002, yet no one has investigated it, likely due to the 
difficulty in isolating their contribution from hepatic UGTs in a toxicity model that takes 
several days to develop (Tukey et al., 2002).  To address the hypothesis that intestinal UGTs 
play a major role in mediating SN-38-induced diarrhea, we utilize a Gunn rat model with 
reconstituted hepatic UGT activity, achieved by adenoviral infection.  As described 
previously, intravenous injection of adenoviral vectors carrying rat UGT1A1, 1A6, and 1A7 
will exclusively infect the liver, and in specific doses, have been shown to elicit a hepatic 
glucuronidation pattern similar to a Wistar/Gunn heterozygote (Amalfitano, 2004; Miles et 
al., 2006b).  By comparing the pharmacokinetic and toxicity profiles from these transfected 
Gunn rats, possessing only hepatic UGTs, to those of heterozygous Gunn rats, possessing 
both hepatic and intestinal UGTs, we show that intestinal conjugation of SN-38 is critical in 
reducing the incidence of gastrointestinal toxicity. 
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C.  MATERIALS AND METHODS 
Materials.  For calibration curves, irinotecan and SN-38G methyl ester were kindly provided 
by Dr. Robert Kelly of Pfizer (Kalamazoo, MI), previously Pharmacia.  The procedure to 
hydrolyze SN-38 from irinotecan is published (Ni, 2001).  SN-38G cleavage from SN-38G 
methyl ester was detailed earlier (Chapter 2).  After β-glucuronidase hydrolysis of an SN-
38G stock solution aliquot to form SN-38, SN-38G stocks were quantitated based upon SN-
38 standard curves (Chapter 2).  Reagents for microsomal experiments were purchased 
through Sigma-Aldrich (St. Louis, MO).  Electrophoresis, gel/membrane transfer boxes, and 
western blot reagents were obtained through Bio-Rad (Hercules, CA) unless stated.  All other 
chemicals and solvents were purchased through commercial sources. 
Generation and Propagation of Recombinant Adenoviruses.  First generation adenoviral 
vectors carrying rat UGT1A1, 1A6, 1A7, or 1A10 isoforms were produced using the 
homologous recombination method in E. coli by the Massey Cancer Center Virus Vector 
Shared Resource Facility at Virginia Commonwealth University.  The vector plasmid, pTG-
CMV, contained the E1 and E3 deleted adenoviral strain H5d1324.  The shuttle plasmid, 
pZero-TG-CMV-rUGT1A, contained a cloned rat UGT isoform within the E1 deleted region.  
After the vector plasmid was cut with restriction enzyme ClaI, both plasmids were co-
transformed into E.coli.  Selected recombinant plasmids were transfected into human 
embryonic kidney 293B cells, which provide the deleted viral E1 proteins necessary for 
reproduction, and were used to propagate the viruses (American Type Culture Collection, 
Manassas VA).  Replication-deficient viruses were then isolated from cellular components 
through freeze-thaw and centrifugation cycles, then purified and concentrated through 
cesium chloride gradients and dialysis (Miles et al., 2006b).  By lysing and measuring the 
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absorbance of an aliquot of diluted virus at 260 nm, the final viral concentration was 
determined and given in optical density units (OD), where 1 OD 260  is 1 x 1012 viral particles 
per mL of dialysate.  Adenoviral stocks were stored at -80° C. 
Animals.  Male Gunn (j/j) and heterozygous (j+) Gunn rats (weighing 200-275 g) used in 
this study were colony-bred from j/j males and j+ females at Virginia Commonwealth 
University.  Gunn rats were selected from j+ littermates by jaundice evident on their feet and 
ears.  During the study, animals were housed two per cage in a temperature and humidity-
regulated room with a 12 hour light-dark cycle.  Standard rat chow and water were made 
freely available.  All care and conducted procedures were approved by the University of 
North Carolina at Chapel Hill and Virginia Commonwealth University Institutional Animal 
Care and Use Committees. 
Animal Treatment and Toxicity.  On day 1, j/j rats (n = 5) received 0.15 mL adenovirus as 
a bolus through the tail vein.  The total dose of 0.13 OD of adenovirus consisted of 0.1 OD of 
adenovirus encoding rat UGT1A1, 0.025 OD of 1A6, and 0.005 OD of 1A7.  To control for 
any effects adenoviral injection may have in the j/j rats, j+ rats (n = 5) received 0.13 OD 
units of adenovirus carrying rat UGT1A10, an isoform with no activity towards SN-38 (data 
not shown).  Hepatic UGT expression in the infected Gunn (j/jAV) animals was deemed 
adequate four days after adenoviral infection, as determined by visually inspecting the 
plasma for the resolution of hyperbilirubenemia.  Thus, four days after infection, j/jAV and 
infected (j+AV) rats received 20 mg/kg of commercially available irinotecan (Camptosar, 
Pfizer, 20 mg/mL) in a final volume of 0.4 mL in their intraperitoneal space.  Blood (0.1 mL) 
was then taken at 0.25, 0.5, 1, 2, 4, 8, and 12 hours after this first dose of irinotecan.  The 
blood was centrifuged and plasma was stored at -20° C until analysis.  Irinotecan was 
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administered daily to j/jAV and j+AV for three days.  Prior to each dose of irinotecan, the 
rats were weighed and assessed for the extent of diarrhea on a scoring system:  0, firm stool; 
1, malformed stool; 2, watery stool with perianal staining; 3, severe perianal staining (Stern 
et al., 2006).  On the seventh day after adenovirus administration, the animals were 
euthanized.  Livers from each rat were placed at -80°C.  Colons and cecums were rinsed and 
placed in 10% formalin (Fisher Scientific, Hampton, NH). 
In a separate study, j/jAV (n= 4) and j+AV (n= 2) rats were anesthetized and biliary 
catheters were placed four days after adenovirus injection with the isoforms and doses as 
described above for the respective genotype.  Biliary cannulas were placed, and bile was 
collected over the following intervals:  0-0.25 hr, 0.25-0.5 hr, 0.5-1 hr, 1-2 hr, 2-4 hr, and 4-6 
hr.  After the final collection interval was completed, rats were euthanized.  Livers from each 
rat were placed at -80° C. 
Microsomal preparation and glucuronidation assay.  Livers from all rats in the biliary 
excretion study and the toxicity/pharmacokinetic study were used to make hepatic 
microsomes.  Intestines and colons from irinotecan-naiive j/jAV and j+AV (n = 2 in each 
group) rats were extracted seven days after adenovirus injection and used to make 
microsomes.  The procedures followed to make microsomes from these organs were 
described previously (Chapter 2).  Microsomal protein concentrations were determined by 
the Bradford method, using albumin as a standard. 
 In vitro conjugation reactions of SN-38 with the hepatic and intestinal microsomes 
contained the following components:  magnesium chloride (10 mM assay concentration), Brij 
35 (0.5 mg/ mg protein), D-saccharic acid 1,4-lactone (10 mM), SN-38 carboxylate (300 
µM), and microsomal protein (0.25 mg/mL) in a final volume of 200 µL 0.1 M Tris, pH 7.0.  
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The reaction was initiated by the addition of UDP-glucuronic acid (2mM final concentration) 
and proceeded at 37° C for 40 minutes and quenched with acetonitrile.   
Western blotting.  Hepatic, intestinal, and colonic microsomal proteins (50 µg) were 
subjected to electrophoresis through a 4-15% gradient Tris gel (Ready Gel, Bio-Rad).  Upon 
separation, proteins were transferred to nitrocellulose membranes using 105 volts for one 
hour.  Membranes were then washed in 5% milk/0.2% Tween in Tris-Buffered Saline (TBS-
T) for one hour to prevent non-specific antigen-antibody binding.  After two washes in 0.5% 
TBS-T, blots with hepatic microsomes were incubated with either α-rat UGT1A1 (diluted 
1:1000 in 0.5% milk/0.2% TBS-T) or α-rat UGT1A7 (1:1500 in 0.5%milk/0.2% TBS-T) for 
one hour each.  Membranes with intestinal and colonic microsomes were probed with α-
UGT1A antiserum (1:1000 in 0.5% milk/0.2%TBS-T) overnight.  Information on specificity 
and production of antiserum reacting with rat UGT1A1, 1A7, or with the UGT1A common 
region on all rat UGT1A proteins was formerly published (Kessler et al., 2002; Webb et al., 
2005).  Antiserum was washed off twice with 0.5% TBS-T, and a horseradish peroxidase 
conjugated α-mouse IgG (1:10,000, Chemicon) was incubated with all blots for one hour.  
After two washes with 0.5% TBS-T, chemiluminescent reagent (ECL, Amersham 
Biosciences) was applied to hepatic microsomal membranes, exposed to film (Biomax, 
Kodak) for four minutes, and developed.  For intestinal protein blots, chemiluminescent 
reagent (SuperSignal, Pierce) was applied and a phosphoimager (Versadoc, Biorad) was used 
to visualize theresulting bands.  In all cases, a molecular weight marker was added to the gel 
to verify the presence of the UGT band (approximately 55 kDa). 
Chromatographic Analysis.  High performance liquid chromatography (HPLC) with 
fluorescence detection was used to quantify irinotecan, SN-38, and SN-38G concentrations 
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from plasma, bile, and in vitro microsomal incubations.  Acetontrile (300 µL), internal 
standard (camptothecin, 200 ng) and perchloric acid (5 µL, 5% solution) were added to each 
plasma sample (25µL).  Bile was first diluted 1 to 200 in Tris, and 200 µL were subject to 
acetonitrile (800 µL) and perchloric acid precipitation and the addition of camptothecin (100 
ng).  For microsomal samples, acetonitrile (800 µL) containing perchloric acid and irinotecan 
as an internal standard (50 ng) was added.  All samples were then centrifuged at 15,000 g for 
10min.  Next, the aceontrile layer was extracted and evaporated under a stream of nitrogen.  
Samples were then reconstituted with 200 µL of 30% methanol/ 100 mM ammonium acetate.  
Standards were prepared as above for each matrix and contained blank bile, blank plasma, or 
microsomal protein. 
 The HPLC system used to inject, separate, and detect analytes was as described in 
Chapter 2, however an SIL10A autosampler was used (Shimadzu, Tokyo, Japan).  Mobile 
phase consisted of 37% methanol/100 mM ammonium acetate and 5 mM 
tetrabutylammonium sulfate, pH 4.9 run at 1.5 mL/min for microsomal samples.  For plasma 
and bile samples, 39% methanol/100 mM ammonium acetate and 15 mM 
tetrabutylammonium sulfate, pH 4.9 was run as mobile phase at 1.3 mL/min.  Standard 
curves in each matrix were linear and validated if the lower limit of quantitation coefficient 
of variance was ≤ 15% and the analyte to internal standard ratio normalized to concentration 
was constant.  Calibration curve ranges were as follows: for plasma, 2.5-200 ng/mL SN-38G, 
100-10,000 ng/mL irinotecan, 2.5-50 ng/mL SN-38; for bile,  1.25 ng -100 ng/mL SN-38G, 
12.5 ng-1000 ng/mL irinotecan, 2.5-75 ng/mL SN-38; and for microsomes, 2-300 ng/mL SN-
38G.  Excitation and emission wavelengths were 229 and 420 nm, respectively, for SN-38G, 
irinotecan, and camptothecin.  The emission wavelength used to detect SN-38 was changed 
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to 543 nm during each chromatographic run.  To avoid inter-day variability, all samples in a 
given matrix were processed and run on the same day.  A representative chromatograph for 
bile, plasma, and microsomes is given in Figure 4.1.  
Histology.  Colon and cecum samples were removed from formalin, rinsed, and stored in 
70% ethanol.  Samples were then emedded in paraffin, sectioned, mounted on slides, and 
stained with hematoxylin and eosin by the Histopathology Core Lab in the Lineberger 
Comprehensive Center at UNC.   
Data Analysis.  Pharmacokinetic parameters for irinotecan, SN-38, and SN-38G were 
determined by noncompartmental analysis using WinNonlin software (version 5.0, Pharsight, 
Mountain View, CA).  Statistical tests were perfomed using Sigma Stat software (version 
2.0, Systat, Point Richmond, CA).  A t-test was used to assess differences between j/jAV and 
j+AV rats given irinotecan, as the data were found to be normally distributed with equal 
variance. The Mann-Whitney rank sum test was used to analyze differences between the 
groups with respect to diarrhea scores.  To assess biliary excretion, the amounts of irinotecan 
and metabolites excreted over the collections intervals were summed.  Statistical significance 
was reached at p≤0.05.   
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D. RESULTS 
All rats injected with adenovirus tolerated the dose well, with no immunological 
response or behavorial or pathophysiological changes evident after administration.  Gunn rats 
receiving 0.13 OD of adenovirus expressed rat UGT1A1 and 1A7, the isoforms relevant to 
SN-38 glucuronidation, in the liver (Figure 4.2).  By visual inspection of the blots and 
glucuronidation profiles in individual rats, it appears that rat UGT1A7 expression is more 
highly associated with SN-38 glucuronidation when compared with the expression of rat 
UGT1A1 (Figure 4.2).  In the j/jAV rats, hepatic SN-38 glucuronidation reached its 
maximum expression four days after adenoviral infection (average of 38.8 pmol SN-38G 
formed/min/mg protein), and was sustained over the experimental period to seven days post-
infection (average of 34.8 SN-38G formed/min/mg protein).  Over this time frame, the j/jAV 
rats have an average of three to four times greater SN-38 hepatic glucuronidation capacity 
versus the j+AV rats (Figures 4.2 and 4.3).  The difference in activity between j/jAV and 
j+AV rats was significant at seven days post-infection (p=0.003) (Figure 4.2).  Hepatic 
glucuronidation of SN-38 in the j/jAV rats was solely due to the adenovirus delivery, as 
uninfected Gunn rats possess no intrinisic SN-38 catalytic activity (data not shown).  Figure 
4.4 reveals that an intravenous injection of adenovirus does not impart any UGT1A 
expression or function to the intestine or colon of a j/jAV rat. 
The pharmacokinetic profile and parameters of irinotecan and its metabolites are 
shown in Figure 4.5 and Table 4.1.  The pharmacokinetics of irinotecan were similar between 
j/jAV and j+AV rats.  SN-38 exposure, as represented by AUC, was significantly higher in 
j/jAV rats.  The elimination half-life of SN-38G was not calculated due to the lack of a 
reproducible terminal concentration/time slope in the profiles of most rats.  Despite higher in 
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vitro SN-38 glucuronidation rates, the AUCSN-38G in j/jAV rats was approximately two-fold 
lower than j+AV rats on average. 
In a separate experiment to determine whether intestinal exposure to irinotecan, SN-
38, and SN-38G was similar between j/jAV and j+AV rats, bile was collected from rats from 
both groups after a single dose of irinotecan 20 mg/kg i.p. four days after adenovirus 
injection.  Although statistical analysis is not applicable (n=2 j+AV rats), it appears that 
irinotecan is excreted to a greater degree in j+AV rats relative to j/jAV rats over a six hour 
period (Figure 4.6).  Little or no difference in the excretion of SN-38 and SN-38G between 
the two groups is apparent. 
The two groups of rats studied tolerated repeated doses of irinotecan with dissimilar 
results.  Twenty-four hours after the second and third dose of irinotecan (20 mg/kg/day i.p.), 
j/jAV were found to have lost a greater percent of their body weight relative to baseline 
(Figure 4.7).  After finding that several j/jAV rats had reached the predetermined weight loss 
limit of 20% the morning after the third irinotecan dose was administered, the study was 
ended and all animals were euthanized.  At this time, every j/jAV had at least grade 2 
diarrhea, characterized by loose stools and peri-anal staining.  This outcome was significantly 
different from all j+AV rats, which did not exhibit any diarrheal symptoms (Table 4.2)  Since 
toxicity differences between the groups were strikingly evident on a macroscopic basis, 
microscopic differences in colon and cecum integrity and composition were compared 
(Figure 4.8).  In the colon and cecum of j/jAV rats, there was a significant collapse of crypts.  
Inflammatory cell debris and mucoid material filled the crypts.  Infiltrating neutrophils were 
also evident.  Goblet cells were widely depleted.  Epithelial cells lining the crypt were fused 
or severely necrosed.  In patchy areas, low cuboidal epithelial cells with thin cytoplasm and 
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large nuclei lined the crypt, indicative of regeneration.  In cecum and colon samples from 
j+AV rats, tall columnar epithelial cells lined intact villi.  Goblet cells containing mucous 
filled the crypts.  Overall, colon and cecal mucosa in j+AV rats was normal in appearance.  
In several j/jAV and j+AV cecum and colon samples, moderate submucosal edema was 
present. 
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E. DISCUSSION 
 In this study, we examine the importance of intestinal UGTs in modulating 
irinotecan-induced diarrhea.  This has been accomplished by using a rat model essentially 
engineered to differ from its control in intestinal UGT expression only.  By utilizing an 
adenoviral vector containing rat UGT1A isoforms constitutively expressed in other Wistar-
derived rat strains, Gunn rats were found to have systemic SN-38 conjugation activity.  After 
intravenous injection of adenoviruses, any virions not sequestered by Kupffer cells will be 
exclusively taken up by surrounding hepatocytes, precluding intestinal infection (Amalfitano, 
2004).  The lack of intestinal UGT expression and function in j/jAV rats was indeed shown 
in this study.  Therefore, by j/jAV rats gaining hepatic UGT activity and j+AV rats naturally 
possessing both hepatic and intestinal UGTs, we could test the hypothesis that intestinal 
UGTs are local, protective mechanisms inherent in enteric cells, the site of SN-38 
cytotoxicity, and their expression is critical in the prevention of diarrhea.  As striking 
differences in the incidence of diarrhea and lower intestinal pathology were noted after both 
groups of rats were challenged with irinotecan, further experiments were conducted to ensure 
that the toxicity that ensued was due to a lack of intestinal SN-38 conjugation and not due to 
differences in systemic or intestinal irinotecan, SN-38, or SN-38G exposure. 
 Ideally, hepatic glucuronidation and the systemic disposition of irinotecan, SN-38, 
and SN-38G in the j/jAV rats would precisely mimic that in the j+AV rats.  Over the entire 
irinotecan-dosing interval, microsomal reactions demonstrated that j/jAV rats possessed 
significantly higher SN-38 conjugation rates.  This is most likely due to higher expression of 
UGT1A7 in j/jAV animals, as glucuronidation rates mimic rat 1A7 levels.  Additionally, 
UGT1A7 is the major rat isoform responsible for SN-38 catalysis as determined by 
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recombinant isoform studies (Tallman et al., 2005).  Despite higher in vitro SN-38 
glucuronidation rates, the exposure to SN-38G in the plasma of j/jAV rats was two-fold 
lower than the j+AV rats.  It is only speculative to compare data from these two different 
measures of glucuronidation.  However, one explanation for this apparent discrepancy may 
be more efficient SN-38G basolateral transport mechanisms in the j+AV rat, which would 
manifest in higher plasma glucuronide levels despite lower intracellular glucuronidation 
rates.  In these rats, there is a physiological need for basolateral transporters that recognize 
glucuronides, most notably MRP3.  Conversely, in an uninfected j/j rat, levels of these 
transporters may be low due to the lack of glucuronide substrates present intracellularly.  
Similar theories have been proposed, where MRP3 expression is regulated by accumulating 
intracellular substrates (Donner and Keppler, 2001; Johnson et al., 2005).  In j/jAV rats, 
induction of MRP3 may lag behind UGT expression, which would explain why less SN-38G 
was measured in plasma.  To address this, Western blots of hepatic membrane proteins from 
j+AV, j/jAV, and j/j rats were run.  From this data, there is no observable difference in the 
expression of MRP3 between these groups (data not shown).  Thus, factors influencing the 
discordance between in vitro and in vivo measures of SN-38 glucuronidation are currently 
unknown. 
 SN-38 levels are significantly higher in j/jAV rats.  This may be a function of less 
SN-38 consumed, as reflected in lower SN-38G levels, differences in transport of SN-38 
from the hepatocyte to blood, or more efficient reabsorption of SN-38 in j/jAV animals.  In a 
rat without functional intestinal glucuronidation, enteric cycling of SN-38 would be 
nonexistent and more SN-38 could be reabsorbed into the blood.  This is not very likely, as 
apical secretion of SN-38 was several fold more efficient than basolateral flux as determined 
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in Caco-2 cells (Kehrer et al., 2000).  Additionally, the inhibition of β-glucuronidase does not 
reduce plasma AUCSN-38 relative to control-treated rats, indicating little enterohepatic 
circulation (Takasuna et al., 1998). 
 With the knowledge that high intestinal SN-38 concentrations may be a predisposing 
factor in the development of diarrhea, differences in irinotecan, SN-38, and SN-38G biliary 
excretion in j/jAV and j+AV rats were studied.  In the intestinal lumen, irinotecan may be 
converted to SN-38 by carboxylesterases and SN-38G excreted into bile is almost completely 
hydrolyzed to SN-38 by fecal β-glucuronidases (Takasuna et al., 1998; Khanna et al., 2000; 
Slatter et al., 2000).  Differences in excretion of these compounds between the two groups of 
rats may be a confounding factor in describing the precise role that intestinal UGTs have in 
mediating toxicity.  Although the data were derived from a small number of rats, the amounts 
of SN-38 and SN-38G extruded into bile were similar.  The excretion of irinotecan was 
approximately double in the j+AV animals.  From this data, j+AV rats may then have a 
slightly greater intestinal SN-38 burden by iriniotecan hydrolysis.  Overall, in vitro, biliary 
excretion, and pharmacokinetic data indicate that the disposition of irinotecan and its 
metabolites are similar in j/jAV and j+AV rats.  The small differences observed between the 
groups of rats with regards to these parameters likely do not explain the extraordinary degree 
of intestinal toxicity experienced only by the j/jAV animals. 
 The in vivo data presented here support published in vitro data relating to UGT 
protection in intestinal cells.  Propofol, a competitive substrate for UGT1A9, reduced the 
concentration of SN-38 needed to elicit death in 50% of HT-29 colon carcinoma cells in 
culture.  In contrast, propofol did not affect this value in HCT-116 colon cancer cells.  As the 
former cells have demonstrated UGT activity while the latter cells do not, the results from 
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this study also indicate toxicity is inversely related to SN-38G formation (Cummings et al., 
2003). 
Currently, it is unknown what level of constitutive intestinal UGT function will spare 
an animal from toxicity to SN-38.  Heterozygote Gunn rats have only intermediate intestinal 
UGT1A expression relative to a Wistar rat, yet the residual activity in the former animals was 
sufficient to protect them from diarrhea.  As with rats, patients with the lowest intestinal SN-
38G formation may be those experiencing diarrhea.  In humans, large differences in intestinal 
SN-38 conjugation are noted, and may result from numerous factors (Chapter 3).  Various 
components of food, such as chrysin or octylgallate, have been found to selectively induce or 
potently inhibit intestinal SN-38G formation, respectively (Cummings et al., 2003; Tobin et 
al., 2006).  As UGT1A1 and UGT1A9 are found in the lower intestine and recognize SN-38 
as a substrate, polymorphisms in these isoforms may impart low or high catalytic turnover 
and effect gastrointestinal adverse events (Strassburg et al., 1998; Tallman et al., 2005).  For 
instance, SN-38G formation was lower in hepatic microsomes from patients with Gilbert’s 
syndrome, caused by a mutation in the UGT1A1 promoter, relative to the glucuronidation in 
patients with a wild-type promoter (Iyer et al., 1999).  The presence of this polymorphism 
was found to be predictive of patients developing diarrhea in one clinical study (Marcuello et 
al., 2004).   
To date, low hepatic SN-38 glucuronidation has most commonly been linked to the 
development of diarrhea, as evident through the establishment of the biliary index (Gupta et 
al., 1994).  However, our data indicate that intestinal toxicity ensues regardless of hepatic 
UGT expression and supports the following scenario.  Patients with inefficient hepatic 
glucuronidation (i.e., Gilbert’s patients) will excrete less SN-38G and similar levels of SN-
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38.  In contrast to a patient with efficient hepatic activity, these patients will have less total 
intestinal SN-38 for several reasons.  SN-38G is more efficiently transported into bile and all 
SN-38G in the intestine is cleave to SN-38 by β-glucuronidase (Chu et al., 1997; Slatter et 
al., 2000).  Despite this, Gilbert’s patients may still experience diarrhea, because of low 
enteric SN-38G formation.  Thus, the biliary index proposed by Gupta et al. (1994) may 
correlate with the incidence of diarrhea in these patients, although toxicity has little to do 
with systemic glucuronidation (Gupta et al., 1994).  Patients with a low biliary index may 
also suffer adverse effects, resulting from poor intestinal turnover of a high SN-38 burden.  
This scenario, similarly proposed by others, may explain the poor correlation between the 
biliary index calculation and diarrhea (Tukey et al., 2002). 
The j/jAV and j+AV model is being utilized in our laboratories to study the influence 
of intestinal UGTs on local toxicity.  This model should be applicable to a wide range of 
toxic substrates which are highly glucuronidated by intestinal isoforms to inactive 
conjugates, such as mycophenolic acid (MPA).  MPA is the active metabolite of the 
immunosuppressant mycophenolic acid mofetile (MMF) which induces gastrointestinal 
toxicity in a higher percentage of treated patients.  Indeed, despite similar pharmacokinetic 
profiles, j/jAV rats treated with 45 mg MMF/kg/day i.p. for three days exhibited severe 
diarrhea in constrast to the j+AV rats that were spared this adverse effect (Miles et al., 
2006a).  In summary, the studies with MPA and SN-38 in j/jAV and j+AV rats demonstrate 
that intestinal UGTs function in a primary role to protect the integrity of the gastrointestinal 
mucosa against cytotoxic agents. 
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Table 4.1  Pharmacokinetic parameters after a single dose of irinotecan, 20 mg/kg i.p., in 
j/jAV and j+ AV rats (n = 5 each) as determined by noncompartmental analysis.  AUC refers 
to that determined over the blood collection interval, from 0-12 hrs.  ** p<0.01 or *** p < 
0.001 compared with parameter average j+AV rats.  Values are given as mean ± SE.   
Parameter j/j AV j+AV 
 
Irinotecan AUC 
(min*µg/mL) 
 
602 ± 120 411 ± 71 
 
Irinotecan V/F 
(mL) 
 
1103 ± 190 1540 ± 170 
 
Irinotecan Cl/F 
(mL/min) 
 
7.10 ± 1.5 12.7 ± 2.2 
 
Irinotecan t1/2 
(min) 
 
127 ± 35 88.6 ± 9.1 
 
SN-38 AUC 
(min*µg/mL) 
 
8.64 ± 0.83** 5.37 ± 0.45 
 
SN-38 t1/2 
(min) 
 
651 ± 98 478 ± 39 
 
SN-38G AUC 
(min*µg/mL) 
 
21.3 ± 1.3*** 45.5 ± 2.6 
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Table 4.2  Diarrhea score in j/jAV and j+AV rats (n = 5 in each group) as determined 24 
hours after each daily dose of irinotecan, 20 mg/kg i.p.  Scoring criteria are given under 
MATERIALS and METHODS.  ** indicates p<0.01 compared with scores in j+AV rats after 
the same dose. 
 
Diarrhea Score 
Group/irinotecan  
dose number 
 
0 
 
1 
 
2 
 
3 
 
Mean Score 
 
j/jAV/Dose 1 
 
5a 
 
0 
 
0 
 
0 
 
0 
 
j+AV/Dose 1 
 
 
5 
 
0 
 
0 
 
0 
 
0 
 
j/jAV/Dose 2 
 
 
5 
 
0 
 
0 
 
0 
 
0 
j+AV/Dose 2 
 
5 0 0 0 0 
 
j/jAV/Dose 3 
 
 
0 
 
0 
 
1 
 
4 
 
2.8** 
j+AV/Dose 3 
 
5 0 0 0 0 
     
   anumber of rats experiencing the grade of diarrhea the specified group 
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Figure 4.1  Chromatographs of SN-38G (1), irinotecan (2), camptothecin (3), and SN-38 (4) 
standards in bile, diluted 1:200, 200 µL (A); plasma, 25 µL (B); or microsomal reaction, 200  
µL (C).  Concentrations are:  A)  1, 25 ng/mL; 2, 250 ng/mL; 4, 50 ng/mL.  B)  1, 100 
ng/mL; 2, 10 µg/mL; 4, 100 ng/mL.  C)  1, 125 ng/mL.  
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Figure 4.2  Hepatic expression of rat UGT1A1 (A) and rat UGT1A7 (B) in j+ AV rats (lanes 
1-5) and j/jAV rats (lanes 6-10) seven days after adenoviral injection of rat UGT1A10 to j+ 
rats or UGT1A1, 1A6, and 1A7 to j/j rats.  Corresponding in vitro SN-38 glucuronidation 
rates for j+ AV (□, bars 1-5) and j/jAV (■, bars 6-10) (C).  Bars represent data from a single 
rat and are an average of duplicate activity measurements.  Hepatic microsomes were 
prepared from rats involved in the pharmacokinetic/toxicity study.   
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Figure 4.3  Hepatic SN-38 glucuronidation rates for j+ AV (□) and j/jAV (■) four days after 
adenoviral injection of 0.13 OD rat UGT1A10 or 1A1, 1A6, and 1A7, respectively.  Bars 
represent data from a single rat and are an average of duplicate activity measurements.  
Hepatic microsomes were prepared from rats used for the biliary excretion study.  Rats 
received one dose of irinotecan 20 mg/kg/day i.p.   
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Figure 4.4  Intestinal and colonic rat UGT1A expression (A) and SN-38 glucuronidation 
rates (B) for j/jAV and j+AV colon (open bars) and intestinal (thatched bars) microsomes 
seven days after adenoviral injection of 0.13 OD rat UGT1A10 or 1A1, 1A6, and 1A7, 
respectively.  Bars represent data from a single rat and are an average of duplicate activity 
measurements.  Rats did not receive irinotecan.
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Figure 4.5  Plasma profiles of irinotecan (A), SN-38 (B), and SN-38G (C) in j/jAV (-♦-) and 
j+AV (-◊-) rats after a 20 mg/kg dose of irinotecan i.p. (n = 5 rats per group).  Each data 
point is the mean concentration in rats of that group with associated standard error bars. 
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Figure 4.6  Biliary excretion (0-6 hr collection) of irinotecan (A), SN-38 (B), and SN-38G 
(C) in j+AV (-□-) and j/jAV (-■-) rats after a single 20 mg/kg i.p. dose of irinotecan.  Bars 
represent data from a single rat and are an average of duplicate activity measurements.
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Figure 4.7  Percentage weight loss relative to baseline over time in j/jAV (-♦-) and j+AV     
(-◊-) rats (n = 5 in each group) treated with irinotecan 20 mg/kg/day i.p. x3 doses.  Each 
weight measurement was taken 24 hours after the dose of irinotecan was administered.  
Points represent mean ± S.E.  **p<0.01, ***p<0.001.
***
**
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Figure 4.8  Representative micrographs (10x magnification) of j/j AV colon (A) and cecum 
(B) and j+AV colon (C) and cecum (D).  Tissues were extracted upon euthanizing the rats, 24 
hours after the third dose of irinotecan, 20 mg/kg/day i.p.  A description of the observed 
toxicity on each group of rats is given under RESULTS.
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THE INFLUENCE OF PIPERINE ON SN-38 GLUCURONIDATION AND 
CYTOTOXICITY IN HT-29 COLON CARCINOMA CELLS
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A. ABSTRACT 
Diarrhea is a main, dose-limiting adverse effect experienced by some patients treated 
with the chemotherapeutic agent, irinotecan.  Poor intestinal UDP-glucuronosyltransferase 
(UGT) activity may be the antecedent factor to the development of diarrhea in patients, as 
SN-38, the active metabolite of irinotecan, is detoxified through glucuronidation.  The 
purpose of these experiments was to assess whether lower SN-38 glucuronidation rates, via 
UGT inhibition, corresponded to higher rates of cytotoxicity in vitro in a colon cancer cell 
line.  Several substrates were screened for their ability to inhibit SN-38G formation in HT-29 
cells.  Borneol did not inhibit SN-38 glucuronidation, and the inhibition achieved with 
valproic acid was not consistent over time or concentration.  Piperine, a component of black 
pepper, exhibited a concentration-dependent, competitive inhibition of SN-38 
glucuronidation.  However, piperine did not increase the cytotoxicity of SN-38 in HT-29 
cells, and actually may have prevented it, as determined by a slight increase in SN-38 IC50 in 
cells treated with piperine.  Potential reasons for this apparent discrepancy may be that the 
residual catalytic activity after piperine treatment is sufficient to protect the cells from harm 
or that piperine may prevent uptake or facilitate efflux of SN-38 from the cells.  Alternative 
research avenues in in vitro systems should be explored to support or confirm the intestinal 
SN-38 protection theory, such as transfection of UGTs into a cell line naturally devoid of 
them or inducing UGTs in a cell line with poor expression. 
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B. INTRODUCTION 
 Irinotecan is an anti-cancer agent given to patients suffering from a multitude of solid 
tumors.  Its chemotherapeutic effects are mediated through the active metabolite, 7-ethyl-10-
hydroxy-camptothecin (SN-38), which is then detoxified by glucuronidation (Kawato et al., 
1991).  SN-38G, the resultant glucuronide, is formed in humans by UDP-
Glucuronosyltransferases (UGT) 1A1, 1A7, and 1A9 (Figure 1.1) (Gagne et al., 2002; 
Tallman et al., 2005).  All three compounds are excreted into the bile, where irinotecan may 
be hydrolyzed to SN-38, and all SN-38G is converted back to SN-38 via lower intestinal β-
glucuronidase (Slatter et al., 2000; Wadkins et al., 2004).  High intestinal concentrations of 
SN-38 have shown to be a predisposing factor for the development of diarrhea, a major dose-
limiting side effect of irinotecan (Gupta et al., 1994; Kehrer et al., 2001; Horikawa et al., 
2002).  However, enteric cells possess UGT1A1 and 1A9 and gut epithelium has 
demonstrated catalytic turnover of SN-38 (Strassburg et al., 1998) (Chapter 2).  Thus, 
intestinal UGT activity may be an important predictor in gastrointestinal toxicity, as 
proposed by us and others (Tukey et al., 2002). 
 Testing this hypothesis with a complex in vivo model may preclude mechanistic 
insight.  In vitro models have demonstrated the protective effects of UGTs for SN-38 and 
other toxic substances.  HT-29 colon carcinoma cells required much higher concentrations of 
mycophenolic acid (MPA) to reduce their cloning efficiency relative to EMT6 cells.  The 
former cells efficiently glucuronidated MPA, whereas the latter cells did not (Franklin et al., 
1995; Franklin et al., 1996).  A subculture of a lung cancer cell line (PC-7/CPT) continuously 
exposed to irinotecan was found to be resistant to SN-38 and to have upregulated levels of 
UGTs relative to parent cells.  The resistance of PC-7/CPT was abolished when a 
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competitive UGT inhibitor was co-incubated (Takahashi et al., 1997).  The simultaneous 
administration of high-dose propofol and SN-38 resulted in a 50% reduction in the 
concentration of SN-38 needed to inhibit HT-29 proliferation.  After further investigation, the 
increase in SN-38 toxicity with propofol was attributed to competitive inhibition for 
glucuronidation, as propofol glucuronides were detected in media and propofol significantly 
raised intracellular SN-38 concentrations (Cummings et al., 2003).  Similary, in another 
investigation, intracellular SN-38 levels correlated with toxicity in HT-29 cells (Kobayashi et 
al., 1999).  Overall, mounting evidence suggests that in vitro, conjugation can reduce 
intracellular levels of SN-38 and spare the cell from death. 
Thus, the goal of these experiments was to modulate glucuronidation in a colon-
derived immortal cell line to lend support to the theory that intestinal UGTs are an important 
factor in the incidence of toxicity.  To do this, several compounds with notable UGT 
inhibitory capacity (valproic acid, piperine, and borneol) were screened for their effect on 
SN-38 glucuronidation in HT-29 cells (Gupta et al., 1997b; Lambert et al., 2004; Dong et al., 
2006).  Although significant inhibition was achieved by piperine, a component of black 
pepper, it did not facilitate SN-38 induced cytotoxicity.  Mitigating considerations for these 
observations are discussed.
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C. MATERIALS AND METHODS 
Materials.  HT-29 cells were obtained through the Lineberger Comprehensive Cancer Center 
Tissue Culture Facility at UNC.  Cell culture media, trypsin, and antibiotics were obtained 
through Gibco (Invitrogen, Carlsbad, CA).  Charcoal/dextran treated fetal bovine serum was 
purchased from Hyclone (Logan, UT).  SN-38 was hydrolyzed from irinotecan, which was 
graciously provided by Dr. Robert Kelly (Pfizer, Kalamazoo, MI).  A description of the 
hydrolysis process is provided in another text (Ni, 2001).  Procedures detailing SN-38G 
cleavage from SN-38G methyl ester (also provided by Dr. Kelly) and quantitation are given 
in Chapters 2 and 3.  Piperine, valproic acid, borneol, and methylthiazolyldiphenyl-
tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO).  All 
chemicals involved in high performance liquid chromatography (HPLC) analysis were 
reagent-grade and purchased through commercial vendors. 
Cell Culture.  HT-29 cells were grown at 37° C in Dulbecco's Modified Eagle Medium, 
supplemented with 10% fetal serum albumin, 100 u/mL penicillin, and 100 µg/mL 
streptomycin at 5% CO2.  Cells were passaged at 90% confluence, with passage numbers 
121-149 used in all experiments. 
Inhibition Screen.  Dimethyl sulfoxide (DMSO), valproic acid, borneol, or piperine stocks 
were added to media at to yield the following concentrations:  0.1% DMSO; 20, 50, 100 µM 
piperine; 1 mM borneol; or 1, 5, or 10 mM valproic acid (Figure 5.1).  Media (3 mL) was 
then added to HT-29 cells (80% confluent) plated in 60 mm dishes (in duplicate for each 
inhibitor concentration).  After a pre-incubation period of 30 min, SN-38 (10 µM) was added 
to each dish.  Aliquots (300 µL) of media were removed from one plate at 0.5, 2, and 8 hours 
after the addition of SN-38 and at 1, 4, and 24 hours in another plate.  After the 8 and 24 hour 
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time points, cells were scraped into 1 mL phosphate-buffered saline (PBS) and sonicated.  An 
aliquot of cell sonicate was used to assess the total protein content of the plate, as determined 
by the Bradford assay using bovine serum albumin as a standard. 
 Acetonitrile (900 µL) and perchloric acid (5%, 5 µL) containing irinotecan (30 ng) as 
an internal standard were added to each tube of media.  After centrifugation at 15,000g for 10 
minutes, the aceonitrile layer was saved and blown down under a stream of nitrogen.  The 
residue was then reconstituted in 30% methanol/ 100 mM ammonium acetate (200 µL), and 
30 µL was injected onto HPLC to measure SN-38G media concentrations. 
 Additional experiments with different piperine concentrations were performed as 
above, with some procedural differences.  In the first experiment, piperine (0, 75, 100, or 150 
µM) was incubated with cells for up to 48 hours in an attempt to discern whether or not 
piperine was a competitive UGT inhibitor (Figure 5.2).  At 3, 7, 23, and 47 hours after adding 
piperine, SN-38 (5 µM) was added to each dish for 1 hour.  At 4, 8, and 24 hours, an aliquot 
of media was removed for analysis from all plates, and fresh media was replaced, with or 
without piperine.  Plates with 0 and 75 µM piperine were treated for the full 48 hours with 
piperine; plates with 100 µM piperine were treated from 0-8 hrs, and plates with 150 µM 
were treated from 0-4 hrs.  For these high concentrations of piperine, after 4 and 8 hours, 
media without piperine was replaced for the remaining 44 and 40 hour experimental period.  
At 48 hours, an aliquot of media was removed, and the cells were scraped into PBS, 
sonicated, and analyzed for protein content.  A portion of the cells (300 µL) were then 
analyzed similarly to media.   
In a second experiment, piperine-containing media (0, 20, 50, or 75 µM) was added 
to dishes thirty minutes prior to SN-38 (5 µM).  Two aliquots each of media and cell 
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sonicates were saved (300 µL per aliquot) after a four-hour SN-38 incubation.  After 
centrifugation, the acetonitrile from the duplicate samples was pooled and evaporated. 
HPLC Analysis.  The HPLC system used to inject, separate, and detect analytes was as 
described in Chapter 2, however an SIL10A autosampler was used (Shimadzu, Tokyo, 
Japan).  Mobile phase consisted of 37% methanol/100 mM ammonium acetate and 5 mM 
tetrabutylammonium sulfate, pH 4.9 run at 1.5 mL/min.  Excitation and emission 
wavelengths were held constant at 229 and 420 nm, respectively, and SN-38 was not 
monitored.  Standards were prepared in media and prepared similarly to samples.  Standard 
curves were linear and reproducible (coefficient of variance ≤ 15% for replicates) from 1.4 
ng SN-38G/mL (0.13 ng on column) to 125 ng SN-38G/mL (5.6 ng on column).  A sample 
chromatogram is given in Figure 5.3. 
Cytotoxicity assay.  HT-29 viability after the addition of SN-38, piperine, or a combination 
of the two was determined by the methylthiazolyldiphenyl-tetrazolium (MTT) assay.  
Formazan, a purple product of the reduction of MTT by mitochondrial dehydrogenases, will 
accumulate in viable cells.  After lysing these cells, formazan can be solubilized and 
quantified (Marshall et al., 1995).  HT-29 cells were seeded in 96 well plates (5,000 
cells/well) and were cultured for 2 days.  On the third day, media (100 µL) containing 
piperine (0-75 µM) or SN-38 (0-13 µM) or a combination of both was added for 8-48 hours.  
When piperine and SN-38 were co-incubated, piperine containing media was initially added 
to all wells, followed by the addition of SN-38 stock in thirty minutes.  After these 
incubations, media was removed and replaced with fresh media containing MTT (0.5 
mg/mL).  Following a three hour incubation, the media was removed, and cells were lysed 
with 75% isopropyl alcohol/25% 0.04 N hydrochloric acid (200 µL).  Absorbance (abs) was 
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determined at 595 nm with a 96-well plate reading spectrophotometer (Biorad).  Background 
absorbance (wells with no MTT) was subtracted from all values, and the percent viability in 
the presence of each drug concentration was normalized to the viability attained with no 
piperine, SN-38 or combination given as: 
              
The percent viability at each SN-38 concentration (with or without piperine) was input data 
for an inhibitory effect model using nonlinear regression analysis software (Winnonlin; 
Pharsight, Mountain View, CA), and SN-38 IC50 values (concentration that induces 50% of 
cell death) were found by iteration: 
 
  
 In a similar set of experiments designed to assess the influence of treatment protocol 
upon the S-phase specific toxicity of SN-38, piperine (0 or 50 μM) was coadministered with 
SN-38 for 24 hours.  In some plates, piperine (0 or 50 μM) was incubated for an additional 
24 hours after SN-38 was removed.  After piperine removal, all cells were subjected to a 
drug-free period of 24-48 hours prior to MTT analysis. 
Viability (%) =    100 x               Abs595, treated – Abs595, no MTT reagent 
         Average (Abs 595, no treatment – Abs 595, no MTT reagent) 
Inhibition (%) = Maximal Inhibition (%)   x    (  1 -         C        ) 
        C + IC50 
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D. RESULTS 
UGT catalysis of SN-38 was detected in HT-29 cells, with roughly 5% of SN-38 (10 
µM) glucuronidated in 24 hours.  The effect of various UGT inhibitors on SN-38 
glucuronidation is given in Figure 5.4.  Valproic acid generally inhibited SN-38 
glucuronidation, however, inhibition was variable over time and the strength of inhibition 
was modest (average of 25% inhibition) despite high concentrations of valproic acid (10 
mM).  Co-incubation of SN-38 with borneol (1 mM) did not reduce the glucuronidation rate 
of SN-38 relative to controls over this same period.  Piperine consistently inhibited SN-38G 
formation, with 20 µM piperine reducing SN-38G formation by an average of 43%, 50 µM 
reducing the rate by 54%, and 75 µM by 75%.  Thus, piperine was chosen to modulate 
glucuronidation and to test its effects on SN-38 cytotoxicity. 
In order to attain a satisfactory concentration-response curve for SN-38 toxicity in 
HT-29 cells, a 48-hour incubation with the drug was necessary.  A one-day incubation did 
not achieve sufficient cell killing at high SN-38 concentrations, which precluded estimation 
of a reliable IC50 value (data not shown).  Accordingly, the cytotoxicity of piperine in HT-29 
cells was assessed at 48 hours (Table 5.1).  Concentrations of piperine greater than 75 µM 
elicited significant cell death at 48 hours, but not at 4 or 8 hours.  Because higher piperine 
concentrations also inhibited more SN-38G formation (Figure 5.4), short-term, high-dose 
piperine exposure was evaluated for its inhibitory capabilities over 48 hours (Figure 5.5).  
After removal of 150 µM piperine at 4 hours or 100 µM at 8 hours, SN-38 glucuronidation 
rates increased, indicating that piperine must be present in the media for inhibition (i.e. likely 
acts through competitive inhibition).  By observing the increase in glucuronidation rate over 
time in the 100 and 150 µM piperine treated cells relative to control, piperine treatment may 
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have induced UGT1A expression (Figure 5.5).  Continual exposure to piperine ensured 
inhibition over a 48 hour period, as evident in the studies with 75 µM piperine.  As high 
concentrations of piperine were too cytotoxic for prolonged exposure to 48 hours, 
concentrations greater than 75 µM piperine were not utilized in further inhibition or 
cytotoxicity assays.   
The effect of piperine at non-toxic concentrations was then assessed for its inhibition 
in HT-29 cells (Table 5.2).  A stepwise increase in SN-38 glucuronidation inhibition was 
seen from 20-75 µM, similar to that observed in the pilot inhibitor screen study (Figure 5.4).  
By analyzing cell content, SN-38G was shown to be efficiently extruded into media and total 
glucuronide formed (sum of media and cells) was less in piperine-treated cells.  
Subsequently, the cytotoxicity of SN-38 was measured in the presence and absence of 
piperine, 20-75 µM (Table 5.3, Figure 5.6).  Highest toxicity (i.e. lowest IC50) was observed 
in cells treated with SN-38 alone.  A 2.3-fold higher SN-38 concentration was needed to kill 
50% of cells treated with 50 µM piperine versus 0 µM piperine.  The additional experiment 
comparing IC50 values for SN-38 in cells treated with 0 or 50 µM piperine with a washout 
period showed that piperine had no effect on toxicity (data not shown). 
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E. DISCUSSION 
In this study, several compounds were examined for their capability to inhibit SN-38 
glucuronidation in vitro.  In rat hepatocytes co-incubated with borneol (1 mM), virtually all 
glucuronidation of ibuprofen, benoxaprofen, and flunoxaprofen was abolished (Dong et al., 
2006).  Most findings of UGT inhibition with borneol are with UGT2B family substrates, for 
which it is also a substrate (Tian et al., 2005a).  Previous studies report that borneol depletes 
UDP-glucuronic acid (UDPGA), the cofactor necessary for glucuronidation, presumably by 
efficient borneol glucuronidation (Watkins and Klaassen, 1982).  Although this is an effect 
that should reduce glucuronidation of all compounds, borneol had no effect upon SN-38, a 
UGT1A substrate.  The lack of an effect by borneol may be attributed to low expression of 
UGT2B isoforms in HT-29 cells, as glucuronides for UGT2B4, 2B7, and 2B15 probes were 
negligible after cellular incubations (Cummings et al., 2003).  Valproic acid is a substrate for 
UGT1A6 and 1A9 and UGT2B7, albeit with poor affinity and turnover (i.e., mM Km values 
and high pmol/min turnover of conjugate) (Ethell et al., 2003).  Valproic acid has been found 
to inhibit both UGT1A and 2B substrates, both competitively and non-competitively (Ethell 
et al., 2003).  In rats, valproic acid raised systemic exposure to SN-38 by three-fold and 
lowered exposure to SN-38G by 99% (Gupta et al., 1997b).  Despite the in vivo inhibition of 
SN-38G formation, the strength of the inhibition was not reciprocated in this cellular system.  
Piperine has demonstrated UGT inhibitory effects in microsomes, cells, and in vivo.  It is 
glucuronidated, within several metabolic pathways (after oxidative metabolism), and has 
been found to deplete UDPGA (Bhat and Chandrasekhara, 1986; Singh et al., 1986).  
Piperine inhibits first-pass metabolism, concomitantly increasing bioavailability of some 
aglycones, and in HT-29 cells has demonstrated similar potent inhibitory effects upon UGT 
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substrates in this and other studies (Shoba et al., 1998; Lambert et al., 2004).  The potency of 
inhibition of SN-38 glucuronidation and another UGT1A substrate, epigallocatechin-3-
gallate, by piperine in HT-29 cells was similar in that piperine concentrations slightly greater 
than 20 µM reduced glucuronidation by 50% (Lambert et al., 2004).  In this cell line, 
piperine concentrations of 100 µM or greater for extended periods caused toxicity, which is 
likely because of generation of free radicals and lipid peroxidation (Unchern et al., 1998).  
Although these concentrations more strongly inhibited glucuronidation, it was difficult to 
generate SN-38 concentration-response curves due to low viability in the control cells 
exposed to piperine (i.e. piperine with no SN-38). 
The objective of the work described here was to support data showing that UGT 
inhibition by propofol in HT-29 cells predisposes cells to SN-38 toxicity (Cummings et al., 
2003).  The outcomes from these two studies were completely different, with the current 
study not supporting the intestinal UGT protection hypothesis.  This may have arisen due to 
one or more differences between the experimental procedures employed.  The IC50 for SN-38 
in this study was 10-fold higher than that reported in another study in HT-29 cells (161 nM v. 
16.5nM) (Cummings et al., 2003).  SN-38 cytotoxicity is highly dependent on the 
dosing/recovery regimen employed, as the drug is S-phase specific in its effects.  For 
example, treating cells with SN-38 for one day and waiting two days before performing the 
MTT assay lowered the IC50 to 15 nM (data not shown).  The schedule employed for the 
MTT assay described in this work was chosen because of decreased variability at high SN-38 
concentrations.  In this experiment, regardless of the regimen used, piperine did not increase 
SN-38 mediated cytotoxicity in cells.  Additionally, cytotoxicity measurements were 
different between the two studies.  Selection of a poorly sensitive cytotoxicity assay may 
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yield completely different results from those of a more sensitive assay, and the degree of 
assay sensitivity is often drug/cell line dependent (Petty et al., 1995; Fotakis and Timbrell, 
2006).  However, it is likely that if a robust difference in SN-38 toxicity between piperine 
and control treated cells did exist, the MTT assay could discriminate this. 
Another difference between this and a similar study showing that UGT inhibition in 
HT-29 cells induces toxicity is the choice of inhibitor (piperine versus propofol).  As 
mentioned, the toxicity inflicted upon cells by piperine may be a complicating factor.  
Additionally, little is known about its effects upon the disposition of compounds, namely 
through its potential interaction with transport proteins.  Should piperine inhibit the uptake of 
SN-38, glucuronidation of the compound might decrease (as shown in Table 5.2), yet 
because intracellular levels of the aglycone are low, toxicity would be reduced.  The increase 
in IC50 for SN-38 toxicity shown in Table 5.3 may also be substantiated if piperine was found 
to facilitate the efflux of SN-38.  Piperine has been found to inhibit P-glycoprotein transport 
of digoxin and verapamil in the Caco-2 system with IC50 values in the µM range (Bhardwaj 
et al., 2002).  Although P-glycoprotein is not found in HT-29 cells and inhibition of efflux 
would predispose cells to toxicity, the interaction with other uptake/efflux transporters is 
highly conceivable (Guichard et al., 2005).  Unfortunately, intra-and extra-cellular levels of 
SN-38 were not monitored in the current study due to modifications necessary for its 
detection via HPLC. 
Overall, the reasons why this series of experiments with piperine did not support 
several other studies substantiating the intestinal UGT protection hypothesis is unknown.  As 
the focus of these experiments was not to uncover why piperine did not increase SN-38 
toxicity, but was to prove that intestinal glucuronidation modulates toxicity in vitro, it is 
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likely the outcome of this experiment will not be mechanistically explained.  Instead, new 
methods to simplify the testing of this hypothesis should be explored.  It may be possible to 
upregulate intestinal UGTs in a cell line possessing constitutively low levels.  Inducing 
UGTs should increase IC50 values, in contrast to reducing them with an inhibitor.  In Caco-2 
cells treated with 50 µM chrysin, another phytochemical, for four days, SN-38G formation 
was increased by 16-fold relative to control cells in microsomes (data not shown).  However, 
chrysin has been found to be a BCRP inhibitor, which may lead to the accumulation of 
intracellular SN-38 (Zhang et al., 2004).  Alternative ways to increase UGTs in vitro would 
be through transfection of plasmids or adenoviral-mediated UGT gene expression.  These 
approaches are more likely to be a more conclusive system, as less confounding factors are 
introduced versus the myriad of possible effects a foreign chemical may have on cellular 
function and homeostasis. 
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Table 5.1  Percent of viable HT-29 cells as a function of piperine concentration (no SN-38).  
Cells were exposed to piperine for 4, 8, or 48 continuous hours.  Viability was assessed by 
the MTT assay and normalized relative to viability measured in cells without piperine 
treatment.  Data is presented as mean ± SE (6 replicates per concentration). 
[Piperine]  
(µM) 
Percent Viability  
at 4 hours 
Percent Viability  
at 8 hours 
Percent Viability  
at 48 hours 
0 100 ± 2.0 100 ± 1.9 100 ± 2.7 
10 101 ± 1.8 97.5 ± 1.9 118 ± 2.4 
20 93.9 ± 2.3 97.1 ± 1.1 130 ± 1.2 
50 110 ± 3.7 92.0 ± 2.1 100 ± 4.1 
75 95.0 ± 3.7 83.9 ± 1.4 79.3 ± 2.8 
100 97.9 ± 6.4 74.7 ± 2.8 58.9 ± 4.6 
150 93.2 ± 3.1 56.9 ± 3.0 29.6 ± 0.79 
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Table 5.2  SN-38G formation in the presence of piperine, 0- 75 µM, in HT-29 cells over four 
hours.  A total of 5.9 µg SN-38 was added to each dish at a concentration of 5 µM.  Data are 
an average amount of SN-38G formed from three 60 mm dishes ± SE. 
[Piperine] 
(µM) 
SN-38G in media 
(ng) 
SN-38G in cells 
(ng) 
0 43.7 ± 6 10.8 ± 0.3 
20 33.3 ± 6 3.5 ± 0.3 
50 17.3 ± 2 1.4 ± 0.1 
75 7.52 ± 0.3 0.81 ± 0.05 
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Table 5.3  IC50 values of SN-38 in the presence or absence of piperine.  The SN-38 
concentration ranged from 0-13 µM, and viability was determined in six wells for each 
concentration.  Values are determined by non-linear regression software and the associated 
coefficient of variance is given in parenthesis.  
 0 µM piperine 20 µM piperine 50 µM piperine 75 µM piperine 
IC50  
(nM) 
161  
(15) 
198  
(15) 
371  
(16) 
285  
(15) 
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Figure 5.1  Chemical structures of the UGT inhibitors valproic acid (A), borneol (B), and 
piperine (C).
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Figure 5.2  Experimental design to ascertain whether piperine is a competitive or noncompetitive inhibitor.  Piperine (0, 75, 100, or 
150 µM) was incubated with cells for up to 48 hours.  At 3, 7, 23, and 47 hours after adding piperine, SN-38 (5 µM) was added to 
each 60 mm dish for 1 hour.  At 4, 8, and 24 hours, an aliquot of media was removed for analysis from all plates, and fresh media was 
replaced, with or without piperine.  Plates with 0 and 75 µM piperine were treated for the full 48 hours with piperine; plates with 100 
µM piperine were treated from 0-8 hrs, and plates with 150 µM were treated from 0-4 hrs.  For high concentrations of piperine, after 4 
and 8 hours, media without piperine was replaced for the remaining 44 and 40 hour experimental period.   
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Figure 5.3  Representative SN-38G (125 ng/mL, 3.9 min) and irinotecan (internal standard, 
30 ng, 8.1 min) chromatogram in cell culture media.  Compounds were extracted from media 
and analyzed via HPLC with fluorescence detection. 
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Figure 5.4  Time-dependence of valproic acid (A), borneol (B), and piperine (C) inhibition 
of SN-38 glucuronidation in HT-29 cells relative to control (DMSO 0.1%, 100% formation) 
as assessed by SN-38G release into media from 0.5-24 hour exposure to both SN-38 and 
piperine.  Inhibitor concentrations are given in each legend.  Bars indicate analysis of one 
aliquot/time point. 
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Figure 5.5  Effect of piperine on SN-38G formation in HT-29 cells.  SN-38 (5 µM) was 
incubated for one hour at 3, 7, 23, and 47 hours following prior exposure to piperine.  Plates 
contained either piperine 0 µM (0-48 hrs), 75 µM (0-48 hours), 100 µM (0-8 hrs, then 0 µM 
piperine from 8-48 hrs) or 150 µM (0-4 hrs, then 0 µM from 4-48 hrs).  At 4, 8, 24, and 48 
hours, an aliquot of media was saved for SN-38G analysis from all plates.  Bars are mean 
velocity ± SE and corresponding concentrations are identified in the legend (n = 3 plates per 
concentration). 
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Figure 5.6  Concentration response curves for SN-38 in the presence and absence of piperine 
in HT-29 cells over 48 hours.  Viability is relative to baseline (i.e., 100% viability at 0 ng/mL 
SN-38).  Treatment is given in the legend, and each point represents the average viability 
from six replicates. 
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CONCLUSIONS
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 The experiments conducted in this dissertation have advanced the understanding of 
intestinal glucuronidation and the role these metabolic enzymes play in the disposition and 
toxicity of a selected compound, 7-ethyl-10-hydroxy-camptothecin, or SN-38.  SN-38 is the 
active metabolite of the anti-cancer topoisomerase I inhibitor, irinotecan, given to thousands 
of patients yearly as treatment for solid tumor carcinoma.  SN-38 is metabolically detoxified 
by UDP-Glucuronosyltransferases (UGTs), which exist primarily in the liver, kidney, and 
intestine.  Irinotecan/SN-38 has been extensively studied, and it is one of the first compounds 
where a dose-limiting adverse event (neutropenia) can be predicted in part by 
pharmacogenomic analysis (UGT1A1*28 homozygosity) (de Jong et al., 2005).  A 
mechanistic basis for the incidence of the other main dose-limiting toxicity of irinotecan/SN-
38, diarrhea, is much less clear.  Investigations in elucidating the causative mechanisms 
behind the incidence of diarrhea have focused broadly upon the reduction of luminal SN-38 
available to the enterocytes (Takasuna et al., 1996; Kehrer et al., 2001; Horikawa et al., 2002; 
Innocenti et al., 2004b).  In the literature, intestinal UGT capacity has been largely ignored as 
a crucial factor in protecting or predisposing patients to SN-38-induced diarrhea.  These 
enzymes afford a local means of SN-38 detoxification, which may be particularly important 
in the colon, due to the high level of unconjugated SN-38 in the intestinal lumen via effective 
β-glucuronidase cleavage of all luminal SN-38 glucuronide (SN-38G).  Thus, we 
hypothesized that intestinal UGT expression may mediate diarrhea, which then guided the 
experiments in this text.  
Prior to this dissertation research, most investigators utilized the ionized, carboxylate 
form of SN-38 for in vitro glucuronidation experiments, due to its increased solubility, 
relative to the closed, lactone form.  SN-38 carboxylate is not active and displays differing 
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pharmacokinetics and affinities for transport proteins from the lactone form.  As such, using 
the carboxylate as a surrogate for the pharmacologically and physicochemically distinct 
lactone form of SN-38 was a considerable assumption.  Thus, studies to decipher differences 
in UGT isoform specificity and tissue glucuronidation for these two forms were formulated 
and conducted.  Experiments involved assessing the stability of the forms in various in vitro 
matrices, conducting glucuronidation assays, and using pharmacokinetic modeling to recover 
pure rates of elimination for each form.  This study also identified the rat UGT isoforms 
responsible for SN-38 conjugation.  The very high rate of SN-38G formation by the 
intestinally-expressed UGT1A7 supports the finding that the greatest rates of SN-38 
glucuronidation occur in the rat intestine (Shelby et al., 2003).  Additionally, intestinal rat 
UGT1A7 expression may explain why Sprague-Dawley rats were refractory to diarrhea when 
treated with extremely large doses of irinotecan (200 mg/kg/day) (data not shown).  Results 
from this study also indicated that SN-38 lactone conjugation proceeded at a much faster rate 
relative to the carboxylate in virtually all matrices, so using carboxylate-derived intrinsic 
clearance values or in vitro-in vivo scaling with such data is not accurate.  Both forms were 
found to be glucuronidated by the same UGT isoforms in a similar rank order.  Given the 
regional expression of several UGT1A isoforms, this is important, and indicates that when 
comparing SN-38G formation rates between tissues or individuals with differing levels of 
UGT expression, the carboxylate is a suitable surrogate for the poorly-soluble and toxic SN-
38 lactone (Chapter 2). 
As an extension of the hypothesis that intestinal UGTs mediate diarrhea in patients, 
we surmised that patients with low intestinal UGT expression might be susceptible to 
diarrhea while those with higher expression might be spared this adverse effect.  For this to 
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be feasible, significant variability in intersubject intestinal SN-38G formation must exist.  
Therefore, a bank of normal duodenal, jejunal, and colon samples was screened, with 
variability in SN-38 glucuronidation that ranged 8, 37, and 36-fold in the intestinal regions, 
respectively.  This variability is on par with that observed with SN-38 in the liver (Iyer et al., 
1998).  These rates were also highly correlated with UGT1A1 and UGT1A9 expression, as 
assessed through probe substrate glucuronidation.  Preliminary evidence from this study 
suggested that homozygosity for UGT1A1*28 did not predict low SN-38 glucuronidation 
rates, indicating that analysis at the protein level is a better predictor of SN-38 conjugating 
ability in the intestine relative to UGT1A1 genetic analysis.  Currently, UGT1A1*28 has not 
reliably been associated with intestinal toxicity status, while there is only one study assessing 
UGT1A9 promoter genotypes, which found an association between one polymorphism and 
diarrhea (Marcuello et al., 2004; Carlini et al., 2005).  The results of the current study 
indicate that UGT1A9 may play a primary role in the intestinal detoxification of SN-38.  In 
fact, there have been no in vitro studies assessing a possible correlation between hepatic 
UGT1A9 expression and SN-38 glucuronidation.  In addition to the variability found in 
intestinal conjugation of SN-38, this work indicates that efforts should be directed towards 
determining the influence of UGT1A9 polymorphisms and expression upon systemic and 
intestinal SN-38 disposition and toxicity (Chapter 3).  Further, a large study whereby the 
colonic glucuronidation of SN-38 is correlated with the incidence diarrhea in patients 
receiving irinotecan is obviously needed to ultimately test the influence of intestinal UGTs 
on regional toxicity. 
Due to a lack of access to patients for the above-mentioned clinical study, we tested 
the hypothesis that intestinal UGTs mediate irinotecan/SN-38-induced diarrhea utilizing a 
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unique, genetically-modified Gunn rat model.  Hepatic glucuronidation was reconsitituted in 
the UGT1A-deficient Gunn rat via adenoviral delivery of UGT isoforms typically expressed 
in a heterozygote Wistar (j+AV).  This reconstitution slightly “overshot” UGT levels found 
in the livers of j+AV rats, although systemic exposure of SN-38 and SN-38G was higher and 
lower in the transfected Gunn rats (j/jAV), respectively, after a dose of irinotecan.  
Regardless of this, similar levels of irinotecan and its metabolites were found in bile of both 
groups of rats.  After repeated administration of irinotecan, j/jAV rats had high rates of 
weight loss, gross histopathological changes in the colon and cecum, and severe diarrhea.  
Following a similar irinotecan regimen, j+AV rates had modest rates of weight loss, and had 
no evidence of intestinal tissue damage, manifest by normal cecum and colon tissue structure 
and no diarrhea.  Overall, these findings indicate that intestinal glucuronidation is critical to 
preventing SN-38-induced intestinal damage and diarrhea (Chapter 4).  Future studies with 
this animal model should focus upon the influence of UGT expression upon transporter 
protein levels.  Members of the multidrug resistance-associated protein family appear to be 
regulated, in part, by intracellular concentrations of glucuronides in rats, as shown in studies 
with bile-duct ligated and MRP2-decifient rats (Ogawa et al., 2000).  Enterocytes from the 
j/jAV and j+AV rats should contain different levels of glucuronide conjugates, which may 
cause subsequent alteration of transporter expression.  As SN-38 and SN-38G are both 
substrates for similar transporters, altered transporter expression may also influence toxicity 
profiles. 
The influence of UGT inhibition on SN-38 cytotoxicity was studied in HT-29 colon 
carcinoma cells.  To validate the hypothesis, UGT inhibition via the phytochemical piperine, 
would increase toxicity relative to control-treated cells.  Although an 85% decrease in SN-38 
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glucuronidation at the highest concentration of piperine was achieved, these cells were not 
predisposed to toxicity.  Several reasons for this lack of relationship were previously 
outlined, and include possible transport modulation by piperine or sufficient residual 
glucuronidation to protect cells despite significant inhibition.  In hindsight, this study is 
frought with too many unidentified variables to discount the hypothesis.  Future in vitro 
studies should include well-studied inhibitors and inducers, or cleaner, less complex systems 
such as single interfering RNA or UGT transfection of cells, which may simplify analysis 
(Chapter 5). 
Intestinal UGT expression may be crucial in mediating both toxicity and efficacy for 
a number of compounds, though only one compound, SN-38, was explored in this 
dissertation research.  For instance, mycophenolic acid (MPA), the prodrug of the 
immunosuppressive agents mycophenolate mofetil and mycophenolate sodium, is eliminated 
primarily through glucuronidation and causes severe diarrhea in significant numbers of 
patients (Wang et al., 2004).  In j/jAV rats, MPA systemic exposure was similar to that in 
control rats with both hepatic and intestinal conjugation (data not shown).  However, only 
j/jAV rats experienced diarrhea, indicating that intestinal UGT capacity is a better indicator 
of toxicity relative to pharmacokinetic parameters (Miles et al., 2006a).  In addition to 
toxicity, intestinal glucuronidation may also influence the efficacy of certain medications.  
For example, ezetimibe is an anti-hyperlipidemic medication that binds to cholestrol 
transporters in the gastrointestinal tract, and is glucuronidated by UGT1A1 and 1A3.  In a 
recent study, rifampin-mediated induction of intestinal UGT1A1, evaluated via pinch 
biopsies, reduced the chlosterol-lowering effect of ezetimibe (Oswald et al., 2006).  Although 
hepatic UGTs are also likely influenced by rifampin, the idea that intestinal UGTs can shift 
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the equilibrium from active aglycone to purportedly inactive glucuronide and mediate the 
pharmacologic efficacy is highly feasible with ezetimibe (Oswald et al., 2006).  Another 
example where intestinal UGTs may alter intestinal drug levels necessary for effect is with 
tegaserod, a serotonin agonist used to treat irritable bowel syndrome (Vickers et al., 2001).  
As substrates for glucuronidation are rarely subject to drug interactions in constrast to those 
metabolized by cytochromes P450, the former route of metabolism is desirable from a drug 
development standpoint (Williams et al., 2004).  Thus, it is likely that in the future, intestinal 
UGTs will play a role in the detoxification and efficacy profiles to a wider range of new drug 
candidates. 
Although significant effort was devoted to evaluating the role of intestinal UGTs in 
SN-38 metabolism and toxicity, we cannot discount that a considerable number of factors 
probably contribute to the occurance of this toxicity.  As previously mentioned, transport 
proteins influence luminal concentrations of irinotecan and metabolites through biliary 
excretion, as well as the initial exposure of enterocytes to these compounds (Horikawa et al., 
2002).  Hepatic glucuronidation likely plays an indirect role in intestinal toxicity.  High 
levels of hepatic glucuronidation may lead to increased intestinal levels of SN-38, as SN-38G 
is transported into bile and all SN-38G is hydrolyzed to SN-38 in the intestinal lumen 
(Chapter 4) (Chu et al., 1997; Slatter et al., 2000).  A patient’s diet may also greatly influence 
toxicity.  For instance, ingestion of high amounts of basic antacids favor the existence of SN-
38 carboxylate, which is poorly taken up by enterocytes relative to the lactone form (Takeda 
et al., 2001).  Thus, multiple mechanisms are likely to influence toxicity, with intestinal UGT 
catalysis being one such mechanism. 
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In summary, the work presented here has advanced the understanding of intestinal 
UGT catalysis of SN-38, as well as the regional glucuronidation by specific UGT1A 
isoforms.  Most importantly, through studies with a unique Gunn rat model, this dissertation 
supports the hypothesis that intestinal UGTs are an important mediator of SN-38-induced 
diarrhea.  Should this hypothesis be conclusively proven in humans, steps could be taken to 
proactively exploit intestinal UGT expression.  For instance, poorly absorbed UGT inducers 
may locally provide the increase in SN-38 glucuronidation needed to spare susceptible 
patients from diarrhea.  Currently, chrysin, a phyochemical that we found would increase 
SN-38 turnover in Caco-2 cells by 15-fold, is being explored as such an agent in clinical 
trials (data not shown) (Tobin et al., 2006).  Alternatively, physicians could excise intestinal 
biopsies and assess in vitro SN-38 glucuronidation similar to that in Chapter 3, prior to 
determining a patient’s dose of irinotecan.  Since most patients undergo diagnostic 
colonoscopy for colon carcinoma, the primary cancer treated with irinotecan, this procedure 
would not be unusual or intrusive.  Ultimately, these strategies, based upon work performed 
in this thesis, may lead to drug treatment which every physician and patient desires—optimal 
pharmacological efficacy with minimal debilitating adverse effects. 
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